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IL-17 signaling to the intestinal epithelium is a critical regulator of the intestinal 
microbiome. There is a growing body of research linking alterations in both Th17 cells and the 
intestinal microbiome to extra-intestinal pathologies including hepatitis and neuroinflammation.  
For example, many patients with autoimmune, fulminant, and viral hepatitis exhibit increased 
systemic IL-17, and Il17ra-\- mice are protected in concanavalin A (Con A)-induced hepatitis, a 
murine model of immune-mediated hepatitis. In Multiple Sclerosis (MS), elevated IL-17 was 
found in CNS lesions, and disrupted Th17 differentiation in mice ameliorates disease in the 
experimental autoimmune encephalomyelitis (EAE) mouse model of MS. In addition, many 
patients with hepatitis and MS display an altered intestinal microbiome, and germ-free mice as 
well antibiotic-treated mice have decreased disease in Con A hepatitis and EAE. Despite these 
data, few studies have investigated how the relationship between enteric Th17 cells and the 
microbiome influences extra-intestinal pathologies. 
Based on these reported links, we hypothesized that intestinal IL-17R signaling plays a 
critical role in mitigating hepatic and neuroinflammation. To test this, we generated intestinal 
epithelial specific IL-17RA knockout mice (Il17rafl/fl x villin cre+ mice). Because enteric Th17 
signaling regulates the commensal microbiota, these mice exhibited an altered intestinal 
microbiome along with a subsequent expansion of intestinal Th17 cells. We then tested these mice 
in the Con A hepatitis model and EAE neuroinflammation model.  
 v 
Our results showed that perturbation of intestinal IL-17RA signaling was sufficient to 
exacerbate both liver and neuroinflammation in a microbiome-dependent manner. Abrogation of 
intestinal IL-17RA disrupted the intestinal microbiota and promoted translocation of bacterial 
products to the liver. Together, this induced IL-18 production and subsequent lymphocyte 
activation and cell death to worsen hepatitis. In EAE, intestinal IL-17RA deficiency induced 
intestinal dysbiosis and increased intestinal Il17 and Csf2 and systemic responses in both 
cytokines. Preliminary data suggested a potential increase of inflammatory monocyte infiltration 
into the CNS, together exacerbating disease. These dissertation studies elucidate the differential 
role of enteric Th17 cells and the microbiome in extra-intestinal pathologies and more broadly in 
mucosal immunology. Moreover, it provides insight into novel therapeutic strategies that target 





Table of Contents 
Preface ......................................................................................................................................... xiv 
1.0 Introduction ............................................................................................................................. 1 
1.1 Intestinal Th17 Signaling ............................................................................................... 2 
1.1.1 Interleukin 17 (IL-17) and IL-17 Receptor ....................................................... 2 
1.1.2 Pathogenic and Non-Pathogenic Th17 Cells ..................................................... 4 
1.1.3 Th17 Cells and Maintenance of Intestinal Homeostasis .................................. 5 
1.2 Intestinal Microbiome .................................................................................................. 10 
1.2.1 Immunogenic Commensal Bacteria................................................................. 10 
1.2.2 Bacterial Mechanisms to Influence Host Immune Responses....................... 11 
1.3 Disruption of Th17 Signaling & the Intestinal Microbiome In Disease .................. 14 
1.3.1 Intestinal Diseases ............................................................................................. 14 
1.3.2 Extra-Intestinal Diseases .................................................................................. 15 
2.0 Gut-Liver Axis: Intestinal IL-17R signaling constrains IL-18 driven liver 
inflammation by the regulation of microbiome-derived products ......................................... 20 
2.1 Introduction .................................................................................................................. 20 
2.1.1 Liver Anatomy and Physiology ........................................................................ 20 
2.1.1.1 Structure and Blood Supply ................................................................. 20 
2.1.1.2 Hepatic Portal System ........................................................................... 22 
2.1.1.3 Function .................................................................................................. 23 
2.1.2 Hepatic Response to Intestinal-Derived Factors ............................................ 24 
2.1.2.1 Initial Cell Responders at the Liver Sinusoids .................................... 24 
 vii 
2.1.2.2 Effects of Bacterial Translocation ........................................................ 26 
2.1.3 The Intestinal Microbiome & Bacterial Translocation in Liver Disease ..... 30 
2.1.4 Th17 Cells in Liver Disease .............................................................................. 32 
2.1.5 Study Overview ................................................................................................. 33 
2.2 Methods ......................................................................................................................... 34 
2.2.1 Experimental Model and Subject Details ....................................................... 34 
2.2.2 Method Details ................................................................................................... 35 
2.2.3 Quantification and Statistical Analysis ........................................................... 43 
2.2.4 Data and Software Availability ........................................................................ 46 
2.3 Results ............................................................................................................................ 46 
2.3.1 Deletion of IL-17RA in intestinal epithelium exacerbates Concanavalin A 
hepatitis. ...................................................................................................................... 46 
2.3.2 Exacerbated liver injury is dependent on the intestinal microbiota. ........... 49 
2.3.3 Intestinal IL-17RA constrains TLR9-induced Type I immune responses in 
the liver. 55 
2.3.4 Intestinal IL-17RA constrains hepatic and intestinal IL-18. ........................ 63 
2.3.5 IL-18-induced FasL exacerbates liver inflammation. .................................... 66 
2.3.6 Anti-IL18 mitigates liver injury in intestinal IL-17RA-deficient mice. ....... 69 
2.4 Discussion ...................................................................................................................... 70 
2.5 Working Model ............................................................................................................. 80 
3.0 Gut-Central Nervous System Axis: Disruption of Intestinal Th17 Signaling and 
the Microbiome Exacerbate Autoimmune Neuroinflammation ............................................. 81 
3.1 Introduction .................................................................................................................. 81 
 viii 
3.1.1 Overview of Multiple Sclerosis ........................................................................ 82 
3.1.1.1 Epidemiology .......................................................................................... 82 
3.1.1.2 Disease Manifestations .......................................................................... 83 
3.1.1.3 Diagnosis ................................................................................................. 84 
3.1.1.4 Prognosis ................................................................................................. 84 
3.1.1.5 Treatment ............................................................................................... 85 
3.1.2 Th17 Cells and the Microbiome in Multiple Sclerosis ................................... 87 
3.1.2.1 Barriers of the CNS ............................................................................... 87 
3.1.2.2 Th17 Cells in Multiple Sclerosis ........................................................... 91 
3.1.2.3 Intestinal Microbiome in Multiple Sclerosis ....................................... 93 
3.1.3 Study Overview ................................................................................................. 94 
3.2 Methods ......................................................................................................................... 95 
3.2.1 Experimental Model and Subject Details ....................................................... 95 
3.2.2 Method Details ................................................................................................... 97 
3.2.3 Quantification and Statistical Analysis ......................................................... 101 
3.2.4 Data and Software Availability ...................................................................... 103 
3.3 Results .......................................................................................................................... 103 
3.3.1 Disruption of enteric IL-17RA signaling exacerbates neuroinflammation.
 103 
3.3.2 Disease in Il17rafl/fl x villin cre+ mice is microbiome-dependent. ................ 107 
3.3.3 Il17rafl/fl x villin cre+ mice exhibit increased splenic IL-17 responses and 
increased antigen-specific GM-CSF responses. ..................................................... 108 
3.3.4 Il17rafl/fl x villin cre+ disease exacerbation is IL-1β-independent. ............... 111 
 ix 
3.3.5 Il17rafl/fl x villin cre+ mice have increased intestinal Ccr2 and Ccr6 and spinal 
cord Nos2 prior to EAE onset. ................................................................................ 113 
3.4 Discussion .................................................................................................................... 116 
3.5 Working Model ........................................................................................................... 125 
4.0 Overall Conclusions & Future Directions ........................................................................ 126 
Bibliography .............................................................................................................................. 135 
 x 
List of Tables 
Table 1-1. Experimental Assays Used to Measure Th17 Responses in Current Dissertation Studies
......................................................................................................................................................... 4 
Table 1-2. Pathogenic & Non-Pathogenic Th17 Differentiation .................................................... 5 
Table 1-3. Experimental Assays Used to Assess the Microbiome in Current Dissertation Studies
....................................................................................................................................................... 14 
Table 2-1. Single Cell RNAseq Cluster Gene Lists. ..................................................................... 56 
Table 3-1. 2017 McDonald Criteria .............................................................................................. 84 
Table 3-2. Disease-Modifying Therapies Approved for MS ........................................................ 86 
 xi 
List of Figures 
Figure 1-1. Intestinal Th17 Cells Contribute to the Mucosal Firewall. .......................................... 7 
Figure 1-2. Diseases w/ Evidence Implicating Th17 cells & the Intestinal Micrbiome ............... 16 
Figure 2-1. Liver Anatomy ........................................................................................................... 21 
Figure 2-2. Deletion of IL-17RA in intestinal epithelium exacerbates Concanavalin A hepatitis.
....................................................................................................................................................... 48 
Figure 2-3. Exacerbated liver injury is dependent on the intestinal microbiota. .......................... 50 
Figure 2-4. Il17rafl/fl x villin cre+ mice have an increased fecal bacterial burden, enriched with 
neomycin-sensitive, IgA-unbound bacteira. ................................................................................. 52 
Figure 2-5. Il17rafl/fl x villin cre+ mice do not have elevated serum or liver LPS. ....................... 54 
Figure 2-6. CpG DNA promotes fatal Con A hepatitis. ............................................................... 54 
Figure 2-7. Intestinal IL-17RA constrains TLR9-induced Type I immune responses in the liver.
....................................................................................................................................................... 58 
Figure 2-8. Cohousing eliminates differences in liver IFNγ between Il17rafl/fl x villin cre+ mice 
and floxed controls. ....................................................................................................................... 60 
Figure 2-9. CD4 and CD8 T cells comprise the majority of IFNγ+ cells following CpG DNA 
stimulation..................................................................................................................................... 62 
Figure 2-10. Intestinal IL-17RA constrains hepatic and intestinal IL-18. .................................... 64 
Figure 2-11. IFNγ blockade did not ameliorate hepatitis in Il17rafl/fl x villin cre+ mice. ............. 66 
Figure 2-12. Fasl is expresed by liver T cells, NK cells, and NKT cells. .................................... 67 
Figure 2-13. IL-18-induced Fasl exacerbates liver inflammation. ............................................... 68 
 xii 
Figure 2-14. Cohousing eliminated liver FasL differences between Il17rafl/fl x villin cre+ mice and 
floxed controls. ............................................................................................................................. 69 
Figure 2-15. Anti-IL18 mitigates liver injury in intestinal Il17RA deficient mice. ..................... 70 
Figure 2-16. Liver IL-17 is not increased in Il17rafl/fl x villin cre+ mice at the naïve state or 5h-post 
Con A. ........................................................................................................................................... 72 
Figure 2-17. Naïve Il17rafl/fl x villin cre+ mice do not exhibit baseline intestinal barrier defects. 74 
Figure 2-18. TLR9 ligands in Il17rafl/fl and Il17rafl/fl x villin cre+  liver homogenate are DNase-
resistant. ........................................................................................................................................ 75 
Figure 2-19. Excess intestinal IL-18 partnered with decreased systemic IL-18 control exacerbate 
hepatitis. ........................................................................................................................................ 76 
Figure 2-20. Liver mononuclear cells from naïve Il17rafl/fl x villin cre+ exhibit increased IFNγ upon 
ex vivo stimulation. ....................................................................................................................... 78 
Figure 2-21. Working Model ........................................................................................................ 80 
Figure 3-1. CNS Barriers .............................................................................................................. 89 
Figure 3-2 Disruption of enteric IL-17RA signaling exacerbates neuroinflammation. .............. 105 
Figure 3-3. Moderately exacerbated EAE in Il17rcfl/fl x villin cre+ mice is microbiome-dependent.
..................................................................................................................................................... 106 
Figure 3-4. Disease in Il17rafl/fl x villin cre+ mice is microbiome-dependent. ........................... 108 
Figure 3-5 Il17rafl/fl x villin cre+ mice exhibit increased splenic IL-17 responses and increased 
antigen-specific GM-CSF responses. .......................................................................................... 110 
Figure 3-6 Il17rafl/fl x villin cre+ disease exacerbation is IL-1β-independent. ............................ 112 
Figure 3-7 Il17rafl/fl x villin cre+ mice have increased intestinal Ccr2 and Ccr6 and spinal cord 
Nos2 prior to EAE onset. ............................................................................................................ 115 
 xiii 
Figure 3-8. Il22ra2-/- mice are protected from EAE. .................................................................. 119 
Figure 3-9. Terminal ileum tight junction protein gene expression at day 9 post EAE immunization.
..................................................................................................................................................... 123 
Figure 3-10. Working Model ...................................................................................................... 125 
 xiv 
Preface 
These past four years have undoubtedly been a trying but immensely rewarding journey. 
As the saying goes, it takes a village. Therefore, to start this dissertation, I first want to 
acknowledge all the individuals who brought me to where I am today.  
I would first like to thank my mentor, Dr. Jay Kolls for his guidance, support, and overall 
scientific brilliance that he has shared and offered to me throughout my PhD training. This 
partnered with our weekly in-depth discussions of the science and data allowed me to develop my 
skills as an independent researcher. Though I rarely vocalized this, I always counted it as a “win” 
when I came to the same experimental ideas and next steps as Dr. Kolls. While he would often 
come to these conclusions 1000x faster, I was gratified to know my scientific thinking was 
progressing toward that of a successful physician-scientist like himself. He has been a great role 
model for what a career as a successful physician-scientist can look like. Even through the move 
of the Kolls lab to Tulane, Dr. Kolls maintained his unwavering support and commitment to my 
training, and for all of this I am truly grateful.  
I would also like to thank my second mentor, Dr. Timothy Hand, who kindly adopted me 
into the Hand Lab for the past two years. My thesis work falls at the intersection of Th17 
immunology and the intestinal microbiome. As such, moving into the Hand Lab was a great fit. 
Dr. Hand’s expertise in the field, valuable mentorship advice, enthusiasm for the work, and daily 
support have greatly benefited my research and development as a young scientist. Therefore, far 
from being a detriment to my training, being in both the Kolls and Hand labs has afforded me the 
opportunity to learn from two outstanding mentors and learn in incredibly rich and welcoming 
laboratory environments.   
 xv 
I would like to acknowledge laboratory members of the Kolls and Hand labs as well. Dr. 
Taylor Eddens and Dr. Waleed Elsegeiny were former graduate students in the Kolls lab that were 
always willing to assist and answer the many questions I had as a new (and not so new) PhD 
student. I sincerely thank them for their patience and friendship. I would also like to thank Dr. 
Pawan Kumar, who helped develop the groundwork for the projects detailed within this 
dissertation, as well as Dr. Kong Chen and Dr. Giraldina Trevejo for their invaluable support in 
my training. A big thank you the other past and present members of the Kolls lab including Kara 
Kracinovski and William Horne who always offered a helping hand, and Alanna Wanek who 
contributed largely to the sequencing studies described in this work. To the members of the Hand 
Lab—Ansen Burr, Dr. Abby Overacre-Delgoffe, Dr. Kathy Gopalakrishna, Justin Tometich, and 
Dr. Amrita Bhattacharjee, thank you for warmly welcoming me into the lab with huge smiles and 
an equal if not greater passion for all things related to mouse stool. The lab environment fostered 
by these two groups over the years was indispensable to my scientific training, sanity, and overall 
joy throughout my PhD. 
In addition to the Kolls and Hand labs, I would like to thank the other members of my 
thesis committee—Dr. Jennifer Bomberger, Dr. Mandy McGeachy, and Dr. Anuradha Ray. Their 
insightful suggestions regarding my thesis work have advanced and shaped this dissertation 
immensely. Beyond that, all of them are models of successful women in science. In a field still 
predominantly male, I believe it is important for trainees to see individuals who look like them 
accomplish similar future goals. A big thank you to the neighboring labs in Rangos as well—the 
Campfield, Canna, and Poholek Labs, all of whom contributed to building an enriching lab 
environment. I would also like to thank the Pitt-CMU MSTP and Dr. Steinman for the ongoing 
support as well as giving me the privilege to pursue my MD/PhD at this institution. I would also 
 xvi 
like to acknowledge the Meyerhoff Program at the University of Maryland, Baltimore County, 
though which I attained the research experiences and encouragement that shaped my desire to 
pursue an MD/PhD.  
Last but definitely not least, I would like to thank all of my family and friends who were 
essential to my success. I would like to specifically acknowledge my parents, Antonio and Leila 
Castillo, for their constant love, support, and prayers throughout this journey. I would truly not be 
where I am today without the examples they set for me, the belief they have in my capabilities, 
and their constant encouragement to be better and seize the opportunities we came to the United 
States for. Finally, I would like to thank my husband, Kc dela Cruz. In the midst of all the 
uncertainty research brings and more broadly in this career path I have chosen, he has been a 
constant source of love, support, and laughs throughout these many years. I cannot express my 












Parts of this introduction have been adapted from the publication:  
Castillo, P. A. C., and T. W. Hand. 2018. A little fiber goes a long way. Immunity 48: 844–846. 
 
One of the underlying drivers of this work was the idea that the immunologic interaction 
between different organ systems and how this impacts health and disease is an understudied but 
critical avenue by which to advance science. As such, the projects detailed within this dissertation 
investigate the gut-liver and gut-central nervous system axes in the context of liver and neuro-
inflammation. This focus stemmed from the rapidly growing body of literature describing how the 
intestinal microbiome had implications beyond the gut. In addition, ongoing research in 
laboratories including the Kolls lab were showing that the intestinal microbiome actually had a 
reciprocal regulatory relationship with T helper 17 (Th17) cells, a subset of T helper cells 
implicated in a wide range of diseases. The synthesis of these findings led to the overarching 
hypothesis of this thesis—Disruption of intestinal Th17 signaling and subsequent effects on the 
microbiome contribute to extra-intestinal pathologies. 
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1.1 Intestinal Th17 Signaling 
1.1.1  Interleukin 17 (IL-17) and IL-17 Receptor 
IL-17 and IL-17 receptor A (IL-17RA) were first cloned over two decades ago by Rouvier 
et al. and Yao et al., respectively (1, 2). This ultimately led to the identification of a new class of 
T helper (Th) cells, Th17 cells, that was separate from the established Th1/Th2 lineages (3). 
Identification of Th17 cells as a distinct subset was prompted by the observation that the Th1/Th2 
dichotomy could not fully explain inconsistencies observed in some autoimmune and infectious 
pathologies (3).  Almost 10 years since the discovery of IL-17, data from multiple labs showed 
that specific cytokines including IL-23, TGFβ, IL-21, and IL-6 could promote Th17 differentiation 
(4–10). Concurrently, Th17 master transcription factor retinoic acid-related orphan receptor 
gamma T (Rorγt) was identified and found to be mediated by STAT3 (11–14). Since the initial 
discovery of the founding ligand: receptor relationship, five IL-17R family members (IL-17RA-
E) and six ligands (IL-17A-F) have been identified (15). The first ligand and receptor cloned, IL-
17A and IL-17RA, are the most well described and are a larger focus of these studies.  
IL-17RA is a type I transmembrane protein with a 293 amino acid extracellular domain, 
21 amino acid transmembrane domain, and a 525 amino acid cytoplasmic tail (2). It functions in 
multimeric complexes, such as a multimeric complex with IL-17RC and itself and a dimeric 
complex with IL-17RB or IL-17RD (15). It remains undetermined whether these receptors reside 
on the surface as monomers and form complexes in a ligand-dependent manner or if they reside 
on the surface as preformed complexes independent of ligand (15). IL-17RA is ubiquitously 
expressed in many tissues. mRNA expression was identified in the intestine, lung, spleen, and 
kidney (12). At the cellular level, expression was observed in leukocytes, epithelium, endothelium, 
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fibroblasts, and some myeloid cells (2, 12, 13). While Il17ra expression is observed in 
hematopoietic cells, most functional effects of IL-17A and IL-17F through IL-17RA have largely 
been documented in non-hematopoietic cells such as the epithelium (15, 16). This is indeed one 
reason why the following dissertation studies targeted IL-17R signaling specifically in the 
intestinal epithelium as a means to investigate role of IL-17R signaling in the intestine.  
IL-17A is a 155 amino acid, disulfide-linked homodimeric glycoprotein (2). It is capable 
of signaling through IL-17RA and IL-17RC as a homodimer or heterodimer with IL-17F, which 
shares over 40% homology with IL-17A (12, 15). However, the affinity of the IL-17A homodimer 
for the IL-17R receptor is greater than that of the IL-17A-F heterodimer or IL-17F homodimer 
(17). Similar to the receptor, Il17a is expressed by multiple cell types including T cells, NK cells, 
innate lymphoid cells, and lymphoid tissue inducer cells (15, 18).  
Activation of the IL-17R by IL-17 induces the NFκβ pathway and alternatively, the 
C/EBPβ and C/EBPδ pathways (16). Signaling results in transcriptional regulation, such as the 
induction of Lcn2 (19), and mRNA stability regulation as with Cxcl1 and Cxcl5 (20–22). As such, 
IL-17 signaling can result in a wide range of downstream inflammatory processes. With this in 
mind, the general consequences of IL-17 can largely be broken down into five categories: 1. 
Proinflammatory chemokine release (CXCL9, CXCL10, CCL2, CCL20), 2. Hematopoietic 
cytokine production (IL-6, TNF, G-CSF, GM-CSF, etc.), 3. Upregulation of acute phase response 
genes (Serum amyloid A, CRP, Lipocalin), 4. Induction of anti-microbial factors (Defensins, S100 
proteins, sIgA, etc.), and 5. Proliferation of epithelial and lymph node stromal cells (16, 23). As 
expected, these effects can have massive consequences on the immune system and therefore must 




Table 1-1. Experimental Assays Used to Measure Th17 Responses in Current Dissertation Studies 
RNA-based Assays Protein-based Assays 
Quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR) 
Enzyme-linked Immunosorbent Assay 
(ELISA) 
Single Cell RNA sequencing Luminex 
 Flow Cytometry 
 
 
There are a number of factors upstream of Th17 signaling that help regulate Th17 responses 
(18). For example, IL-27 has been shown to inhibit IL-17 release and protect against autoimmunity 
(24, 25). Conversely, IL-21 is a cytokine produced by Th17 cells that promotes Th17 generation 
in an autocrine fashion (6). IL-23 is required for maintenance of Th17 responses in vivo (26), but 
can also favor more pathogenic Th17 responses as described in the next section (27–29). 
1.1.2  Pathogenic and Non-Pathogenic Th17 Cells 
More recent work has suggested that Th17 cells can be subcategorized as pathogenic versus 
non-pathogenic based on cytokine production. While IL-17 is a hallmark cytokine of Th17 cells, 
these cells also secrete other cytokines such as IL-21, IL-22, IFNγ, and GM-CSF. The more 
“pathogenic” Th17 cells are characterized by their ability to double produce IL-17 and IFNγ or IL-
17 and GM-CSF (28). Different inflammatory milieus support the differentiation of pathogenic 





Table 1-2. Pathogenic & Non-Pathogenic Th17 Differentiation 
 Cytokines that promote 
differentiation of Th17 Cells 
Non-Pathogenic TGFβ1 and IL-6 
Pathogenic 
1. TGFβ1, IL-6, IL-23 
2. TGFβ3, IL-6 
3. IL-1β, IL-6, IL-23 
 
 
TGFβ1 and IL-6 together induce a non-pathogenic Th17 cell while three different 
combinations have been shown to induce pathogenic Th17 cells: [l] TGFβ1, IL-6, IL-23; [2] 
TGFβ3, IL-6; [3] IL-1β, IL-6, IL-23(30). These categories have been defined by in vivo functional 
studies where pathogenic Th17 cells were shown to exacerbate disease in the experimental 
autoimmune encephalomyelitis (EAE) model of MS (30). More specifically, adoptive transfer of 
naïve myelin oligodendrocyte glycoprotein-specific cells differentiated in the “pathogenic” 
conditions listed in Table 1-2 resulted in exacerbated disease as compared to disease induction by 
cells differentiated in non-pathogenic conditions (28). There are now ongoing studies in other 
diseases such as rheumatoid arthritis investigating the potential role of these “pathogenic” Th17 
cells (31). However, these studies are partially biased by the use of systems that are inherently 
self-reactive. If these cells bore an anti-pathogen specific TCR, it may be the case that 
“pathogenic” Th17 may be more effective in host defense.   
1.1.3  Th17 Cells and Maintenance of Intestinal Homeostasis 
It is important to note that while Th17 cells have been subcategorized as pathogenic and 
non-pathogenic, consequences of Th17 cell activation are contextual and can be detrimental or 
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beneficial depending on the circumstance. This is because Th17 cell signaling has a wide variety 
of immune consequences including neutrophil recruitment, chemokine release, and more. In the 
context of these studies, a major interest in its function lies in the role of Th17 cells in maintaining 
intestinal homeostasis.  
The intestine is a very complex dynamic environment that must be able to balance 
tolerogenic and inflammatory responses to an array of antigens, both external and otherwise. There 
is constant exposure to food antigens, external pathogens, and the intestinal microbiota, comprising 
of the more than 1014 microbes inhabiting the intestine (32). While the microbiome will be 
discussed in more detail later, it is important to note that the microbiota are key drivers of T cell 
development in the intestinal lamina propria. Indeed, germ-free mice exhibit decreased lamina 
propria lymphocytes (33). However, left uncontrolled, the microbiota can have detrimental effects. 
Therefore, the body has built a “mucosal firewall” to help regulate and contain the microbiota and 
aforementioned factors to promote intestinal homeostasis (Figure 1-1) (34). Evidence suggests that 
the most immunogenic bacteria are those that gain access to the epithelial layer (35). Indeed, 
known immunogenic bacteria segmented filamentous bacteria (Sfb) actually require adhesion to 
the intestinal epithelium to exert its effects (36). The mucosal firewall helps prevent access to the 
host through the physical intestinal epithelium as well as the overlying mucus layer, antimicrobial 
peptides, and secretory IgA (34). Actions of IL-17 and IL-22, another hallmark Th17 cytokine, on 
the intestinal epithelium contribute largely to these elements.  
IL-22 is an IL-10 family member produced by numerous cells types including T cells, NK 
cells, and ILCs (37). It signals through a dimeric receptor complex comprised of IL-22RA1 and 
IL-10R2 (38). While IL-22RA1 is localized on other cell types such as hepatocytes, within the  
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Figure 1-1. Intestinal Th17 Cells Contribute to the Mucosal Firewall. 
Intestinal T helper 17 (Th17) cells contribute to the mucosal firewall in multiple ways. Production of interleukin 17 
(IL-17) and binding of IL-17 to the IL-17 receptor (IL-17R) promote polymeric immunoglobulin receptor (pIgR) 
expression, which transports dimeric IgA from B cells across the intestinal epithelium to be secreted into the intestinal 
lumen as secretory IgA (sIgA). Interleukin 22 (IL-22), another hallmark Th17 cytokine, binds to the IL-22 receptor 
(IL-22R) on the intestinal epithelium to promote mucin production by goblet cells. In addition, both IL-17 and IL-22 
affect tight junction proteins between enterocytes and promote antimicrobial peptide release, specific examples 
including alpha defensins (α-defensins) and Regenerating islet-derived 3 gamma (Reg3γ), respectively. *Images 
adapted from Servier Medical Art by Servier. Original images are licensed under a Creative Commons Attribution 




intestine, the IL-22RA1 subunit is limited to the epithelial cells, restricting the consequences of 
enteric IL-22 signaling to the intestinal epithelium (39).  
There are data  in vivo and in vitro demonstrating that IL-17 and IL-22 regulate intestinal 
barrier integrity. IL-17 affects tight junction complexes between enterocytes through alterations of 
tight junction proteins such as occludens (40). Specifically, in a mouse model of acute intestinal 
injury, IL-17 from gamma delta T cells contributed to barrier integrity in an IL-23-independent 
manner (40). Conversely, IL-22 has been shown to alter intestinal permeability by promoting 
Claudin 2 expression in the intestinal epithelium through the JAK/STAT pathway (41). In vitro 
treatment of Caco2 cells with IL-22 in a transwell system reduced transepithelial resistance, 
suggesting that IL-22 enhances permeability of colonic epithelial cells (41). In addition to affecting 
tight junctions, there is also evidence in a mouse model of colitis showing that IL-22 enhances 
mucus production from goblet cells, thereby fortifying the mucus barrier above the enterocytes 
(42). Moreover, IL-22 supports intestinal epithelial stemness independent of Paneth cells to induce 
epithelial regeneration and maintain barrier integrity (43).  
Beyond the physical intestinal barrier, IL-17 and IL-22 induce strong antimicrobial peptide 
(AMP) responses. Antimicrobial peptides promote bacterial killing by both enzymatically and 
non-enzymatically targeting cell wall structures and synthesis, as well as assisting with detection 
and response by the immune system (44). Alpha defensins are a subset of AMPs expressed by 
small intestinal Paneth cells (44). In mice, they are produced as pro-alpha defensins and stored in 
intracellular secretory granules where they are cleaved to active alpha-defensins exclusively by 
matrix metalloproteinase 7 (45). Following exocytosis, alpha-defensins target the bacterial 
membrane and are critical in maintaining the intestinal microbiota and protecting against bacterial 
invasion (44). For example, transgenic mice expressing human alpha defensin 5 exhibit baseline 
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changes in the composition of the intestinal microbiota and are protected against oral Salmonella 
infection (46, 47). Kumar et al. showed that global knockout of IL-17A and global or intestinal-
specific knockout of IL-17RA dramatically decreased alpha defensins in the intestine (48), 
suggesting that IL-17 regulates intestinal AMPs. Regenerating islet-derived 3 gamma (Reg3γ), 
another type of intestinal AMP, is a soluble lectin induced by IL-22 (49, 50). Colonization of 
bacteria into germ-free mice actually induced secretion of Reg3γ into the intestinal lumen where 
it bound gram-positive bacteria, demonstrating a regulatory relationship between bacteria and host 
(51). This relationship has implications beyond the intestine as well; McAleer et al. showed that 
oral supplementation of  Reg3γ in Il22-/- mice protected them from pulmonary inflammation 
induced by Aspergillus fumigatus (52).  
Along with AMPs, immunoglobulin A (IgA) plays a large role in regulating the intestinal 
microbiota. IgA is secreted into the intestinal lumen through the polymeric immunoglobulin 
receptor (pIgR) (53). More specifically, dimeric IgA from plasma cells is transported across 
intestinal epithelial cells through pIgR. Cleavage of pIgR near the apical membrane releases both 
the secretory component of pIgR and the bound dimeric IgA into the lumen, together forming 
secretory IgA (sIgA) (53). pIgR is upregulated by Th17 cells in vivo (54). Indeed, both global and 
intestinal-specific knockout of IL-17R resulted in decreased levels of intestinal pIgR and sIgA (48, 
54). Moreover, both IgA deficient mice and pIgR knockout mice exhibited an altered commensal 
microbiome (55, 56). These data suggest that IL-17 also regulates the intestinal microbiome 
through its role in pIgR expression and sIgA release.  
Taken together, these studies demonstrate that intestinal homeostasis is maintained in large 
part by Th17 hallmark cytokines that reinforce the mucosal firewall. Given this role, it is not 
surprising that Th17 cell signaling is predominantly involved in constraining microbes residing 
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close to the intestinal epithelium, thus playing a prominent role in regulating the intestinal 
microbiome. 
1.2 Intestinal Microbiome 
As previously mentioned, there are over 1014 bacteria residing in the intestine, with 
increasing bacterial concentrations from the duodenum to the colon (32). The outdated view of the 
intestinal microbiota was that there were pathogenic and nonpathogenic bacteria. While there are 
indeed certain pathogens whose presence in the intestine will undoubtedly cause illness, the 
understanding of the field has moved from a dichotomy of “good versus bad” bacteria to the idea 
that a “healthy” microbiota is more about balance. Indeed, bacterial diversity indices are common 
descriptive measures used in microbiome studies with increased diversity often, but not always, 
correlating with health (57–59). More research is also emerging detailing regulatory mechanisms 
between the host and microbiome. For example, Sfb induces Th17 cells, which then work to 
constrain the Sfb population (36, 48, 60). In these ways, balance in terms of both the composition 
of the microbiota and in host-microbiome interactions is required to maintain intestinal 
homeostasis. 
1.2.1  Immunogenic Commensal Bacteria 
There are multiple commensals identified that induce intestinal immune responses. For 
example, Clostridia spp. and  Bacteroides fragilis have been shown to promote colonic Treg 
responses (61–64), and Sfb induces small intestinal Th17 responses (48, 60). The resulting effects 
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of a particular bacterium, however, are often contextual, not only in terms how its immune 
consequences align with the current health/disease state, but there is also emerging evidence that 
the immune sequelae of a specific bacterium may actually differ depending on the environment it 
is in. To illustrate the first point, Sfb colonization of the intestine and subsequent enteric Th17 
responses (60) were detrimental in neuroinflammation during EAE (48) but associated with 
protection against spontaneous diabetes in nonobese mice (65). Toward the second point, there is 
literature showing that Helicobacter hepaticus induces strong Th1-Th17 responses in an Il10-/- 
model of colitis, but induces T regulatory responses during colitis in IL-10 sufficient mice (66). In 
addition, the commensal Akkermansia muciniphila induced T follicular helper responses in mice 
with an altered Schaedler flora and a complex microbiota, but only induced proinflammatory T 
effector responses in the latter environment (67). Together, these data illustrate how immune and 
bacterial signals present in the gut can dictate the resulting responses to bacteria.  
1.2.2  Bacterial Mechanisms to Influence Host Immune Responses 
Bacteria exert their effects on the host through direct and indirect mechanisms. As 
mentioned above, many known immunogenic bacteria are located close or adhere to the intestinal 
epithelium. In addition to Sfb, Citrobacter rodentium and Escherichia coli O157 are examples of 
microbes that require adhesion to trigger Th17 immune responses. Atarashi et al. showed that these 
bacteria adhere to the intestinal epithelium and induce immune responses, whereas mutants lacking 
the ability to adhere could not induce enteric Th17 responses (36). Direct access to the intestinal 
epithelium allows the bacteria to prompt inflammation through utilization of their own virulence 
factors such as the type three secretion system in Salmonella (68), or via pattern recognition 
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receptor signaling pathways including those of toll like receptors (TLRs) and the NOD-like 
receptors (NLRs) (69).  
Pattern recognition receptors can also be engaged more distantly from the bacteria due to 
release of bacterial products such as lipopolysaccharide (LPS) and unmethylated CpG DNA. These 
products are released during normal bacterial growth, division, and lysis (70, 71). These and other 
inflammatory mediators can also be released via extracellular vesicles. For example, outer 
membrane vesicles (OMVs) are a type of bacterial extracellular vesicle produced by gram-negative 
bacteria through the budding of the bacterial outer membrane along with periplasmic content (72). 
Bacterial OMVs can carry cargo from the bacteria to more distant sites in the body (72). Data has 
shown that there are not only differences in the types of cargo encased in these vesicles, but that 
selection of the cargo is a regulated process (72). As such, OMVs from one bacterium do not 
necessarily exert the same effects as that of another bacterium. For example, OMVs isolated from 
Akkermansia muciniphila, but not E. coli, increased intestinal barrier integrity in Caco2 cells (73). 
Differential effects in bacterial OMVs have been documented in disease as well—OMVs from B. 
fragilis were protective in experimental colitis (74), while OMVs from B. theta were detrimental 
(75). 
Another major mechanism through which bacteria indirectly affect host health and disease 
is bacterial metabolites. Research over the past decade has shown that short-chain fatty acids 
(SCFAs) derived from bacterial fermentation of dietary fiber have anti-inflammatory properties 
(76, 77). Three prominent examples of these SCFAs are acetate, propionate, and butyrate (76). 
These compounds exert their effects through multiple mechanisms, including the binding of G-
coupled Protein receptors, inhibition of Histone deacetylases, and effects on cell metabolism (78). 
SCFAs are capable of signaling to a variety of immune cells including T cells, neutrophils, and 
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macrophages. For example, butyrate has been shown to induce colonic Tregs (79). There are also 
data showing that a high fiber diet and subsequent SCFAs increased CD8+ T cell effector function 
and altered bone marrow hematopoiesis to increase the differentiation of Ly6Cneg patrolling 
monocytes and alternatively activated macrophages (80–82). In addition, SCFAs have been 
associated with a reduction in neutrophil and macrophage activation (76, 78). Interestingly, 
ingestion of dietary fiber also influences bacterial composition and how bacteria can affect health 
and disease. Data has shown that a fiber-deficient diet caused bacteria within the colon to feed on 
the mucus glycoproteins as opposed to the nutrients normally attained from dietary fiber (83). As 
a result, the protective mucus layer was degraded. This changed the bacterial environment and 
indeed altered the composition of the intestinal microbiota to favor mucophilic bacteria (83). It 
also provided greater access to the intestinal epithelium, affording commensal bacteria and 
invading pathogens an additional opportunity by which to directly interact with the host and induce 
immune responses.   
Bile acid metabolism is another arena where bacteria influences human health. Bile acids, 
which are required for lipid metabolism, are made in the liver and stored in the gallbladder. 
Consuming food triggers the release of bile through the bile ducts into the duodenum where it 
facilitates breakdown of lipids. Most bile acids are then recycled back up and stored in the 
gallbladder (84, 85). Bile acids not reabsorbed are metabolized from primary bile acids to 
secondary bile acids by specific intestinal bacteria able to facilitate this conversion (86, 87). This 
switch in bile acid structure allows secondary bile acids to passively diffuse through the colon to 
re-enter the enterohepatic circulation. In addition, secondary bile acids can also affect host 
metabolism though various signaling pathways including through the Farnesoid-X-Receptor 
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(FXR) and TGR5 bile-acid responsive receptors (85, 87, 88). In this way, bile acid metabolism 
allows the intestinal microbiota to indirectly influence host health and metabolism (87).  
As with other aspects of the microbiota previously discussed, there is a host to microbiome 
regulation in bile acid metabolism as well. Changes in bile acid type and amount can favor certain 
bacterial species over others, altering the composition of the intestinal microbiota (87). For 
example, there is evidence that deoxycholate, a bacterial-derived metabolite of bile, promotes 
germination of C. difficile spores (89). Considering the bidirectionality of this and many other 
host-microbiome interactions, disruption of either can often lead to disease.  
 
Table 1-3. Experimental Assays Used to Assess the Microbiome in Current Dissertation Studies 
Assay: Utility in Current Studies: 
Quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR) 
To measure bacterial DNA signal in intestinal 
content and tissues 
16S rRNA Sequencing To describe the relative abundances of 
bacterial communities in a given sample 
Bacterial Culture To assess live bacteria in organs 
Flow Cytometry  To quantify fecal bacterial burden  
Mouse Toll Like Receptor (TLR) Reporter 
Cell Lines 
To quantify the amount of TLR ligands in a 
given biological sample 
1.3 Disruption of Th17 Signaling & the Intestinal Microbiome In Disease 
1.3.1  Intestinal Diseases 
Th17 signaling and the microbiome play an extensive role in intestinal homeostasis. As 
such, perturbations in these factors have been documented in many diseases. In the intestine, these 
factors have been implicated separately in diseases such as inflammatory bowel disease (IBD) and 
colon cancer. In IBD patients, there was an increase in Th17 cells within inflamed tissue biopsies 
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(90). In mouse models of IBD, IL-21 or IL-23 deficiency was protective, though IL-17A deficiency 
was not (90). In models of colorectal cancer (CRC), IL-17 promoted tumor progression, and in 
CRC patients, increased Il17a expression was associated with worse disease outcomes (90). Data 
in CRC also implicates the “Pathogenic” Th17 cell co-expressing IFNγ and IL-17A (91). The 
microbiome composition is also altered in both of these diseases (92, 93). Mouse models supported 
the role of the microbiome in disease pathogenesis as germ free mice were highly susceptible to 
the DSS-colitis model of IBD (94), but were protected in a colitis-associated CRC model (95). 
These are only two examples of how Th17 cells and the intestinal microbiome have been 
implicated in intestinal pathology. Yet within these two examples alone, the contrasting effects of 
IL-17 and the microbiome illustrate the complexity of these two components in disease and further 
reaffirm the contextual nature of their consequences.  
1.3.2  Extra-Intestinal Diseases 
Beyond the intestine, Th17 cells have been linked to a wide range of diseases throughout 
the body. More recently, the microbiome has been associated with extra-intestinal pathologies as 
well. What is especially interesting in the context of these dissertation studies are that many of 
these extra-intestinal diseases that the microbiome has been implicated in have a previously 
described Th17-related component. This ranges from barrier and non-barrier tissues anatomically 
close to the intestine, such as liver and pancreas, to the lung, and even further to immunoprivileged 




Figure 1-2. Diseases w/ Evidence Implicating Th17 cells & the Intestinal Micrbiome  
*Images adapted from Servier Medical Art by Servier. Original images are licensed under a Creative Commons 
Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/legalcode). 
 
 
Within the abdominal cavity, there have been links to both the pancreas and liver. In the 
pancreas, Zhao et al (2018) integrated human and mouse studies to show that a high fiber diet 
(HFD) selectively caused an increase in SCFA-producing bacteria that were associated with a 
significant reduction in symptoms associated with Type 2 Diabetes (T2D), a disease linked to Th17 
cells and Th17/Treg imbalance (96, 97). In a study by Zhao et al., patients with T2D were treated 
with standard of care therapies supplemented with a regulated HFD and an inhibitor to increase 
the bioavailability of fermentable fiber to intestinal bacteria. These additional interventions 
improved clinical outcomes as measured by hemoglobin A1c and glucose tolerance tests. To 
determine the contribution of the microbiota in their results, fecal transplant from patients into 
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germ-free mice showed that mice receiving stool from HFD patients demonstrated the best 
metabolic outcomes (59). This suggested that the microbiota was the primary mediator of the effect 
of HFD, and that a patient’s microbiota can be manipulated via dietary changes to improve 
metabolic health.   
In the liver, there have been links to non-alcoholic fatty liver disease (NAFLD), alcoholic 
hepatitis, autoimmune hepatitis, hepatocellular carcinoma, and more (98, 99). In NAFLD, which 
includes nonalcoholic fatty liver that can progress to nonalcoholic steatohepatitis, patients 
exhibited increased hepatic Il17 expression and increased Th17 cells in peripheral blood (100). In 
addition, studies showed disease progression in humans was associated with increased hepatic IL-
17-producing CD4+ lymphocytes (101). In mice, Henao-Mejia et al. showed that alterations in the 
inflammasome prompted changes in the composition of the intestinal microbiome, consequently 
exacerbating NAFLD (102). In viral and autoimmune hepatitis, patients exhibited intestinal 
dysbiosis (103, 104) and increased serum IL-17 (105–107). In some mouse models of these 
diseases, manipulation of the microbiome through antibiotics ameliorated liver inflammation 
(108).  Finally, in hepatocellular carcinoma (HCC), the intestinal microbiota and TLR4 signaling 
were required for disease progression in mice (109), which aligned with the increases in bacterial 
translocation seen in patients (110).  
Moving further to the thoracic cavity, Th17 cells and the microbiome have been linked 
lung pathology in asthma, influenza, and fungal infections. In a mouse model of asthma, two 
studies showed that dietary fiber and subsequent bacterial-derived SCFAs decreased disease 
severity by altering macrophage, T cell, and dendritic cell activation (82, 111). In patients, studies 
described a dysbiotic microbiota in both children diagnosed with asthma and at risk for asthma 
(112). Both mouse and patient data have implicated Th17 cells in the pathogenesis of steroid-
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resistant asthma as well (113–115). More specifically, in an adoptive transfer model of allergic 
airway inflammation, steroid treatment was able to ameliorate both inflammation and airway 
hyperresponsiveness during adoptive transfer of Th2-polarized cells but not of Th17-polarized 
cells (116). In humans, increased IL-17 responses were observed from PBMCS of patients with 
steroid-resistant asthma as compared to PMBCs from patients with steroid-sensitive asthma (113, 
115). With regards to infectious agents, there is data suggesting that IL-17RA mediates 
immunopathology during influenza (117). Microbiome involvement in influenza infection has 
been described as well. Marsland and colleagues found that dietary fiber and bacterial-derived 
SCFAs decreased immunopathology and mortality associated with influenza A viral infection by 
increasing CD8+ T cell effector function and altering bone marrow hematopoiesis to increase the 
differentiation of Ly6Cneg patrolling monocytes and alternatively activated macrophages (82). In 
fungal infection, a study by McAleer et al. examined how intestinal Th17 cells and the microbiome 
contributed to pulmonary Aspergillus fumigatus infection. They found that protection against this 
fungal pathogen was dependent on the AMP Reg3γ and Sfb, both factors intimately involved in 
intestinal Th17 cell signaling (52).  
Finally, moving even more distally from the intestine, there are data linking Th17 cells and 
the intestinal microbiome to pathologies in immune privileged sites such as the eye and the central 
nervous system (CNS). In patients with acute uveitis associated with Vogt–Koyanagi–Harada 
(VKH) disease, there were increased serum IL-23 and elevated IL-17 production from stimulated 
PBMCs (118). In a mouse model of experimental autoimmune uveitis (EAU), neutralization of IL-
17 was protective (119, 120). Interestingly, Caspi and colleagues demonstrated that the 
autoreactive T cells responsible for ocular pathology in EAU were actually primed in the intestine 
by commensal antigens, migrated to the eye via the systemic circulation, and cross-reacted with 
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ocular antigens (121, 122). This proposes molecular mimicry as another mechanism by which the 
microbiota can influence disease. As further evidence of the role of the microbiome in autoimmune 
uveitis, treatment with broad-spectrum antibiotics or germ-free rederivation of a spontaneous 
autoimmune uveitis mouse strain ameliorated disease (122).  
In addition to the eye, the central nervous system is another immune privileged site in 
which Th17 cells and the intestinal microbiome have been implicated. Numerous studies have 
described the role of Th17 cells in multiple sclerosis (MS). There are increased levels of IL-17 in 
MS patient serum and CNS lesions (123, 124), and in mice blocking IL-17 globally via neutralizing 
antibodies or genetic knockout ameliorated EAE (125, 126). As further support, neuronal protease 
BACE1 promoted IL-17 production and increased EAE susceptibility (127). Patients with MS also 
exhibit commensal dysbiosis (128). Fecal transplant from MS patients into germ-free mice resulted 
in decreased Tregs and exacerbated EAE as compared to mice receiving normal control feces, 
together suggesting a role for the microbiome in disease severity (129).  
Though Th17 cells and the microbiome have individually been implicated in these diseases, 
few studies have investigated how the extensive relationship between the two contribute to 
pathologies. Thus, the focus of the following chapters will be on investigating this Th17 cell-
microbiome relationship in the context of extra-intestinal diseases, beginning with the gut-liver 
axis, then moving more distally to the gut-brain axis. A more in-depth review of the literature 
specific to those organ systems will be discussed in the respective chapters.  
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2.0 Gut-Liver Axis: Intestinal IL-17R signaling constrains IL-18 driven liver inflammation 
by the regulation of microbiome-derived products 
2.1 Introduction 
2.1.1  Liver Anatomy and Physiology 
The liver is a unique organ in terms of its intimate association with the intestine. To 
appreciate this link, it is important to understand the basic liver anatomy and physiology that 
connect these two organ systems. 
2.1.1.1 Structure and Blood Supply 
The liver is located in the upper right quadrant of the abdominal cavity (Figure 2-1A). The 
human liver typically has four lobes which are comprised of the basic liver structural unit, the 
hepatic lobule (Figure 2-1B). Each lobule has a central vein, which drains blood from the liver and 
empties it into the hepatic vein to the inferior vena cava and heart. Emanating from the central vein 
are specialized capillaries called the liver sinusoids. Surrounding the sinusoids are the hepatocytes, 
which make up most of the cellular density of the liver, and other cell types that reside within the 
liver parenchyma and vasculature. This includes the liver sinusoidal endothelial cells and Kupffer 
cells, specialized macrophages of the liver. These sinusoids connect to the portal triad, which 
includes three components: 1. Bile duct, 2. Hepatic artery, and 3. Portal vein (Figure 2-1C). The 
bile duct connects the liver to the gallbladder nested at the inferior part of the liver, which stores 
the bile produced by the liver. The hepatic artery is a branch of the descending aorta that supplies  
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Figure 2-1. Liver Anatomy 
(A) The liver is located in the upper right quadrant of the abdominal cavity. The hepatic portal circulation drains the 
spleen, pancreas, and gastrointestinal tract from the lower esophagus to the upper anal canal, thereby connecting other 
organs in the abdominal cavity to the liver. (B) Structure of the liver lobule—The hepatic lobule is the basic liver 
structural unit. Each lobule has a central vein, which drains into the hepatic vein, to the inferior vena cava, and then 
to the heart. Emanating from the central vein are specialized capillaries called the liver sinusoids. Surrounding the 
sinusoids are the hepatocytes and other cell types that reside within the liver parenchyma and vasculature. This 
includes Kupffer cells, specialized liver macrophages. The liver sinusoids connect the central vein to the portal triad—
the bile duct, hepatic artery, and portal vein. (C) Inputs and outputs of liver as indicated by arrow direction—Inputs: 
the hepatic artery (25% percent of the liver blood supply); hepatic portal vein (~75% percent of the liver blood supply). 
Outputs: The hepatic vein (drains the central veins of each liver lobule); the common bile duct (releases the bile made 




oxygenated blood to the liver parenchyma via the sinusoids. The hepatic artery supplies about 25% 
of the hepatic blood supply. The remaining 75% comes from the hepatic portal vein which brings 
both nutrients and deoxygenated blood to the liver. This structure creates a dynamic interface at 
the liver lobule that’s a mixture of products derived from hepatic cells, oxygenated blood, 
deoxygenated blood, and the nutrients and other products entering the liver through the portal vein. 
(88, 130, 131) 
2.1.1.2 Hepatic Portal System 
The portal vein is part of the hepatic portal system. A portal system differs from the 
traditional route of circulation in which oxygenated blood from the heart flows through arteries, 
arterial capillary beds, and then to the target organ. In this traditional circuit, the target tissue then 
utilizes the oxygen and nutrients from the arterial blood, and venous capillaries drain the 
deoxygenated blood from the tissue. This blood is transported to veins draining into the vena cava 
and then to the heart for reoxygenation and redistribution. In a portal system, the tissue-draining 
venous capillaries empty that blood into another venous capillary bed.  In the case of the hepatic 
portal system, the receiving venous capillary bed drains into the hepatic portal vein and into the 
liver. In doing so, there is a direct connection from organ to organ without going through the heart. 
The hepatic portal vein drains the spleen, pancreas, and gastrointestinal tract from the lower 
esophagus to the upper anal canal (Figure 2-1A). As such, there is a direct mode of transportation 




The extensive connections between the liver and other organ systems facilitate the liver’s 
many functions in the body. All of the blood, nutrients, and products the liver receives through the 
portal and arterial inputs are filtered through the liver and also act as starting blocks for some of 
its functions. Examples include amino acid and protein synthesis. The liver is responsible for 
producing carrier proteins such as albumin and transferrin as well as numerous proteins involved 
in immune responses including opsonins, complement, and serum amyloid proteins. The liver is 
also heavily involved in carbohydrate metabolism, regulating both glucose storage and synthesis, 
and lipid metabolism due its role in bile acid metabolism. As mentioned above, the liver produces 
bile, which is stored in the gallbladder. Bile is released into the intestinal lumen via the common 
bile duct post-prandially to promote fat emulsification and digestion. The intestinal microbiome 
contributes to this process by metabolizing primary bile acids into secondary bile acids, which 
facilitate bile acid reabsorption into the hepatic portal system for  recycling and future use. This 
circuit is termed the enterohepatic circulation and offers another line of communication from the 
gut to the liver. Another major function of the liver is detoxification. Many drugs in the blood 
stream are metabolized in the liver and filtered out from systemic circulation by the prominent 
liver macrophage population. With regards to this dissertation, the most relevant aspect of the liver 
in terms of its function as gatekeeper to the rest of the body is its ability to filter out bacteria and 
bacterial products coming from the arterial and venous inputs. Research performed as early as the 
1920s showed that the liver was very effective in bacterial clearance from the vasculature (132). 
In these studies, a known concentration of bacteria was perfused into the liver and other organs. 
Bacterial concentration of the output was measured as an indicator of the efficacy of bacterial 
clearance. Indeed, the liver was the most efficient as compared to spleen, brain, lung, and intestine 
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(132). These results reflect the requirement and capability of the liver to manage the high exposure 
to intestinal-derived components whether it be cytokines, cells, microbes, or bacterial products. 
The mechanisms by which the liver manages this interaction with the intestine are described in 
more detail in the next section.    
2.1.2  Hepatic Response to Intestinal-Derived Factors 
2.1.2.1 Initial Cell Responders at the Liver Sinusoids 
Numerous cell types contribute to liver management and response to intestinal-derived 
products. At the interface of the liver and the incoming vascular supply are liver sinusoidal 
endothelial cells (LSECS), hepatic stellate cells (HSCs), and Kupffer cells (KCs). 
LSECS and HSCs are two types of hepatic stromal cells. Because of their location, these 
cells are highly exposed to the incoming components from portal and arterial supplies. The LSECs 
line the liver sinusoids to form a fenestrated endothelium which is unique in that it also lacks a 
basement membrane (88). Together, this allows for increased hepatic access of blood-borne factors 
including bacteria, bacterial products, proteins, lipids, and other nutrient and macromolecule 
transport (133). This fenestration is critical for the liver to effectively receive these substances for 
metabolism, detoxification, and hepatocyte maintenance. Indeed, this fenestrated structure is 
eliminated during some liver diseases, depriving the liver of necessary nutrients and allowing 
access of potentially harmful substances to the systemic circulation (133). HSCs are vitamin A-
rich pericytes that reside in the space of Disse between the endothelial layer and hepatocytes. They 
comprise close to 10% of resident liver cells and remain largely quiescent, but can be activated 
and transdifferentiate into collagen-producing myofibroblasts with diverse immune consequences 
(134, 135).  
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Both LSECs and HSCs play a role in innate and adaptive immunity. LSECs and HSCs 
express toll like receptors (TLRs) and scavenger receptors, allowing them to filter and respond to 
incoming pathogen- and danger-associated molecular patterns (133, 136). The enrichment of 
scavenger receptors such as mannose receptor afford LSECs a high endocytic capacity (133), 
which has been shown to be critical in blood-borne pathogen clearance (137). In activated HSCs, 
TLR9 activation promoted chemokine release and Kupffer cell chemotaxis (138), while TLR3 
activation enhanced γδ T cell-derived IL-17A (134). With regards to adaptive immunity, LSECs 
are able to present antigens to CD8+ T cells and CD4+ T cells through MHC I and MHC II, 
respectively (139, 140). Similarly, HSCs can act as antigen presenting cells, especially to invariant 
NKT cells via CD1d (141, 142). Both stromal cell types largely produce more anti-inflammatory 
responses. This includes production of IL-10, PD-1, and TGFβ that favor T regulatory cells and 
more tolerogenic responses (88). When considering the volume and diversity of potentially 
inflammatory agents these cells are be exposed too, it is appropriate that part of their role is limiting 
the overactivation of T cell responses to these substances.  
The Kupffer cell (KC) is the third cell type mentioned that resides at the liver sinusoids. 
KCs are specialized liver-resident macrophages, which comprise the largest macrophage 
population in the body (88). They are developmentally distinct from monocyte-derived 
macrophages, because of their origin from fetal liver-derived progenitor cells (143).  These cells 
take up a larger role in surveillance compared to the migratory infiltrating monocyte-derived 
macrophages. Because of the high demand of immune surveillance in the liver, it is perhaps not 
surprising that for every 100 hepatocytes, there are 20-40 macrophages (143). To facilitate their 
role in immune surveillance, KCs express TLRs, scavenger receptors, and Fc receptors like LSECs 
(143). High expression of these receptors partnered with their extremely high phagocytic activity 
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allow KCs to fulfill their critical role in eliminating bacteria and bacterial products coming from 
the intestine. To promote bacterial clearance, KCs coordinate with LSECs, platelets, and other 
cells to promote bacterial phagocytosis, lysis, and other bactericidal consequences (143). 
Importantly, these cells also act as antigen presenting cells, expressing MHC II (140, 142). They 
can activate NKT cells as well through CD1-mediated antigen presentation (142). Furthermore, 
they secrete various immune mediators including cytokines and reactive oxygen species (142). 
Therefore, the effects of KCs encompass both the regulation of incoming bacterial products as well 
as the interactions with other hepatic and circulating lymphocytes. 
Because LSECs, HSCs, and KCs reside at the interface of the liver and intestinal vascular 
supply, they can induce many different effects depending on the incoming products, cells, and 
other immunogenic components. In the context of these dissertation studies, we focused on the 
effects of bacterial translocation from the intestine to the liver. 
2.1.2.2 Effects of Bacterial Translocation 
Translocation of bacteria and bacterial products to the liver can have a wide range of 
consequences. This section will broadly focus on three effects that are pertinent to these 
dissertation studies: immune cell recruitment, immune cell activation, and activation of death 
receptors.  
Immune Cell Recruitment 
As mentioned above, engagement of TLRs on these cells at the forefront of the gut-liver 
interface can prompt chemokine release and immune cell recruitment. Though they largely 
promote a tolerogenic environment to quell aberrant immune activation and maintain homeostasis, 
liver pathology and inciting stimuli can prompt these cells to contribute to a proinflammatory 
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environment.  For example, while Kupffer cells are not a migratory macrophage population, they 
have the capacity to heavily recruit inflammatory monocytes. There are data showing that TLR4 
activation by LPS can induce CCL2 secretion (144), which can promote recruitment of CCR2+ 
monocytes to the liver. Changes in adhesion molecules such as selectins on LSECs in response to 
bacterial products can promote T cell arrest and recruitment from the circulation (145, 146). In 
addition, TLR9 activation in a mouse model of hepatitis promoted recruitment of NKT cells from 
the periphery (147). Beyond these examples, there are also the various cytokines induced in 
response to bacterial products that can trigger chemokine release and further leukocyte 
recruitment.  
Immune Cell Activation 
As eluded to above, bacterial translocation can also activate other immune cells including 
T cells, NKT cells, and NK cells.  
Because CD4+ and CD8+ T cells express TLRs only at low levels, their activation by 
bacterial translocation is often mediated by other cell types. As mentioned above, KCs and LSECs 
can act as antigen presenting cells to circulating T cells. The liver is unique compared to other 
solid organs due to its capability to activate naïve T cells independent of lymphoid tissues (139, 
148, 149). This is facilitated by the structure and organization of the liver which allows high 
exposure to antigen and circulating naïve T cells in the liver sinusoids. There is also evidence of 
tissue resident memory T cells that patrol the liver sinusoids (150), which can be activated when 
exposed to cognate antigen from the incoming vascular supply. In addition to this, T cells can be 
activated in a bystander fashion through the cytokine milieu produced by KCs, LSECs, and HSCs. 
NKT cells make up a large portion of the resident liver cell population. In mice, this can 
be up to 30% of the liver T lymphocytes (151). As such, these cells play large role in maintaining 
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liver homeostasis. Of note, the majority of liver NKT cells in mice are invariant NKTs (iNKTs). 
These cells specifically express Vα14-Jα18 with restricted variations in beta chains (88). iNKTs 
mount strong immune responses to sphingolipids found on and released by bacteria including those 
of the intestinal microbiome. Certain bacteria such that those in the Phylum Bacteroidetes are 
known highly produce these compounds (152). The stimulatory capacity of sphingolipids on 
iNKTs has been shown many times by administration of synthetic sphingolipid, α-
galactosylceramide (α-GalCer). Indeed, treating mice with α-GalCer in vivo results in massive 
activation and cytokine responses by iNKTs, leading to fatal hepatitis (153). This further 
demonstrates that specific bacterial-derived products can have huge immune consequences in the 
liver. However, there is a caveat with this example in terms of human translatability. The human 
counterpart to iNKTs, which express Vα24-Jα18 as opposed to Vα14-Jα18 are a much smaller 
population in the human liver (151). Therefore, the magnitude of the effects seen in mice as a result 
of iNKTs may not parallel effects in humans.  
 NK cells make up about 5-10% of hepatic lymphocytes in mice and about 20-30% in 
humans (151). Liver NK cells differ from peripheral NK cells in their enhanced cytotoxic 
capabilities. There is evidence showing that liver NK cells exhibit higher amounts of TRAIL, 
IFNγ, perforin, and granzyme B (151). NK cells release these inflammatory mediators in response 
to bacterial products including LPS and TLR3 agonist Poly I:C (151, 154, 155). Bacterial 
translocation can also indirectly activate NK cells through Kupffer cells. Indeed, Kupffer cell 
depletion decreased the liver NK population, and stimulation of NK cells with Kupffer cell-
conditioned media in vitro enhanced NK cell activation and toxicity (156).  
Speaking more broadly than specific cell types, bacterial products can also activate cells 
via the inflammasome (157, 158), resulting in release of IL-1β and IL-18 (159). For example, 
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bacterial stimulation of KCs induced inflammasome activation, most notably though NLRP3 
(143). Both IL-1β and IL-18 have a wide range of immunoregulatory effects. Due to its role in 
these gut-liver dissertation studies, the focus will be on IL-18. IL-18 is an IL-1 family member 
produced by macrophages, dendritic cells, and some epithelial cells (160). In the liver, KCs are a 
major source of IL-18. Of note, there is evidence showing that IL-22 can induce IL-18 expression 
by the intestinal epithelium (161). IL-18 binds to a dimeric receptor comprised of IL-18Rα, which 
is relatively ubiquitous, and IL-18Rβ, which is largely on T cells and DCs (160). IL-18 has 
numerous immunoregulatory functions and is therefore highly regulated though IL-18 binding 
protein (IL-18BP). Indeed, there are high amounts of serum  IL-18BP to limit aberrant responses 
(160). Demonstrating the critical role of IL-18BP in health and disease, genetic IL-18BP 
deficiency in patients has been shown to increase susceptibility to viral-mediated fulminant 
hepatitis (162). While IL-18 was first described as an IFNγ inducing factor (163), numerous reports 
have detailed its effects on lymphocyte activation, chemokine release, and cell death, which is 
discussed in more detail below (163–173).  
Death Receptors 
A downstream consequence of bacterial translocation to the liver is activation of death 
receptors. Death receptors are members of the TNF superfamily of receptors that promote cell 
death upon binding of its cognate ligand (174). Notable examples include Fas, TNF receptors 1 
(TNFR1) and 2 (TNFR2), and TNF-related apoptosis inducing ligand receptor (TRAILR) 1 
through 4. The liver is rich in death receptors (174), and therefore very susceptible to death 
receptor-mediated cell death. Indeed, injection of anti-Fas antibody to crosslink and activate Fas 
caused hepatocyte cell death and lethal hepatitis in mice (175). Engagement of these death 
receptors promotes cell death through different signaling cascades.  A key part of many of these 
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signaling cascades is the death domain, which is a 60-80 amino acid cytoplasmic domain that 
recruits the subsequent adaptor molecules required for the signaling cascade (174). Using Fas-
FasL as an example, binding of cognate ligand FasL to Fas recruits the adaptor protein Fas-
associated protein with death domain (FADD) to its death domain. Resulting signaling cascades 
then go through different caspases, ultimately converging at caspase 3 to induce cell death (174, 
176). The many pathways by which this can occur further emphasizes the impact of these death 
receptors in liver health and disease. 
 
The effects of bacterial translocation can, of course, be influenced by changes in the source 
of these products, including the intestinal microbiome. The next section will focus on how the 
microbiome and bacterial translocation have been implicated in liver disease.  
2.1.3  The Intestinal Microbiome & Bacterial Translocation in Liver Disease  
There is now a growing body of research linking alterations in the intestinal microbiome 
to liver pathologies. For example, patients with viral and autoimmune hepatitis (AIH) exhibit 
intestinal dysbiosis (103, 104). This included decreased Bifidobacterium in AIH and increased 
Prevotella in Hepatitis C (103, 104). Changes in the commensal microbiome were similarly seen 
in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFDL). In both diseases, 
there were increased Enterobacteriaceae and decreased Akkermansia muciniphila (177). As these 
were descriptive studies, research in mouse models have been performed to evaluate a causal role 
of the microbiome in disease pathogenesis. In concanavalin A hepatitis, a T cell-dependent liver 
injury model often used to study AIH, germ free mice and mice treated with gentamicin exhibited 
decreased disease severity as measured by liver histology and serum markers of liver inflammation 
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(108, 178). In a mouse model using a genetic predisposition to autoimmune hepatitis, treatment 
with vancomycin or ampicillin ameliorated disease (179). This study by Kriegel and colleagues 
went further to identify Enterococcus gallinarum as an exacerbating factor in the mouse model. 
Moreover, they found DNA from Enterococcus gallinarum in biopsies of patients with AIH (179).  
In a mouse model of alcoholic liver disease, fecal transplant from patients with ALD into germ-
free mice exacerbated disease with increased liver inflammation, lymphocyte infiltration, and cell 
death (180). Together, these examples demonstrate the potential role of the intestinal microbiome 
in liver disease pathogenesis. 
Given the closely related vasculature of the liver and intestine, there is a normal 
physiological flux of bacterial products to the liver through the portal vein draining the intestine 
(88). This flux can become more pronounced in the diseased states. For example, in HIV-
associated liver disease, increases in serum LPS have been documented and are thought to 
contribute to wasting and liver pathology (181).  In patients with ALD and NAFLD, increased 
serum endotoxin as well as systemic and liver TLR ligands were described (177). Indeed, many 
liver diseases and their related models of liver inflammation have been associated with increased 
bacterial translocation (99, 103, 108, 182–184). Focusing on mouse studies, the work by Kriegel 
and colleagues mentioned above also described liver translocation of E. gallinarum (179). 
Furthermore, work by Henao-Mejia et al. showed that the inflammasome induced changes in the 
intestinal microbiota which led to increased bacterial translocation to the liver, exacerbating 
NAFLD (102). 
Many of these diseases with changes in the microbiome and bacterial translocation have 
been associated with increased intestinal permeability as well (99, 103, 183). Increases in intestinal 
permeability allow greater access of the microbiome and bacterial products to the liver and 
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systemic circulation, magnifying their potential effects. Interestingly, Th17 cells, which play 
important roles in maintaining both the intestinal microbiome and permeability, have also been 
heavily implicated in liver disease.  
2.1.4  Th17 Cells in Liver Disease 
There is evidence in patients and mouse models linking Th17 cells to liver pathology. For 
example, both autoimmune and viral hepatitis patients displayed elevated serum IL-17 (105–107). 
In patients with alcoholic liver disease, there was increased Th17 cell infiltration that correlated 
with neutrophil recruitment, a known effect of Th17 cells (185). In non-alcoholic steatohepatitis 
(NASH), a subtype of NAFLD, increased circulating Th17 cells were described (100). Moreover, 
patients who progressed from non-alcoholic fatty liver (NAFL) to NASH exhibited more 
intrahepatic IL-17+ cells (101). In mouse models, the Kolls lab previously showed that global IL-
17RA knockout mice (Il17ra-/-) were protected from  Con A hepatitis (186). In addition, numerous 
studies using high fat diet-induced models of NAFLD showed increased Th17 cells in the liver, 
visceral adipose tissue, and blood (100). The proposed mechanisms by which Th17 cells are 
thought to contribute to liver disease include neutrophil recruitment via Th17-mediated chemokine 
release, fibrogenic effects promoting collagen deposition by HSCs, alteration of lipid metabolism 
via PPARγ, and IL-17 and IL-21-mediated release of proinflammatory cytokines by 
nonparenchymal cells including KCs and HSCs (98, 100, 187, 188). Mechanistically, the following 
dissertation work proposes a novel role for intestinal Th17 cells in liver inflammation. 
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2.1.5  Study Overview 
As previously discussed, Th17 cells play a critical role in regulating the intestinal 
microbiome and maintaining intestinal barrier integrity (35, 38, 40, 41, 48, 54, 189, 190). Given 
the importance of IL-17R in intestinal homeostasis and the reported links between liver disease 
and both intestinal dysbiosis and bacterial translocation, we hypothesized that intestinal IL-17R 
signaling plays a critical role in mitigating hepatic inflammation. To test this, we used intestinal 
epithelium-specific IL-17RA knockout mice (Il17rafl/fl x villin cre+ mice) in the concanavalin A 
(Con A) model of T-cell mediated hepatitis. Absence of enteric IL-17RA signaling induced 
commensal dysbiosis, expansion of intestinal Th17 cells, and intestinal Il18 expression. After Con 
A administration, Il17rafl/fl x villin cre+ mice exhibited more severe hepatitis accompanied by 
increased hepatocyte cell death. Mechanistically, we found that disease exacerbation was 
microbiome dependent, specifically implicating a role of gram-negative bacteria. In addition, we 
found that intestinal specific knockout mice displayed increased translocation of unmethylated 
CpG DNA to the liver. Our data suggested that CpG DNA exacerbates liver inflammation by 
driving expression of hepatic IL-18 to promote lymphocyte activation and FasL production in 
hepatic T-cells. Thus, intestinal IL-17R regulates translocation of TLR9 ligands and constrains 
susceptibility to hepatic inflammation. Our studies elucidate the role of enteric Th17 signaling and 
the microbiome in hepatitis, with broader implications on the effects of impaired intestinal 
immunity and subsequent release of microbial products seen in other diseases. 
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2.2 Methods 
2.2.1  Experimental Model and Subject Details  
Mice 
All mouse work was performed in accordance with the Institutional Animal Care and Use 
Committees (IACUC) and relevant guidelines at the University of Pittsburgh, School of Medicine 
(protocol #16109334). C57BL/6 mice were obtained from Taconic Biosciences (Germantown, 
NY). Nlrc4mutIl18bp-/- mice, which were bred and housed at the UPMC Children’s Hospital of 
Pittsburgh, were kindly provided by Dr. Scott Canna. Il17rafl/fl and Il17rafl/fl x villin cre+ mice were 
generated at the UPMC Children’s Hospital of Pittsburgh by crossing Il17rafl/fl mice to Il17rafl/fl x 
villin cre+ mice. Both male and female age-matched mice from 6-10 weeks of age were used for 
all experiments. The aforementioned breeding strategy allowed for controls and knockout mice 
within each experiment to be littermates. Littermate age-matched males and females were 
randomly assigned to experimental groups. Both males and females were used within each group 
in order to account for sex-differences while maintaining littermate controls and sufficient n for 
statistical power. All mice were housed in pathogen-free conditions at the UPMC Children’s 
Hospital of Pittsburgh.  
 
In vitro and ex vivo cultures 
Mouse TLR9 and TLR4 reporter cells (HEK-blue mTLR9 and HEK-dual mTLR4 reporter 
cells) were obtained from Invivogen and maintained according to manufacturer’s instructions. 
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Ex vivo stimulation of liver cells: Livers from 6-10-week-old naïve Il17rafl/fl mice and 
Il17rafl/fl x villin cre+ mice were harvested and enriched for mononuclear cells by Percoll gradient. 
In addition to detailed experiment-specific stimuli, cells were maintained at 37°C in Iscove’s 
Modified Dulbecco’s Medium (IMDM) with GlutaMAX Supplement (Gibco), 10% heat-




Concanavalin A (Con A) hepatitis was induced using concanavalin A from Canavalia 
ensiformis (jack bean) type IV (Sigma).  
2.2.2  Method Details 
Animal treatments 
C57BL/6, Il17rafl/fl, and Il17rafl/fl x villin cre+ mice were injected with 10mg/kg or 25mg/kg 
Con A intravenously (IV) via tail vein. For antibiotic studies, mice were treated with either five 
days of 1g/L neomycin or 14 days of 0.5g/L vancomycin in the drinking water ad libitum prior to 
Con A injection and remained on antibiotics throughout the hepatitis model. For CpG DNA pre-
treatments, Class C CpG (Invivogen) was injected 3x at 2.5mg/kg intraperitoneally (IP) prior to 
10mg/kg IV Con A. For IFNγ inhibition, mice were injected with Anti-IFNγ (BioXCell, XMG1.2) 
at 500μg/mouse IP one hour prior to 25mg/kg Con A injection. For FasL inhibition, mice were 
injected with 250-500μg/mouse IV into the retro-orbital sinus one hour prior to 25mg/kg Con A 
injection. For IL-18 blockade, anti-IL-18 was injected IP at 0.5mg/mouse one day prior to 25mg/kg 
IV Con A injection.  
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Alanine aminotransferase quantification 
Alanine aminotransferase (ALT) was measured in the serum of mice using the Vitros DT60 
II chemistry system (Ortho-Clinical Diagnostics, Inc.) (191) or ALT Activity Assay (Sigma) per 
manufacturer’s instructions. Method of ALT measurement was consistent within experiments.  
 
TUNEL Staining  
Liver tissues used for TUNEL staining were immediately fixed in 4% paraformaldehyde 
for 24-72 hours, washed 3x in PBS, and stored in 70% ethanol prior to paraffin embedding. 
Following paraffin embedding, slides were stained using the ApopTag® Peroxidase In Situ 
Apoptosis Detection Kit according to manufacturer’s instructions.  
 
Cohousing studies  
Littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were either kept cohoused or separated 
for one week prior to Con A injection and remained in assigned housing conditions throughout 
hepatitis model. 
 
qRT-PCR and RNA Sequencing 
Livers and intestines from naïve 6-10-week-old littermate Il17rafl/fl and Il17rafl/fl x villin 
cre+ mice were homogenized in Trizol buffer (Life Technologies). Total RNA extraction was 
performed according to Trizol manufacturer’s instructions. RNA was transcribed into cDNA using 
iScript reagent (Bio-RAD) according to manufacturer’s instructions.  
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For qRT-PCR, SYBR Green supermix (Bio-RAD) was used for analysis of small subunit 
ribosomal RNA gene (16S rRNA) expression. 16S primers included: forward: 
ACTCCTACGGGAGGCAGCAGT, reverse: ATTACCGCGGCTGCTGGC (47, 48, 192). 
SsoFast supermix (Bio-RAD) was used for qRT-PCR analysis with primers for mouse Hprt 
(Integrated DNA Technologies), Ifng (Applied Biosystems), and Fasl (Applied Biosystems). 
Expression of all genes was normalized relative to housekeeping gene mouse Hprt. Reaction: 95°C 
for 3 minutes, 49 cycles at 95°C for 10 seconds (s) and 60°C for 30s. SYBR Green reactions also 
had an additional melt curve at the end of the reaction above: 60°C for 5s with +0.5°C increment 
every cycle up to 95°C. 
Terminal ileum bulk RNA sequencing data was sourced from dataset we previously 
published (48). See previous manuscript for detailed methods.  
 
Single Cell RNA Sequencing  
Livers from 6-week-old littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were harvested 
at the naïve state or ninety minutes post 25mg/kg IV Con A injection. Single cell suspensions were 
isolated and enriched for mononuclear cells via Percoll gradient. Briefly, livers were collected in 
IMDM with GlutaMax (Gibco) supplemented with 10% FBS, penicillin, streptomycin, and L-
glutamine (“complete media”). Livers were minced into small pieces and digested in neat IMDM 
with 1mg/mL collagenase and 0.2mg/mL DNase at 37°C for 30 minutes with shaking. Cell 
suspension was further homogenized by flowing through an 18G needle in a 3mL syringe followed 
by filtering through a 70μm filter. Following a wash in complete media, mononuclear cells were 
enriched using a 70%/30% percoll gradient. Cells were washed 2x in complete media and 
resuspended for downstream applications.  
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For single cell RNA sequencing library preparation, liver cells were then separated into 
mini-reaction "partitions" or Gel bead in emulsion (GEM)s formed by oil micro-droplets, each 
containing a gel bead and a cell, by the Chromium instrument (10X Genomics). The reaction 
mixture/emulsion with captured and barcoded mRNAs were removed from the Chromium 
instrument followed by reverse transcription. The cDNA samples were fragmented and amplified 
per 10X protocol. The libraries were then purified, quantified, and sequenced on an Illumina 
NextSeq 550. Analysis was performed using the pipeline Cell Ranger developed by 10X Genomics 
as well as Seurat. 
 
16S rRNA Gene Sequencing  
Littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were sacrificed at the naïve state or 8 
hours post Con A injection. Terminal ileum RNA was isolated using Trizol (Life Technologies) 
and transcribed to cDNA using the iScript Reverse Transcription Supermix (Bio-rad), both 
according to manufacturer’s instructions. Extracted DNA was PCR amplified using the 
method/primers of Caporaso (193) and the Q5 HS High-Fidelity polymerase (NEB). Four 
microliters of each sample were amplified in a 25μl PCR reaction with barcoded V4 16S primers. 
Cycle conditions were 98°C for 30s, then 25 cycles of 98°C for 10s, 57°C for 30s, 72°C for 30s, 
with a final extension step of 72°C for 2 min. Reactions were purified with AMPure XP beads 
(Beckman) at a 0.8:1 ratio (beads:DNA) to remove primer-dimers. Eluted DNA was quantitated 
on a Qubit fluorimeter (Life Technologies). Sample pooling was performed on ice by combining 
20ng of each purified band. For negative controls and poorly performing samples, 20μl of each 
sample was used. The sample pool was first purified/concentrated with the MinElute PCR 
purification kit. Next, two-sided AMPure XP bead purification was used at 0.8:1 (left-side) and 
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0.61:1 (right-side) ratios to remove small and large contaminants, respectively. A final cleanup in 
the Purelink PCR Purification Kit (Life Technologies) was performed to insure removal of all 
AMPure XP beads. The final, purified pool was quantitated in triplicate on the Qubit fluorimeter 
prior to sequencing.  
Sequencing pool preparation was as per Illumina’s recommendations, with an added 
incubation at 95°C for 2 minutes immediately following the initial dilution to 20 picomolar. The 
pool was then diluted to a final concentration of 6 pM + 15% PhiX control. Paired-end sequencing 
was done on an Illumina MiSeq platform using a MiSeq Reagent kit v2 (500 cycles). 
 
Fecal Bacterial Flow Cytometry 
Followed protocol as detailed in Gopalakrishna et al. (194). Briefly, fecal matter was 
collected and weighed. 1ml of sterile PBS was added to the fecal content and homogenized by 
vortex and pipetting. Stool suspension was then passed through a 40-micron strainer into a 50ml 
conical tube. 10μl of stool was added to a round-bottom 96-well plate for IgA staining. Plated stool 
was washed 2.5x in BAC-FACS buffer (filtered 1%BSA in PBS) at 4000rpm for 5 minutes at 4 
degrees C. Stool was then stained in BAC-FACS buffer using Hoechst stain (1:1000dil), normal 
rat serum (1:5dil), and anti-mouse IgA PE or isotype control (1:500 dil). Samples were stained for 
one hour on ice in the dark and washed 2.5x with 100μl BAC-FACS buffer. Samples were 
reconstituted in BAC-FACS buffer, and 10μl of Accu-Check counting beads were added to each. 
Samples were analyzed by flow cytometry on the BD Fortessa cytometer. Bacterial calculations 




mTLR reporter assays 
For mTLR4 and mTLR9 reporter cell assays, cells were grown and maintained according 
to manufacturer’s instructions (Invivogen). For the assay, cells were stimulated with serum or liver 
homogenate of naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice. For the liver homogenate, 
livers were homogenized in PBS plus protease inhibitor (Roche). BCA Protein Assay (Pierce) was 
performed according to manufacturer’s instructions to measure total protein concentration. 
Dilutions were performed in PBS plus protease inhibitor to normalize concentrations between 
samples prior to reporter assay. SEAP levels were measured using QUANTI-Blue detection media 
(Invivogen). Assays were conducted according to the manufacturer’s instructions.   
For DNase treatment of liver homogenate, livers were harvested, homogenized in PBS plus 
protease inhibitors, and diluted to normalize total protein concentration as described above. An 
aliquot of liver homogenate was treated with DNase I from bovine pancreas (Sigma) reconstituted 
in PBS + MgCl to activate enzyme per manufacturer’s instructions. Vehicle control treatment was 
PBS + MgCl without DNase. Liver homogenate plus DNase or vehicle control were incubated at 
37 degrees C with shaking for 30 minutes. Digested samples were then plated on mTLR9 reporter 




Liver single cell suspensions were isolated and enriched for mononuclear cells from 
C57BL/6 mice or littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice as described above in Single 
Cell RNA Sequencing.  For staining, cells were washed in HBSS. Surface and live/dead stains were 
performed in 50μl-75μl in a 96 well round bottom plate in the dark on ice for 20 minutes. Cells 
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were washed 2.5x in cold FACS Buffer (0.5% FBS/0.01% NaN3/PBS). Cells were then fixed using 
BD Cyto-fix and incubated in the dark on ice for 20 minutes. If no further staining was required, 
cells were washed 2x in FACS buffer, resuspended in PBS or FACS buffer, and analyzed using 
the BD Fortessa flow cytometer. If additional intracellular stain analysis was required, cells were 
washed 1x in BD Perm/Wash. 50-75μl of intracellular stain cocktail made in BD Perm/Wash was 
then added to the cells and incubated in the dark on ice for 45 minutes. Cells were then washed 2x 
in BD Perm Wash, 1x in FACS buffer, and resuspended in PBS or FACS buffer for analysis on 
the BD Fortessa flow cytometer. Data analysis was performed on FlowJo. Cell number was 
quantified using the Nexcelom Cellometer Auto 2000. Flow cytometry antibodies used included: 
Live/Dead fixable aqua dead cell stain (Life Technologies) (1:500 dilution), BV786 Anti-mouse 
CD4 (BD Clone RM4-5) (1:200 dilution, APC Anti-mouse IFNγ (BD Clone XMG1.2) (1:200 
dilution), APCe780 Anti-mouse TCRβ (BD Clone H57-597) dilution), BV421 Anti-mouse NK1.1 
(BD clone PK136) (1:100 dilution), BV395 Anti-mouse CD3 (BD Clone 145-2C11) (1:200 
dilution), PCP-Cy5 Rat-Anti-Mouse CD3 Molecular Complex (BD clone 17A2) (1:200 dilution), 
BV605 Anti-Mouse CD90.2 (BD clone 30-H12) (1:400 dilution), PE Anti-Mouse FasL (Biolegend 
Clone MFL3) (1:200 dilution), PE-Cy7 Anti-mouse CD8 (Invitrogen clone eBioH35-7.2) (1:400 
dilution), Anti-Mouse CD16/CD32 (eBioscience Clone 93). 
 
Ex vivo liver cell stimulations 
Liver single cell suspensions were isolated and enriched for mononuclear cells from 
C57BL/6 mice or littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice as described above in Single 
Cell RNA Sequencing. Cells were then resuspended in IMDM with GlutaMax (Gibco) 
supplemented with 10% FBS, penicillin, streptomycin, and L-glutamine (“complete media”) and 
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plated at a concentration of 5 x 105 or 1 x 106 cells per well in a 96-well round bottom plate. Cell 
number was kept consistent within experiments. Cells were then stimulated with various 
conditions at 37°C for the detailed incubation times. For TLR ligand stimulations: Lipoteichoic 
acid, flagellin, lipopolysaccharide, and CpG were all attained from Invivogen and used at 
10ng/mL-1μg/mL or 1μM-5μM. Exact concentrations are detailed within each figure. During 
stimulations with TLR ligands ± Concanavalin A, 5ug/mL of Concanavalin A (Sigma) was used. 
Supernatants were harvested at 24 hours and analyzed for IFNγ and IL-18 levels by ELISA or 
Luminex. For downstream flow cytometry analysis, brefeldin A (BD) was added for 3 hours after 
4 hours of 1μM CpG stimulation. Cells were then stained and fixed for flow cytometry analysis as 
described above in Flow Cytometry. For non-TLR ligand stimulations, cells were stimulated with 
Con A (5ug/mL) or anti-CD3/CD28 (Thermo Fisher, Dynabeads) stimulation for three days. 
Supernatants were harvested and cytokine levels were measured via  Luminex. 
 
FITC Dextran Assay for Intestinal Permeability 
Four hours prior to FITC dextran gavage, water bottles were removed from the mouse 
cages. FITC-dextran (4kDa, Sigma) was dissolved in PBS at a concentration of 100 mg/ml and 
administered to each mouse at 44mg/100g body weight by oral gavage. Mice were euthanized after 
4 hours, and blood was collected immediately after via cardiac puncture. Serum was isolated from 
blood samples. 
For analysis, serum was diluted with an equal volume of PBS. 100μl of diluted serum was 
added to a 96-well microplate in duplicate. Concentration of FITC in serum was determined by 
florescence spectroscopy. The plate was read at an excitation of 485 nm (20 nm band width) and 
an emission wavelength of 528 nm (20 nm band width). Serially diluted FITC-dextran (0, 125, 
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250, 500, 1,000, 2,000, 4,000, 6,000, 8,000 ng/ml) was used as a reference standard to calculate 
serum concentrations. Serum from mice gavaged with PBS instead of FITC-dextran was used to 
determine background. 
 
ELISA and Luminex Assays 
Cytokines from serum, liver homogenate, and cell culture supernatants were measured 
using the following ELISA or Luminex kits according to the manufacturer’s instructions: Mouse-
IFNγ ELISA MAX Kit (BioLegend), MILLIPLEX Mouse Th17 Magnetic Bead Panel (Millipore 
Sigma), Cytokine & Chemokine 36-Plex Mouse Procarta Plex Panel 1A (Thermo Fisher Scientific-
Affymetrix), and IL-18 Mouse ELISA Kit (Invitrogen).  
2.2.3  Quantification and Statistical Analysis 
TUNEL Image Quantification 
To quantify TUNEL staining, five images spanning the width of the liver slice were taken 
at 10x magnification. Images were analyzed using Image J. Briefly, images were deconvoluted to 
isolate and analyze only the TUNEL diaminobenzidine (DAB) staining. A threshold of the TUNEL 
DAB stain was determined to minimize background staining (i.e. vascular endothelial cells, 
erythrocytes). Identical threshold was applied to all samples per experiment. Using the “measure” 
feature on Image J, TUNEL+ staining was then quantified as the percent of the total image area 
that was above the set color threshold. To ensure that focal batches of cell death throughout the 
liver were accounted for, the % area TUNEL+ of all five images were averaged to determine the 
% Area TUNEL+ per mouse.  
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Single Cell RNA Sequencing Analysis 
Following sequencing described above, we used Cell Ranger version 2.1.1 (10x Genomics) 
to process raw sequencing data and Seurat suite version 2.2.1 for downstream analysis. Filtering 
was performed to remove multiplets and broken cells, and non-relevant sources of variation were 
regressed out. Variable genes were determined by iterative selection based on the dispersion vs. 
average expression of the gene. For clustering, principal component analysis was performed for 
dimension reduction. Top 10 principal components (PCs) were selected by using a permutation-
based test implemented in Seurat and passed to t-SNE for visualization of clusters. 
 
Bulk Intestinal RNA Sequencing Analysis 
Data presented is sourced from the dataset we previously published (48). See previous 
manuscript for detailed statistical analysis.  
 
16S rRNA Gene Sequencing Analysis 
Sequence read quality control and classifications were completed using the Center for 
Medicine and the Microbiome in-house read processing and classification pipeline. The read 
processing pipeline applied low complexity filtering (NCBI dustmasker), QV trimming, sequence 
adapter trimming and primer trimming modules.  Sequences with both forward and reverse read 
directions passing read processing metrics were assembled using the make.contig command  from 
Mothur (195).  Mated reads were further screened to limit overlap mismatch proportion (<0.2), 
limit N’s allowed (4), and enforce a minimal overlap of 25bp. Merged sequences were classified 
with a Mothur-dependent in-house pipeline that combines OTU generation and taxonomic 
classifications using the RDP/Silva classifier and includes chimera screening, clustering and 
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taxonomic classification. The sample taxonomic profile was subsequently represented as a matrix 
with dimensions: number of samples x number of taxonomic units for compositional analysis with 




Statistical tests used are indicated in the figure legends. Data are presented as mean with 
individual samples visualized or mean + SEM. To compare differences between two groups, 
student-T test or non-parametric Mann-Whitney test was used depending on the distribution of the 
data. When comparing one variable in three or more groups, one-way ANOVA with multiple 
comparisons was used. When comparing multiple variables among two groups, two-way ANOVA 
with multiple comparisons or multiple T-tests per row was used. GraphPad Prism software was 
used to analyze experimental groups. For single cell RNA sequencing, statistical analysis was 
based on the non-parametric Wilcoxon rank sum test. For all data, statistically significant was 




GraphPad Prism was used for statistical analysis described above. Image J was used for 
histology analysis. Seurat, Cell Ranger, and Loupe Browser were used for single cell RNA 
sequencing analysis.  
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2.2.4  Data and Software Availability  
The raw terminal ileum RNA sequencing data have been deposited into the sequencing 
read archive under SRA accession number SRP069071. 16S rRNA sequencing data have been 
deposited in the SRA under SRA BioProject accession number PRJNA526489. The liver single 
cell RNA sequencing data discussed in this publication have been deposited in NCBI's Gene 
Expression Omnibus(197) and are accessible through GEO Series accession number GSE128284 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128284). 
Figure cartoons within this chapter were images adapted from Servier Medical Art by 
Servier. Original images are licensed under a Creative Commons Attribution 3.0 Unported License 
(https://creativecommons.org/licenses/by/3.0/legalcode). 
2.3 Results 
2.3.1  Deletion of IL-17RA in intestinal epithelium exacerbates Concanavalin A hepatitis. 
To investigate how intestinal IL-17 signaling regulates liver inflammation, we generated 
intestinal epithelium-specific Il17ra knockout mice (Il17rafl/fl x villin cre+) (48). Mice were treated 
with intravenous concanavalin A (Con A), a plant lectin, to induce a T-cell dependent liver injury 
(198). We have previously shown that globally deleting Il17ra is protective in this model of 
hepatitis (186). Interestingly, deleting Il17ra signaling specifically in the intestinal epithelium 
exacerbated disease (Figure 2-2). As compared to littermate Il17rafl/fl controls, Il17rafl/fl x villin 
cre+ mice exhibited elevated serum alanine aminotransferase (ALT), a marker of liver 
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inflammation, and increased mortality rates (Figure 2-2A-B). Liver pathology revealed 
substantially larger patches of cell death in the hepatic parenchyma (Figure 2-2C). Indeed, 
quantification of cell death by TUNEL staining showed approximately 50% more cell death on 








Figure 2-2. Deletion of IL-17RA in intestinal epithelium exacerbates Concanavalin A hepatitis. 
Littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were injected IV with concanavalin A (Con A). (A) Serum alanine 
aminotransferase (ALT) at 4 hours post Con A (10mg/kg). (B) Survival curve after 24 hours post Con A (10mg/kg). 
(C) Quantification of TUNEL staining at 8 hours post Con A (25mg/kg). (D) Representative images of TUNEL-
stained liver histology at 8 hours post Con A (25mg/kg). Data are represented as mean + SEM. (n=5-9 mice/group). 
p<0.05*, <0.01**, <0.001***, <0.0001**** (Mann-Whitney test, Gehan-Breslow-Wilcoxon test) 
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2.3.2  Exacerbated liver injury is dependent on the intestinal microbiota. 
Given the role of Th17 cells in regulating the intestinal microbiota (48, 60, 199), we tested 
whether the exacerbated liver injury was microbiome dependent. To do this, we performed 
cohousing studies in which littermates were either cohoused or separated by genotype for one week 
prior to Con A injection. When separated, intestinal specific knockouts continued to demonstrate 
more severe disease as measured by ALT (Figure 2-3A). Cohousing the groups to share the 
intestinal microbiota between mice eliminated significant differences in post-Con A ALT levels 
(Figure 2-3B), suggesting that disease exacerbation is microbiome-dependent.   
IL-17 has been strongly implicated in the regulation of bacteria in the small intestine, 
particularly those closely related to the intestinal epithelium such as segmented filamentous 
bacteria (Sfb) (48, 60). To that end, we performed 16S rRNA gene sequencing on the small 
intestine terminal ileum of littermate Il17rafl/fl x villin cre+ mice and floxed controls to examine 
changes in the microbiome due to IL-17R deficiency (Figure 2-3C). An outgrowth of Sfb in 
Il17rafl/fl x villin cre+ mice was seen in the naïve state and became more pronounced after Con A 
(Figure 2-3C). The only other difference observed at the family level was an outgrowth of 
Enterobacteriaceae seen in some Il17rafl/fl x villin cre+ mice after Con A administration (Figure 
2-3C). To broadly assess which bacteria may be contributing to liver disease, we treated mice with 
2 different antibiotic regimens prior to Con A. Mice either received neomycin to largely target 
gram-negative bacteria or vancomycin to target Sfb and other gram-positive bacteria. Based on 
ALT, neomycin protected mice while vancomycin had no effect, suggesting gram-negative 





Figure 2-3. Exacerbated liver injury is dependent on the intestinal microbiota. 
(A-B) Littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were either cohoused or separated for one week. Mice were 
then treated with IV concanavalin A (Con A) (25mg/kg), and serum alanine aminotransferase (ALT) was measured at 
8 hours. (n=6-14 mice/group). (C) 16S sequencing on terminal ileum of littermate Il17rafl/fl and Il17rafl/fl x villin cre+ 
mice at the naïve state and 8 hours post IV Con A (25mg/kg) (n=7-16 mice/group). (D-E) Mice were treated with 
either five days of 1g/L neomycin (D) or 14 days of 0.5g/L vancomycin (E) in the drinking water ad libitum. Mice 
were then injected with IV Con A and serum ALT was measured 8-9h post injection. (n=4-6 mice/group). (F) 16S 
rRNA transcript was measured by qRT-PCR in the liver of naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice 
(n=7-10 mice/group). (G-H) Serum and liver homogenate from naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ 
mice were plated on mTLR9 SEAP reporter cells. (n=4-8 mice/group). Absorbance of supernatants was measured and 
represented as ratio over null/unstimulated cells. (A-B, D-H) Data are represented as mean + SEM. p<0.05*, <0.01**, 






To characterize this further, we considered how the mechanisms by which Th17 cells 
regulate the microbiome are not necessarily specific to one bacterium. Rather, they affect the 
bacteria that generally reside close to the intestinal epithelium. Therefore, we hypothesized that 
there was a broad bacterial overgrowth in the gut specific knockout mice potentially contributing 
to disease. Utilizing flow cytometry partnered with counting beads (194), preliminary data showed 
increased fecal bacterial burden in Il17rafl/fl x villin cre+ mice as compared to littermate floxed 
controls (Figure 2-4A). Because intestinal secretory IgA is regulated by intestinal IL-17, IgA 
binding on bacteria was also analyzed. Il17rafl/fl x villin cre+ mice had an enrichment for IgA 
unbound (IgA-) bacteria, which were depleted with neomycin (Figure 2-4B-C). This suggested 
that the potentially detrimental bacterium or group of bacteria involved in exacerbating disease in 
gut specific knockout mice were IgA unbound bacteria overgrowing in the absence of intestinal 
IL-17 regulation through IgA.   
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Figure 2-4. Il17rafl/fl x villin cre+ mice have an increased fecal bacterial burden, enriched with neomycin-
sensitive, IgA-unbound bacteira. 
 (A) Fecal bacterial counts from naïve Il17rafl/fl and Il17rafl/fl x villin cre+ mice treated with neomycin or H2O control 
as measured via flow cytometry. (B) Quantification of IgA unbound (IgA-) and IgA bound (IgA+) bacterial counts 
with and without neomycin treatment in Il17rafl/fl and Il17rafl/fl x villin cre+ mice. (C) Representative FACS plots fecal 
bacteria stained with isotype or IgA (Gated by FSC, SSC, and Hoechst+). Data are representative of multiple 
experiments. (n = 4-5 mice/group). Data are represented as mean + SEM. p<0.05*, <0.01**, <0.001***, <0.0001**** 
(Two-way ANOVA with multiple comparisons).  
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Next, we sought to assess how the Il17rafl/fl x villin cre+ microbiota was influencing liver 
disease. Because Th17 signaling is critical for mucosal barrier integrity (40, 189, 199), and 
intestinal blood drains through the portal system to the liver, it is possible that bacteria were 
physically translocating to the livers of our intestinal-specific IL-17RA knockout mice. As an 
initial assessment, we performed 16S qRT-PCR on the livers of naïve Il17rafl/fl x villin cre+ mice 
and littermate controls. Results showed an increased 16S signal in gut-specific knockout mice 
(Figure 2-3F), suggesting more bacteria or bacterial products in the liver of these mice at baseline. 
We determined this signal was not from live bacteria as bacteria failed to grow from the liver in 
both aerobic and anaerobic conditions (data not shown). As such, mouse toll-like receptor (mTLR) 
reporter cell lines were subsequently utilized to assay for bacterial products. With a focus on gram-
negative bacteria, serum and liver homogenate from naïve Il17rafl/fl x villin cre+ mice and 
littermate controls were plated on mTLR4 or mTLR9 reporter cells to measure lipopolysaccharide 
(LPS) and unmethylated CpG DNA levels, respectively. There were no differences in LPS levels 
in the serum or liver homogenate (Figure 2-5). However, there was elevated CpG DNA in the liver 
homogenate of Il17rafl/fl x villin cre+ mice as measured by the mTLR9 reporter line (Figure 2-3G). 
This was not seen in serum (Figure 2-3H), suggesting both that the liver is successfully filtering 
products from entering the circulation, and that CpG DNA may be signaling through TLR9 locally 
in the liver to influence disease. To model if elevated CpG DNA prior to disease induction 
exacerbates disease, wildtype C57BL/6 mice were treated with 3 doses of CpG DNA through the 
week prior to Con A (Figure 2-6A). CpG DNA administration prior to Con A dramatically 
increased mortality rates as compared to Con A, CpG DNA, or vehicle control alone (Figure 2-




Figure 2-5. Il17rafl/fl x villin cre+ mice do not have elevated serum or liver LPS. 
Serum (A) and liver homogenate (B) from naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were plated on 
mTLR4 SEAP reporter cells. Absorbance of supernatants was measured and represented as ratio over 
null/unstimulated cells. Data are represented as mean + SEM. n =7-14 mice/group. Data are represented as mean + 





Figure 2-6. CpG DNA promotes fatal Con A hepatitis. 
Wildtype C57BL/6 mice were pretreated with IP 2.5mg/mL CpG 3x prior to IV Con A injection (10mg/mL). (A) 
Experimental schematic of treatment regimen. (B) Survival curve. (n=4-5 mice/group). (A-B) Data are represented as 
mean + SEM. p<0.05*, <0.01**, <0.001***, <0.0001**** (Log-rank (Mantel-Cox) test) 
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2.3.3  Intestinal IL-17RA constrains TLR9-induced Type I immune responses in the liver. 
CpG DNA and subsequent TLR9 signaling are capable of eliciting a variety of 
inflammatory cytokines such as IL-12, IL-6, and interferons (200–202). To investigate which 
CpG-inducible cytokines may be contributing to worsened liver disease in gut-specific knockout 
mice, we first wanted to establish which cytokines were elevated in Il17rafl/fl x villin cre+ mice. To 
employ a broad, unbiased approach, we performed single cell RNA sequencing. Previous reports 
have detailed cytokine changes at the protein level within hours of Con A injection (203).  
Therefore, we chose a ninety-minute post-injection timepoint to investigate transcriptional 
changes induced early in the model. We compared the liver transcriptome of Il17rafl/fl x villin cre+ 
mice against littermate Il17rafl/fl controls. Based on K-means clustering and upregulation of cell-
specific genes (Table 2-1), we identified 12 distinct cell populations (Figure 2-7A). One of the 
significantly upregulated genes in Il17rafl/fl x villin cre+ mice was Ifng (Figure 2-7B-C). IFNγ is a 
known contributor to liver inflammation in Con A hepatitis and an indicator of lymphocyte 
activation (204–206). In the single cell RNA sequencing dataset, Ifng was expressed by T cells 
(CD4+ and CD8+ T cells), NK cells, and NKT cells (Figure 2-7C). There were also increases in 







Table 2-1. Single Cell RNAseq Cluster Gene Lists. 





Figure 2-7. Intestinal IL-17RA constrains TLR9-induced Type I immune responses in the liver. 
(A-C) Ninety minutes after IV concanavalin A (25mg/kg), single cell RNA sequencing was performed on Il17rafl/fl 
and Il17rafl/fl x villin cre+ liver cells enriched for mononuclear cells. (n=2 mice/group) (A)TSNE of cell type clustering 
based on K means clustering and cell-specific gene expression. There is minor overlap between NK and T cell 
populations. (B) Violin plots of Ifng, Cxcl9, and Cxcl10 expression in Il17rafl/fl (“Neg”) and Il17rafl/fl x villin cre+ 
(“Pos”) liver datasets. All violin plots displayed (B) show gene expression significantly increased in Il17rafl/fl x villin 
cre+ (“Pos”) with a p < 0.05 by Wilcoxon rank sum test. (C) TSNE of Ifng expressing cells in Il17rafl/fl and Il17rafl/fl 
x villin cre+ liver datasets colored according to relative expression level. (D-E) Flow cytometry analysis of liver cells 
of littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice at the naïve state and 5 hours post IV Con A (25mg/kg) injection. 
(n=2-4 mice/group) (D) Representative flow cytometry plots. (E) Number of live IFNγ+ cells, live IFNγ+TCRβ+ cells, 
live IFNγ+TCRβ- cells, and live IFNγ+ NK Cells (gated on CD90+TCRβ-NK1.1+). (F) Total liver cell number plotted 
as fold change over Il17rafl/fl. (n= 3-16 mice/group).  (G) Livers from wildtype C57BL/6 mice were harvested and 
enriched for mononuclear cells. Cells were stimulated ex vivo with varying concentrations of TLR ligands (lipoteichoic 
acid (LTA), flagellin (FLA), lipopolysaccharide (LPS), or CpG) ± Con A (5μg/mL). IFNγ was measured in culture 
supernatants at 24 hours by Luminex. (n=2 replicates/condition). (H-I) Livers from naive littermate Il17rafl/fl and 
Il17rafl/fl x villin cre+ mice were harvested and enriched for mononuclear cells. Cells were stimulated ex vivo with 
1μM CpG for 4 hours plus an additional 3 hours with brefeldin A, and then analyzed by flow cytometry. (H) 
Representative FACS plots. (I) Number of live IFNγ+ cells, CD4+ IFNγ+ cells (gated on live CD90+TCRβ+), and 
CD8+ IFNγ+ cells (gated on live CD90+TCRβ+). (n=3-4 mice/group). (E-G, I) Data are represented as mean + SEM. 
p<0.05*, <0.01**, <0.001***, <0.0001**** (Unpaired T test, Two-Way ANOVA with multiple comparisons, 








To confirm this at the protein level, we performed flow cytometry at the naïve state and 5 
hours post-Con A injection (Figure 2-7D-E). There was a greater number of IFNγ+ cells in the 
liver of Il17rafl/fl x villin cre+ mice after Con A as compared to littermate controls (Figure 2-7D-
E). This was due to significant increases in IFNγ-producing TCRβ- cells, namely NK cells, and 
trends toward increased IFNγ-producing TCRβ+ cells (Figure 2-7E). Though there were no 
differences in the percentage of IFNγ-producing cells, Il17rafl/fl x villin cre+ mice displayed an 
increase in actual IFNγ+ cell number due to a 25-30% increase in liver cellularity observed both 
at the naïve state and 5 hours after Con A (Figure 2-7F). These differences were eliminated upon 









Figure 2-8. Cohousing eliminates differences in liver IFNγ between Il17rafl/fl x villin cre+ mice and floxed 
controls. 
Livers from Il17rafl/fl and Il17rafl/fl x villin cre+ mice at the naïve state and 5h-post Con A were harvested, enriched 
for mononuclear cells, and analyzed via flow cytometry (n = 3-4 mice/group. (A) Number of IFNγ+ cells (gated on 
live cells). (B) Number of IFNγ+TCRβ- cells (gated on live CD90+). (C) Representative FACS plots. (D) Number of 
IFNγ+TCRβ+ cells (gated on live CD90+). (E) Total liver cell count per gram of tissue.  Data are represented as mean 











To confirm that CpG DNA can induce IFNγ in the liver, we harvested livers from naïve 
wildtype C57BL/6 mice, enriched for mononuclear cells, and stimulated with increasing 
concentrations of CpG DNA or other TLR ligands. Moreover, to assess whether these ligands can 
synergize with Con A, each TLR ligand was tested in the absence or presence of Con A. CpG 
DNA, LPS, and lipoteichoic acid (LTA), a TLR2 ligand, all induced IFNγ responses (Figure 2-
7G). In contrast, flagellin (FLA), a TLR5 ligand, did not induce IFNγ responses (Figure 2-7G). 
Even at low concentrations, CpG DNA induced strong IFNγ responses, which added to IFNγ 
responses with Con A alone (Figure 2-7F). These data confirmed that CpG DNA is a potent inducer 
of liver IFNγ and suggested that CpG DNA may not only contribute to the elevated IFNγ observed 
in Il17rafl/fl x villin cre+ mice in vivo but synergize with Con A to enhance responses and worsen 
disease. 
To assess differences in CpG-induced IFNγ responses and determine the cellular source of 
IFNγ, Il17rafl/fl x villin cre+ and littermate control livers were stimulated with CpG DNA ex vivo 
and analyzed by flow cytometry. Interestingly, there was already a slight increase in IFNγ+ cells 
in Il17rafl/fl x villin cre+ liver cells cultured in media alone (Figure 2-7H-I). This supported our 
hypothesis that the elevated CpG DNA at baseline may be inducing inflammatory cytokines 
locally. After CpG DNA treatment, the elevated IFNγ became more pronounced (Figure 2-7I), 
with much of the IFNγ proportionally coming from CD4+ and CD8+ T cells (Figure 2-7I, Figure 
2-9). Of these cell populations, Il17rafl/fl x villin cre+ mice demonstrated significantly increased 




Figure 2-9. CD4 and CD8 T cells comprise the majority of IFNγ+ cells following CpG DNA stimulation. 
Livers from naive littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were harvested and enriched for mononuclear 
cells. Cells were stimulated ex vivo with 1μM CpG for 4 hours plus an additional 3 hours with brefeldin A, and then 
analyzed by flow cytometry. Percent (A) and actual cell number (B) of IFNγ+ cells by cell type (gated on live IFNγ+ 
cells). Data are represented as mean + SEM. (n=3-4 mice/group). p<0.05*, <0.01**, <0.001***, <0.0001**** 
(Multiple T tests per row). 
 
 
Taken together, these data suggest that in addition to having more CpG DNA in their livers 
at baseline, intestinal specific knockouts demonstrate a baseline low-level elevation in IFNγ and 
enhanced responses to CpG DNA. This then prompted the question of what factors were present 
in Il17rafl/fl x villin cre+ mice that were responsible for enhancing IFNγ responses. In addition, 
TLR9 is not highly expressed on T cells or NK cells, potentially implicating an intermediate factor 
to facilitate these IFNγ responses to CpG DNA. 
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2.3.4  Intestinal IL-17RA constrains hepatic and intestinal IL-18. 
Single cell RNA sequencing also revealed increased Il18 expression in Il17rafl/fl x villin 
cre+ livers (Figure 2-10A-B). IL-18 has been implicated in many inflammatory conditions such as 
macrophage activation syndrome, rheumatoid arthritis, and hepatitis (207–209). We chose to 
investigate IL-18 further due to its established ability to enhance IFNγ production (207, 210).  
Within the liver, bacterial products like CpG DNA have been shown to activate cells close 
to the hepatic vasculature, such as Kupffer cells and hepatic stellate cells (159, 211–214). Indeed, 
analysis of the single cell sequencing data showed that Il18 was expressed mainly in Kupffer cells, 
cholangiocytes, and to a lesser extent, a non-Kupffer cell monocyte/macrophage population 
(Figure 2-10A). Consistent with the single cell RNA sequencing data, we observed increased Il18 
transcript in the liver by qRT-PCR and IL-18 protein in liver homogenate and serum of naïve 
Il17rafl/fl x villin cre+ mice (Figure 2-10C-E). 
Interestingly, we also observed elevated Il18 transcript in the small intestine of Il17rafl/fl x 
villin cre+ mice (Figure 2-10F), suggesting that the elevated liver IL-18 may be coming from local 
hepatic IL-18 production as well as intestinal IL-18 through the portal circulation. Furthermore, 
neomycin treatment in the drinking water (which depletes gram-negative bacteria) decreased 
serum IL-18, providing additional support for not just intestinal involvement, but specifically 




Figure 2-10. Intestinal IL-17RA constrains hepatic and intestinal IL-18. 
(A-B, J) Ninety minutes after IV concanavalin A (25mg/kg), single cell RNA sequencing was performed on Il17rafl/fl 
and Il17rafl/fl x villin cre+ liver cells enriched for mononuclear cells. (n=2 mice/group) (A) TSNE of Il18 expressing 
cells in Il17rafl/fl and Il17rafl/fl x villin cre+ liver datasets colored according to relative expression level. TSNE of cell 
type clustering for reference (Identical to Figure 3A). (B) Violin plot of Il18 expression in Il17rafl/fl (“Neg”) and 
Il17rafl/fl x villin cre+ (“Pos”) liver datasets. (C-F) In naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice, liver 
Il18 transcript (C), liver IL-18 (D), serum IL-18 (E), and terminal ileum Il18 (F) was measured. (G) Serum IL-18 was 
measured after mice were treated with 5 days of 1g/L neomycin in drinking water ad libitum. (H-I) Liver cells of naïve 
wildtype C57BL/6 mice (H) or littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice (I) were enriched for mononuclear 
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cells and stimulated with CpG (1μM) ± anti-IL-18 (5μg/mL) for 24 hours. IL-18 (H) and IFNγ (I) were measured in 
culture supernatants by ELISA. (J) Violin plots of various gene expression levels in Il17rafl/fl (“Neg”) and Il17rafl/fl x 
villin cre+ (“Pos”) liver single cell RNA sequencing 90 minutes post IV Con A. All violin plots displayed (B, J) show 
gene expression significantly increased in Il17rafl/fl x villin cre+ (“Pos”) with a p < 0.05 by Wilcoxon rank sum test. 
(C-I) Data are represented as mean + SEM. (n=3-8 mice/group). p<0.05*, <0.01**, <0.001***, <0.0001**** 
(Unpaired T Test, Two-Way ANOVA with Multiple Comparisons Test)  
 
 
To assess whether CpG DNA plays a role in the elevated hepatic IL-18 levels, hepatic 
mononuclear cells were stimulated ex vivo with CpG DNA. Indeed, we observed IL-18 induction 
after CpG DNA stimulation (Figure 2-10H). Moreover, CpG-induced IFNγ was decreased ex vivo 
by treatment with anti-IL-18 antibody, suggesting that CpG DNA is inducing liver IFNγ in an IL-
18 dependent manner (Figure 2-10I).  To assess the contribution of IFNγ to exacerbated disease 
gut-specific knockout mice, Il17rafl/fl x villin cre+ mice were treated with anti-IFNγ prior to Con 
A injection. Interestingly, blockade of IFNγ did not ameliorate disease (Figure 2-11A) despite 
confirmation of IFNγ neutralization by serum ELISA (Figure 2-11B). Because of this, we 








Figure 2-11. IFNγ blockade did not ameliorate hepatitis in Il17rafl/fl x villin cre+ mice. 
 (A) Con A (25mg/kg) was injected IV into Il17rafl/fl x villin cre+ mice treated with Anti-IFNγ or control two hours 
prior to Con A injection. (A) Serum ALT at 8h post injection (n = 9-13 mice/group). (B) Serum IFNγ at 8h post 
injection as measured by ELISA (n = 3-5 mice/group). Data are represented as mean + SEM. (n=3-8 mice/group). 
p<0.05*, <0.01**, <0.001***, <0.0001**** (Unpaired T Test) 
2.3.5  IL-18-induced FasL exacerbates liver inflammation. 
Fas ligand (FasL) has been strongly implicated in Con A hepatitis, as knockout of either 
Fas or Fasl is sufficient to ameliorate disease (215–217). Within the liver, Fasl was mainly 
expressed by T cells, NK cells, and NKT cells (Figure 2-12). In addition to increased Fasl in 
Il17rafl/fl x villin cre+ mice by scRNAseq (Figure 2-10J), we observed increased FasL+ cells in the 
liver of naïve Il17rafl/fl x villin cre+ mice by flow cytometry (Figure 2-13A). There was also more 
FasL produced per cell as measured by geometric mean fluorescence intensity (gMFI) (Figure 2-
13B-C). These differences were eliminated upon cohousing, suggesting these FasL changes were 




Figure 2-12. Fasl is expresed by liver T cells, NK cells, and NKT cells. 
Single cell RNA sequencing was performed on Il17rafl/fl and Il17rafl/fl x villin cre+ liver cells enriched for mononuclear 
cells 90min after IV Con A (25mg/kg). (n=4 mice). (A)TSNE of cell type clustering based on K means clustering and 
cell-specific gene expression. (B) TSNE of Fasl expressing cells colored according to relative expression level. 
 
 
To test whether increases in FasL contributed to Con A hepatitis, we treated mice with anti-
FasL one hour prior to Con A injection. Results suggested that anti-FasL treatment ameliorated 
disease in gut-specific knockout mice as measured by serum ALT and TUNEL staining (Figure 2-
13D-F). To investigate whether IL-18 can induce liver FasL, livers of naïve littermate Il17rafl/fl x 
villin cre+ mice and floxed controls were enriched for mononuclear cells, stimulated ex vivo with 
IL-18 ± anti-IFNγ, and analyzed by flow cytometry (Figure 2-13G-H). While there were no 
significant differences between responses of Il17rafl/fl x villin cre+ mice and floxed controls, results 




Figure 2-13. IL-18-induced Fasl exacerbates liver inflammation. 
(A-C) Flow cytometry analysis of FasL in livers cells of naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice (n=7-
11 mice/group). (A) Number of live FasL+ cells plotted as fold change over of Il17rafl/fl. (B) FasL geometric mean 
fluorescence intensity (gMFI) of live FasL+ cells. (C) Representative histogram of FasL+ cells. (D-F) Wildtype and 
Il17rafl/fl x villin cre+ mice were treated with IV anti-FasL (250-500μg/mouse) one hour prior to IV concanavalin A 
(25mg/kg). (D) Serum alanine aminotransferase (ALT) was measured 8 hours post IV Con A. (E) Quantification of 
TUNEL staining at 8 hours post Con A. (F) Representative images of TUNEL-stained liver histology at 8 hours post 
Con A. (G-H) Livers from naive littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were harvested and enriched for 
mononuclear cells. Cells were stimulated ex vivo with 50ng/mL IL-18 ± 5μg/mL anti-IFNγ (αIFNγ) and analyzed by 
flow cytometry. Percent (G) and actual number (H) of TCRβ+FasL+ cells (gated on live CD90+ cells). Lines connect 
paired samples. Each dot/line represents one mouse. (A-B, D-E) Data are represented as mean + SEM. p<0.05*, 




Figure 2-14. Cohousing eliminated liver FasL differences between Il17rafl/fl x villin cre+ mice and floxed controls. 
Livers from Il17rafl/fl and Il17rafl/fl x villin cre+ mice at the naïve state and 5h-post Con A were harvested, enriched 
for mononuclear cells, and analyzed via flow cytometry (n = 3-4 mice/group). Percent (A) and number (B) of FasL+ 
cells (gated on live cells). (C) Representative FACS plots. (D) FasL gMFI (gated on live FasL+ cells). (E) 
Representative histograms. Data are represented as mean + SEM. p<0.05*, <0.01**, <0.001***, <0.0001**** (Two-
Way ANOVA with multiple comparisons). 
2.3.6  Anti-IL18 mitigates liver injury in intestinal IL-17RA-deficient mice. 
Finally, to assess whether the elevated IL-18 in Il17rafl/fl x villin cre+ mice was contributing 
to worsened liver disease, we treated Il17rafl/fl x villin cre+ mice and littermate controls with anti-
IL-18 or isotype control one day prior to Con A injection. Anti-IL-18 treatment decreased liver 
inflammation in Il17rafl/fl x villin cre+ mice to that of wildtype mice as measured by serum ALT 
(Figure 2-15A). Liver pathology correspondingly showed reduced areas of cell death in the liver 
parenchyma (Figure 2-15B-C). Quantification of TUNEL staining confirmed that cell death in 
Il17rafl/fl x villin cre+ mice was substantially reduced to that of littermate floxed controls (Figure 
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2-15B). Furthermore, anti-IL-18 treatment reduced liver Ifng and Fasl transcript in Il17rafl/fl x villin 
cre+ mice 8 hours post-Con A as measured by qRT-PCR (Figure 2-15D-E). 
 
 
Figure 2-15. Anti-IL18 mitigates liver injury in intestinal Il17RA deficient mice. 
Littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were pre-treated with anti-IL-18 (0.5mg/mouse) one day prior to 
IV concanavalin A (Con A) (25mg/kg) and sacrificed at 8 hours post Con A (n=7-9 mice/group). (A) Serum alanine 
aminotransferase (ALT). (B) Quantification of TUNEL staining. (C) Representative images of TUNEL-stained liver 
histology. Liver Ifng (D) and Fasl (E) gene expression as measured by qRT-PCR. Data are represented as mean + 
SEM. p<0.05*, <0.01**, <0.001***, <0.0001**** (Two-Way ANOVA with multiple comparisons test). 
2.4 Discussion 
Our results provide evidence that perturbation of intestinal IL-17 signaling is sufficient to 
exacerbate liver inflammation. Abrogation of intestinal IL-17RA disrupted the intestinal 
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microbiota and promoted translocation of bacterial products to the liver. Together, this induced 
IL-18 production and subsequent lymphocyte activation and cell death to worsen hepatitis.  
Numerous studies have implicated Th17 cells in liver inflammation. For example, both 
autoimmune and viral hepatitis patients displayed elevated serum IL-17 (105–107). In Con A 
hepatitis, our lab previously showed that global IL-17RA knockout mice (Il17ra-/-) were protected 
from disease (186).  However, the role of Th17 cells in liver disease is complex. Here, by using 
intestinal epithelium-specific knockout mice, we uncouple intestinal IL-17 signaling from 
systemic signaling to reveal a novel protective role of intestinal IL-17RA in mitigating liver 
inflammation. Intestinal-specific IL-17RA knockout mice did have elevations in serum IL-17A 
(48) capable of signaling outside of the intestine to worsen disease. However, there were 
conflicting reports when IL-17A was reduced through genetic manipulation or antibody blockade 
during Con A hepatitis (186, 218–220). These discrepancies may be due to institutional differences 
in the microbiome. Alternatively, it may be due to the contribution of other IL-17RA cytokines. 
Our studies suggest this could also be a result of intestinal IL-17 signaling disruption with 
downstream consequences detrimental to liver inflammation. This unique contribution of intestinal 
IL-17 relative to systemic IL-17 paralleled findings in the experimental autoimmune 
encephalomyelitis (EAE) mouse model of multiple sclerosis described in Chapter 3 of this 
dissertation. In EAE, global IL-17RA knockout was protective (126), while intestinal specific IL-
17RA knockout was detrimental (48), further validating the importance of intestinal IL-17 
signaling in extra-intestinal diseases. 
While reports have separately associated Th17 cells and the microbiome to liver 
inflammation, our study adds to the existing literature by linking these factors together in the 
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context of liver disease (98, 108, 221, 222). Our data showed that there were no differences in liver 
IL-17 in gut-specific knockout mice to exacerbate disease (Figure 2-16).  
 
 
Figure 2-16. Liver IL-17 is not increased in Il17rafl/fl x villin cre+ mice at the naïve state or 5h-post Con A. 
(A) Liver Il17a expression in Il17rafl/fl and Il17rafl/fl x villin cre+ mice at the naïve state and 5h-post Con A as measured 
by qRT-PCR (n = 3-4 mice/group). (B) IL-17 in liver homogenate of naïve Il17rafl/fl and Il17rafl/fl x villin cre+ mice 
were measured by Luminex (n = 4-8 mice/group). (C) Ninety minutes after IV Con A (25mg/kg), single cell RNA 
sequencing was performed on Il17rafl/fl (“Neg”) and  Il17rafl/fl x villin cre+ (“Pos”) liver cells enriched for mononuclear 
cells. (n=2 mice/group). TSNE of Il17 expressing cells colored according to relative expression level and violin plot 
of Il17 expression. (D-F) Percent (D), number (E), and gMFI (F) of live IL-17+ cells in the livers Il17rafl/fl x villin 
cre+  mice at the naïve state and 5h-post Con A (n = 2-4 mice/group). Data are represented as mean + SEM. p<0.05*, 
<0.01**, <0.001***, <0.0001**** (Two-Way ANOVA with multiple comparisons, Multiple T tests, Unpaired T test) 
 
Rather, the data suggested that disruption of intestinal IL-17RA promoted the overgrowth of gram-
negative, IgA unbound bacteria that exacerbated liver inflammation. This corroborates previous 
studies showing that germ free mice and mice treated with gentamicin are protected in Con A 
hepatitis (108, 178). Ruminococcaceae, a vancomycin sensitive gram-positive bacteria, was 
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previously associated with worsened liver inflammation (178), though we did not observe 
differences in this family within Il17rafl/fl x villin cre+ mice. Interestingly, at the naïve state, 16S 
data mainly showed differences in Sfb. However, we showed that vancomycin treatment, which 
eliminated Sfb and other gram-positive bacteria including Ruminococcaeae, had no effect on Con 
A hepatitis. Moreover, others showed that Sfb- wildtype mice sourced from Jackson Laboratories 
actually displayed worse Con A hepatitis than Sfb+ wildtype mice sourced from Taconic (178). 
Taken together, these data suggested that Sfb overgrowth as a result of disrupted enteric IL-17RA 
signaling is not worsening disease in this model. Rather, disruption of intestinal IL-17 receptor 
signaling allowed for greater translocation of bacterial products to the liver, namely TLR9 
agonists, to exacerbate disease. Because intestinal Th17 signaling plays a critical role in 
modulating bacteria close to the epithelium, it is also possible that a lack of intestinal IL-17R led 
to the general loss of host regulation of these bacteria as a whole, rather than specific bacteria. 
After Con A, Il17rafl/fl x villin cre+ mice did display a bloom of Enterobacteriaceae, which have 
particularly stimulatory CpG DNA (223). However, this overgrowth may simply be a consequence 
of inflammation as Enterobacteriaceae is known to outcompete other bacteria and bloom in 
inflammatory environments (224).   
In addition to alterations in the intestinal microbiome, other groups have also observed 
increased bacterial translocation in both patients with and mouse models of liver inflammation 
(103, 108, 182). However, the downstream effects on local hepatic immune cell populations 
remain unclear. Here, we show that at the naïve state, disruption of intestinal IL-17R signaling was 
sufficient to increase flux of bacterial products, specifically CpG DNA, into the liver despite no 




Figure 2-17. Naïve Il17rafl/fl x villin cre+ mice do not exhibit baseline intestinal barrier defects. 
Serum FITC Dextran (4kDA) concentration in control saline-gavaged mice (n=2) and FITC dextran-gavaged Il17rafl/fl 
and Il17rafl/fl x villin cre+ mice (n=3mice/group). Data are represented as mean + SEM. p<0.05*, <0.01**, <0.001***, 
<0.0001**** (One-Way ANOVA with multiple comparisons) 
 
In addition, preliminary data showed that the CpG DNA signal in the liver homogenate 
was not sensitive to DNase treatment, raising the possibility of CpG DNA transport into the liver 
via bacterial outer membrane vesicle (OMV) release (Figure 2-18). This aligns with our data 
implicating gram-negative bacteria in our model, as gram-negative bacteria are producers of 
OMVs. Our data and a study by Jiang et al. both demonstrated that CpG DNA worsened Con A 
hepatitis (147). There was a conflicting report detailing hepatitis attenuation after CpG DNA 
stimulation (225), but we postulate this is due to differences in the CpG DNA and treatment 
regimen used in the experiments. In our study, we showed that CpG DNA induced IL-18-
dependent liver IFNγ production from T cells, providing novel evidence that intestinal IL-17 




Figure 2-18. TLR9 ligands in Il17rafl/fl and Il17rafl/fl x villin cre+  liver homogenate are DNase-resistant. 
Liver homogenate from naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were treated with DNase or vehicle 
control, then plated on mTLR9 SEAP reporter cells. (n=4-8 mice/group). Controls: DNase-sensitive E. coli dsDNA, 
Nuclease-resistant CpG DNA, nuclease free sterile H2O. Absorbance of supernatants was measured and represented 
as ratio over null/unstimulated cells. Data are represented as mean + SEM. p<0.05*, <0.01**, <0.001***, 
<0.0001**** (Two-Way ANOVA with multiple comparisons) 
 
Il17rafl/fl x villin cre+ mice also exhibited increased IL-18 production in the intestine. This 
is consistent with previous reports that IL-18 is produced by intestinal epithelial cells in response 
to IL-22 (161). Indeed, we have previously shown that disrupted intestinal IL-17RA signaling 
increased IL-22+ cells in the small intestine lamina propria (48). Interestingly, serum IL-18 was 
partially decreased with neomycin treatment. Therefore, in addition to elevated IL-22, intestinal 
IL-17 signaling may regulate IL-18 through the microbiota. To further support the potential 
contribution of intestinal IL-18 in disease exacerbation, we have preliminary data with Con A in 
Nlrc4mutIl18bp-/- mice. In these mice, IL-18 binding protein (IL-18BP), which is necessary for 
regulatory inhibition of IL-18, is knocked out, and the NLRC4 T337S mutation causes excess 
inflammasome-mediated IL-18 from the intestine (208). At the same concentration, these mice 
 76 
exhibited lethal Con A hepatitis, while the Nlrc4mut mice and Il18bp-/- mice survived (Figure 2-19). 
This suggested that excess IL-18 partnered with decreased systemic inhibition of IL-18 promotes 
hepatitis, and implies a pathogenic role for excess intestinal IL-18 in Il17rafl/fl x villin cre+ mice.  
 
   
Figure 2-19. Excess intestinal IL-18 partnered with decreased systemic IL-18 control exacerbate hepatitis.  
Con A (25mg/kg) was injected intravenously into wildtype (WT) B6 mice, NLRC4 mutants (Nlrc4mut), IL-18 binding 
protein knockouts (Il18bp-/-), and mice having both the NLRC4 mutation and IL-18BP deficiency (Nlrc4mutIl18bp-/-). 
Survival Curve (n = 3-10 mice/group). p<0.05*, <0.01**, <0.001***, <0.0001**** (Log-rank (Mantel-Cox) test) 
 
The microbiome can influence immunity through direct mechanisms (i.e. activation of 
TLRs, NOD receptors) and indirect mechanisms (i.e. metabolites). Here, we provided evidence of 
CpG DNA inducing liver IL-18. Previous studies have described an indirect regulatory relationship 
between IL-18 and the intestinal microbiota in which unique metabolites derived from healthy and 
dysbiotic microbiota induced IL-18 production from the intestinal epithelium (226, 227). It is 
possible that disrupted intestinal IL-17 signaling and subsequent alterations in the microbiome 
may have induced IL-18 production through these mechanisms as well. Broadly, our data imply 
that perturbations in the microbiome and translocation of microbial products can enhance systemic 
IL-18 levels and affect extra-intestinal pathologies. 
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Excess IL-18 in Il17rafl/fl x villin cre+ mice also induced liver Fasl expression, increasing 
cell death and worsening hepatitis. This is consistent with reports implicating Fas-FasL in Con A 
hepatitis. Indeed, knockout of either Fas or FasL ameliorated disease within this model (215–217). 
In other model systems such as acetaminophen-induced liver injury, IL-18 has also been shown to 
induce Fasl expression (171, 172, 228). Here, we demonstrated that IL-18 induced FasL in an 
IFNγ-independent manner. Therefore, while IL-18 is able to independently induce FasL and IFNγ, 
our data suggest that the elevated IFNγ in Il17rafl/fl x villin cre+ mice was more a reflection of 
increased lymphocyte activation, and FasL was the major IL-18-downstream contributor to disease 
exacerbation. Beyond our model, we established a novel connection between intestinal IL-17 
signaling and hepatic FasL, potentially implicating intestinal IL-17 in the many liver diseases 
linked to Fas-FasL associated cell death including fulminant, alcoholic, and viral hepatitis as well 
as liver carcinoma and fibrosis (229–232).  
There are various unanswered questions remaining. It is unclear if the microbiome is 
influencing IL-18 levels indirectly through bacterial metabolites, cytokines (161), or the 
inflammasome (233). Particularly given the lack of changes observed by 16S sequencing, 
metabolomics to assess bacterial metabolites and metatranscriptomics to investigate changes in 
bacterial behavior would be important to further characterize how the microbiome is influencing 
disease within our model. There is also a regulatory relationship between the liver and intestinal 
microbiome through the modulation of bile acid metabolism (88). Changes in bile acid 
composition within the liver alter the intestinal microbiome, while bacterial metabolites influence 
bile acid production (88, 99, 234). Alternations in intestinal IL-17RA signaling may potentially 
disrupt this relationship to worsen disease as well. Lastly, it appears that the local hepatic immune 
cell populations Il17rafl/fl x villin cre+ mice were poised to secrete more inflammatory cytokines 
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upon stimulation, whether by CpG DNA, Con A, or anti-CD3/CD28 (Figure 2-10I, Figure 2-20). 
Further examination of the epigenetic landscape of these cells may provide insight into how 
alterations in the intestinal microbiome and subsequent bacterial products influence immunity 
through modulation of the epigenome.   
 
 
Figure 2-20. Liver mononuclear cells from naïve Il17rafl/fl x villin cre+ exhibit increased IFNγ upon ex vivo 
stimulation. 
Liver cells of naïve littermate Il17rafl/fl and Il17rafl/fl x villin cre+ mice were enriched for mononuclear cells and 
stimulated with media (unstimulated control), Con A (5μg/mL), or anti-CD3/CD28 beads for 72 hours. IFNγ was 
measured in culture supernatants by luminex. (n = 3-9mice/group).  
 
While the Concanavalin A model certainly has its limitations as with other animal models 
of disease, the data within the literature suggest our work is consistent with observations in human 
disease. There are multiple reports showing the Con A model parallels aspects of autoimmune, 
viral, and fulminant hepatitis. Specific to our data, there is evidence showing that IFNγ and Fas 
were increased in bone marrow mononuclear cells of patients with autoimmune hepatitis (AIH) 
(235). Analysis of liver tissue and peripheral blood lymphocytes of AIH patients further confirmed 
elevated Fas/FasL compared to healthy controls (236, 237). Furthermore, IFNγ in liver biopsies 
(238) and serum IL-18 (239) were both elevated and correlated with disease severity. In chronic 
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hepatitis C, Zeremski et al. showed that intrahepatic levels of IFNγ-inducible chemokines 
including CXCL9 and CXCL10 were increased as compared to controls and associated with 
disease severity (240). Similar to AIH, serum IL-18 levels were also elevated and correlated with 
severity of liver damage (241). In fulminant hepatitis, there were increases in circulating IFNγ+ 
CD8 T cells (242) and serum IL-18 (243). In addition, a recently published report showed that 
excessive IL-18 due to genetic IL-18BP deficiency in human patients can promote fulminant viral 
hepatitis (162). As such, we believe the mechanisms described in our work are potentially 
translatable to clinical hepatitis in patients.  
Our data also have implications on hepatic diseases and illnesses beyond the gut-liver axis 
in conditions with “leaky gut” and increased bacterial translocation. This study reveals potential 
immune consequences of the subclinical bacteremia observed in many patients.  For example, in 
HIV/AIDS, much emphasis has been placed on leakage of LPS across the gut barrier causing 
wasting and chronic inflammation (181). Our data suggests extra-intestinal TLR9 ligand 
dissemination is regulated by intestinal IL-17R signaling and may therefore be another underlying 
mechanism in HIV/AIDS liver dysfunction (244).  Taken together, the connection our data 
established between intestinal Th17 cells, the microbiome, and hepatic immune signaling elucidate 





2.5 Working Model 
 
 
Figure 2-21. Working Model 
At the naïve state, intestinal epithelial-specific IL-17RA-deficient mice (Il17rafl/fl x villin cre+ mice) exhibited 
microbiome dysbiosis and increased translocation of bacterial products (CpG DNA) from the gut to the liver to drive 
intestinal and hepatic IL-18 production, respectively. Upon induction of Concanavalin A (Con A)-mediated hepatitis, 
absence of enteric IL-17RA signaling exacerbated hepatitis and hepatocyte cell death. IL-18 was necessary for disease 
exacerbation and associated with increased activated hepatic lymphocytes based on Ifng and Fasl expression. Thus, 
intestinal IL-17R regulates translocation of TLR9 ligands and constrains susceptibility to hepatitis in a microbiome-
dependent manner. 
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3.0 Gut-Central Nervous System Axis: Disruption of Intestinal Th17 Signaling and the 
Microbiome Exacerbate Autoimmune Neuroinflammation 
Parts of this chapter have been published in the following article:  
Kumar, P., L. Monin, P. Castillo, W. Elsegeiny, W. Horne, T. Eddens, A. Vikram, M. Good, A. A. 
Schoenborn, K. Bibby, R. C. Montelaro, D. W. Metzger, A. S. Gulati, and J. K. Kolls. 2016. 
Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota 
and Autoimmune Inflammation. Immunity 44: 659–671. 
3.1 Introduction 
Connections between the brain and intestine have been historically described. In early 
experiments, Ivan Pavlov showed that visual and auditory stimuli could elicit intestinal secretions 
in dogs (245). In psychiatric disease, patients with major depression were more likely to develop 
intestinal symptoms such as functional gastrointestinal diseases (FGID), while patients with FGID 
were more likely to develop depressive symptoms (246). This interaction of the gut-brain axis is 
also observed in neurologic disease. For example, the intestinal microbiome altered IL-17 
production in γδ T cells to affect neurologic outcomes in a mouse model of ischemic stroke (247). 
This chapter will focus on the gut-central nervous system (CNS) axis in the context of Multiple 
Sclerosis (MS).  
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3.1.1  Overview of Multiple Sclerosis 
MS is a chronic autoimmune demyelinating disease of the central nervous system. Signals 
are communicated within the CNS and to the peripheral nervous system (PNS) through action 
potentials transmitted along axons. Oligodendrocytes, specialized glial cells in the CNS, extend 
processes to support and insulate axons, forming the myelin sheath. Myelin dramatically increases 
the signal transduction through an axon to facilitate effective communication within the brain and 
spinal cord and to the rest of the body. In MS, the myelin sheath around the nerves is damaged 
resulting in motor, sensory, and sometimes cognitive dysfunction. In addition to demyelination, 
there is often inflammation and axonal loss due to the lack of protection and support offered by 
the myelin sheath (248, 249). The etiology of the disease remains unknown, though it is generally 
accepted that it is immune-mediated involving autoreactive lymphocyte activation, microglial 
activation, and chronic degeneration (249).  
3.1.1.1 Epidemiology  
MS is the most prevalent disabling neurologic disease in young adults, affecting nearly 1 
million people in the United States and about 2.5 million people worldwide (250–253). Like other 
autoimmune diseases, MS is more common in women with an estimated female to male ratio of 
about 3-4:1 (254). Disease onset is 28-31 years old on average but varies with the type of MS 
(255). There are a number genetic polymorphisms associated with disease, most notably HLA-
DRB1 (256). Interestingly, there is only a 25.3% concordance rate among monozygotic twins 
(257), suggesting the role of TCR/BCR sequence variation or environmental factors in disease risk 
and development. Indeed, this is one reason why we are investigating the microbiome in the 
context of MS pathogenesis.  
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3.1.1.2 Disease Manifestations 
MS can be broken down into four subtypes: clinically isolated syndrome, relapsing-
remitting MS, primary progressive MS, and secondary progressive MS (249). The clinically 
isolated syndrome represents the first episode of MS symptoms. Recurrence and progression of 
these symptoms categorizes the disease into one of the other three subtypes which differ on the 
basis of disease activity and rate disease of progression. Relapsing-remitting MS (RRMS) is 
episodic with recovery between each episode. There is often little to no disease progression 
between exacerbations. However, recovery from each attack can vary, establishing a new baseline 
of neurological disability. Disease symptoms in primary progressive MS (PPMS) advance 
continually from the clinically isolated syndrome, often causing more substantial deterioration due 
to the continuous progression. Secondary progressive MS (SPMS) begins in a pattern resembling 
RRMS but then shifts to a continual progressive decline as seen in PPMS. (249, 258) 
MS typically presents to the clinic between age 15-50 with acute or subacute development 
of symptoms of sensory dysfunction in the limbs, visual loss or disturbances such as diplopia, or 
impaired motor function in the absence of fever or other illness (258). Clinical signs more 
suggestive of MS include the Lhermitte sign (electric shock sensations going down the back or 
limbs when neck is flexed) and the Uhthoff phenomenon (symptom exacerbation as body 
temperature rises with normal activity) (249). While other symptoms may have occurred at initial 
presentation (i.e. bowel dysfunction, gait disturbance), concrete diagnosis of MS is determined per 
the criteria in the following section.  
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3.1.1.3 Diagnosis 
In addition to the clinical symptoms, MS is diagnosed via MRI confirmation. MS typically 
shows focal enhancing lesions in the white matter of brain and/or spinal cord during MRI. 
Diagnosis of MS depends on the fulfillment of the McDonald Criteria shown below (258). 
 
Table 3-1. 2017 McDonald Criteria  
 






1 (as well as clear-cut historical evidence of a 




Dissemination in space demonstrated by an 
additional clinical attack implicating a different 






Dissemination in time demonstrated by an 
additional clinical attack or by MRI 
OR demonstration of CSF-specific oligoclonal 
bands 
1 
Dissemination in space demonstrated by an 
additional clinical attack implicating a different 
CNS site or by MRI 
AND 
Dissemination in time demonstrated by an 
additional clinical attack or by MRI 
OR demonstration of CSF-specific oligoclonal 
bands 
Table sourced from Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of 
the McDonald criteria. Lancet Neurol 2018; 17:162. (258) 
 
3.1.1.4 Prognosis 
Multiple factors are thought to contribute to patient prognosis. Disease type is one factor 
with RRMS having a better prognosis compared to the progressive types. In patients with RRMS, 
early intestinal or bladder-related symptoms, shorter time between the initial and subsequent 
episode,  and early disability are indicative of poor prognosis (259). Increased CNS lesion burden 
and CNS atrophy are also associated with worse disease outcomes (260). In terms of 
demographics, race has been investigated as a potential prognostic factor, but conclusions from 
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these studies remain controversial. Though women are more likely to develop MS, men who 
develop MS are more likely to undergo a more severe disease course (261). In addition, pregnancy 
is associated with an overall decrease in MS relapse during pregnancy with increased risk 
postpartum (262). Interestingly, there are T cell changes during pregnancy (263, 264) as well as 
significant differences in the microbiome that were associated with changes in host inflammation 
and metabolism (265). 
While assessment of these factors are helpful, it is important to note that their prognostic 
reliability remains limited (260). Ongoing research is required to better identify and describe these 
factors to improve disease management. Beyond this, further studies to investigate the etiology of 
disease are critical to develop novel therapeutics strategies.  
3.1.1.5 Treatment 
Acute exacerbations are treated with glucocorticoids with the purpose of shortening the 
episode rather than addressing long term disease course (266). There is also evidence suggesting 
a benefit of plasmapheresis in RRMS acute episodes (249) but not for treatment in the progressive 
MS subtypes. Symptom-specific treatments are prescribed as well to assist with isolated problems 
such as bladder control (266). While both acute management and targeted symptomatic 
interventions are very important for disease management, disease modifying drugs and 
immunotherapies appear to provide more sustained responses. 
Disease-modifying therapies (DMTs) do not constitute as cures, but they can potentially 
affect disease progression and maintenance. A recent 2019 observational study of over 1500 
patients investigated the role of DMTs on prevention of RRMS conversion to SPMS (267). The 
study found that initial treatment with fingolimod, alemtuzumab, or natalizumab lowered the risk 
of RRMS conversion to SPMS as compared to glatiramer acetate and interferon beta. In 
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progressive MS, the suggested DMTs include ocrelizumab, cladribine, and siponimod. A brief 
description of each of the aforementioned therapies are listed below. 
 






Structural analog of 
natural sphingosine 
Prevents lymphocyte egress from lymphoid tissue 
into circulation by activating and subsequently 
downregulating sphingosine-1-phosphate 
receptor (268, 269) 
Alemtuzumab Lemtrada Monoclonal Human 
anti-CD52 
Depletes circulating T and B cells (270–272) 
Natalizumab Tysabri Humanized anti-
α4β1integrin 
monoclonal  






Mixture of synthetic 
peptides similar to 
myelin basic protein 
Competitive inhibitor of MHC to prevent 
presentation of myelin antigens; promotes 
immunosuppressive responses in CNS (276–278) 
Interferon beta Avonex, Rebif Type 1 interferon, 
Formulations: IFNβ-
1a and IFNβ-1b  
Broad range of anti-inflammatory effects 
including decreasing pro-inflammatory cytokines 
while increasing anti-inflammatory cytokines, 
decreasing cell migration into the CNS, 
promoting nerve growth factor for CNS repair, 
and other effects on T cells, B cells, and DCs 
(279–281) 
Ocrelizumab Ocrevus Recombinant anti-
human CD20 
monoclonal antibody 
B cell depletion (282) 
Cladribine Mavenclad Purine nucleoside 
analogue 
Lymphocyte depletion due to cytotoxic effects on 








Prevents lymphocyte egress from lymphoid tissue 
into circulation by activating and subsequently 
downregulating sphingosine-1-phosphate 
receptors 1 and 5 specifically (284) 
 
 
These therapies demonstrate the critical role of the immune system in MS pathogenesis. In 
addition, the above therapies target different aspects of the immune system, emphasizing the 
complexity of disease pathogenesis and the potential benefit of targeting multiple aspects of the 
immune system for effective treatment. To that end, the dissertation studies in this chapter 
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investigate the role of intestinal Th17 cells and the intestinal microbiome in MS pathogenesis with 
the ultimate goal of identifying novel therapeutic strategies.  
3.1.2  Th17 Cells and the Microbiome in Multiple Sclerosis 
Th17 cells and the intestinal microbiome have both been implicated in MS. When 
considering the mechanisms by which these factors can affect disease, it is important to understand 
the barriers limiting contact with CNS as an immunoprivileged site.  
3.1.2.1 Barriers of the CNS 
The CNS is separated from the rest of the body through its three membranes (the dura 
mater, pia mater, and arachnoid membrane) and specialized barriers (Figure 3-1). The blood brain 
barrier (BBB), which includes the blood-leptomeningeal barrier for the purposes of this discussion, 
separates the CNS parenchyma from the CNS vasculature (Figure 3-1A). In this way, the body can 
tightly regulate vascular entry into the CNS by cells and other potentially inflammatory mediators.  
Indeed, the BBB is able to prevent entrance to greater than 98% of antibodies and small molecules 
while maintaining its ability to transport materials out (285). It is comprised of specialized 
endothelial cells and the combination of the parenchymal basement membrane and astrocyte foot 
processes together termed the glia limitans (286). Therefore, should external components breach 
the specialized tight junction network of the BBB vascular endothelial cells, there exists an 
additional barrier unique to the CNS in the form of the glia limitans. Another interface between 
the CNS and periphery is the blood-cerebrospinal fluid barrier (BCSFB) (Figure 3-1B). This is 
located at the choroid plexus within the ventricles of the brain. The choroid plexus is a structure 
derived form of ependymal cells lining the ventricle and includes the epithelial cells that secrete 
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CSF (286). The endothelial cells lining the choroid plexus do not have specialized tight junctions, 
offering a more accessible entry point for lymphocytes into the subarachnoid space containing the 
CSF. It is thought that this degree of accessibility is actually critical for immune surveillance. 
Indeed, this region is rich in antigen presenting cells, and the CSF actually contains a 
proportionately large amount of memory CD4+ T cells relative to the systemic circulation (286, 
287). Especially interesting in the context of these dissertation studies, research from patients with 
non-inflammatory neurological disease showed the presence of skin and gut homing memory T 
cells in the CSF (287). This emphasizes the potential for crosstalk between the gut and the brain 
and suggests direct communication between the two systems via lymphocyte migration.  
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Figure 3-1. CNS Barriers 
(A) The CNS is separated from the rest of the body through its meninges (3 membranes: the dura mater, pia mater, 
and arachnoid membrane) and specialized barriers. The blood-brain barrier separates the CNS parenchyma from the 
CNS vasculature. It is comprised of specialized non-fenestrated endothelial cells and the combination of the 
parenchymal basement membrane and astrocyte foot processes together termed the glia limitans. (B) Another interface 
between the CNS and periphery is the blood-cerebrospinal fluid barrier (BCSFB). This is located at the choroid plexus 
within the ventricles of the brain. The choroid plexus is a structure derived form of ependymal cells lining the ventricle 
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and includes the epithelial cells that secrete CSF. The fenestrated endothelial cells lining the choroid plexus do not 
have specialized tight junctions, offering a more accessible entry point for lymphocytes into the subarachnoid space 
containing the CSF. 
 
 
There are physiological mechanisms to enter the CNS. Trafficking of small molecules, 
antigens, and other potentially immunomodulatory components can occur through passive 
diffusion, transcytosis, or specific transporters located at the BBB/BCSFB (288). Proper 
trafficking of immune cells into the CNS requires expression of specific signaling and adhesion 
molecules on both the part of the entering cell as well as the cells comprising the CNS barriers. 
For example, expression of α4 and β2 integrin expression on the immune cells are required for 
interaction with intercellular and vascular adhesion molecules (i.e. ICAM1-2, VCAM-1) on the 
BBB endothelial cells in order to adhere and commence rolling on the endothelium (286). In EAE, 
integrin β3 is important for CNS migration (289). Studies have also shown that endothelial P-
selectin is required to cross the brain-leptomeningeal barrier (290). Though brain-specific 
chemokine/receptors have not been identified, there are certain chemokines commonly expressed 
in the brain. For example, CCL19 is constitutively expressed by CNS endothelial cells (286), and 
CCL20 is  expressed by the choroid plexus, promoting migration of CCR6+ CD4+ T cells (285). 
Beyond these interactions, studies tracing radioactively labeled resting and active T cells showed 
that lymphocyte activation is necessary to cross the BBB in the spinal cord (291). These 
physiological mechanisms can be manipulated to recruit immune assistance during infection and 
inflammation. Conversely, they can be compromised during disease, allowing aberrant breach the 
brain barriers. 
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In MS and the EAE mouse model, the BBB becomes compromised, permitting increased 
lymphocytic infiltration. The mechanisms through which this disruption occurs is a topic of 
continued investigation. However, there is evidence that matrix metalloproteinases (MMPs) play 
a role. Specifically, MMP2 and MMP9 were shown to disrupt the astrocyte-parenchymal basement 
membrane interaction to decrease the integrity of the glia limitans (292). Lymphocytic breach of 
the BBB is accompanied by proinflammatory changes that induce additional infiltration. When 
autoreactive T cells enter the CNS and encounter their cognate antigen, they set off a positive 
feedback loop in which chemokine and adhesion signaling changes in the CNS barriers promote 
immune cell recruitment to further exacerbate inflammation and subsequent damage (286).  While 
different cells may promote BBB compromise and MS immunopathology, many reports have 
described Th17 cells as a major contributor. 
3.1.2.2 Th17 Cells in Multiple Sclerosis 
Numerous studies have linked Th17 cells to MS pathogenesis. As previously mentioned, 
patients with MS have increased serum IL-17 and increased IL-17 in MS lesions (123, 124). In 
RRMS, there was also a correlation with serum IL-17F levels and 2 year relapse rate (293). In 
terms of the BBB, hallmark Th17 cytokines have been implicated in disruption and infiltration. 
Specifically, in a human brain-derived microvascular endothelial cell model of the BBB, there was 
greater migration of Th17-polarized human CD4+ T cells as compared to Th1- polarized CD4+ T 
cells (294). This study showed that IL-17 and IL-22 stained positively in highly infiltrated MS 
lesions, and that there was an upregulation of IL-17 and IL-22 receptors on the brain endothelial 
cells within these lesions (294). Ex vivo, both cytokines were able to promote migration of 
lymphocytes through the human BBB model, accompanied with increases in CCL2 and CXCL8 
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(294). Together, these human and patient data support a role for Th17 in MS with specific 
involvement in immune infiltration.  
In the EAE model of MS, mice were protected by deficiency of IL-17RA (126), IL-17RC 
(295), and transcription factors required for Th17 differentiation including RORγt, BATF, and 
JUNB (14, 296, 297). However, there are conflicting reports regarding relative contributions of 
IL-17A and IL-17F to EAE (125, 298, 299), raising the possibility of institutional microbiome 
differences contributing to these mixed reports as well as the potential role of other Th17 related 
cytokines in disease pathogenesis.  
Pathogenic Th17 cells that double produce IL-17 and IFNγ or IL-17 and GM-CSF have 
been identified. Mice deficient in IFNγ and knockout of the IFNγ receptor actually developed 
worse EAE, suggesting a protective role of IFNγ in disease pathogenesis (300–302). Conversely, 
GM-CSF has been shown to be detrimental, as GM-CSF deficient mice were resistant to EAE 
(303, 304). Two cytokines known to favor the differentiation of pathogenic Th17 cells are IL-23 
and IL-1β (30). Both cytokines are thought to contribute to EAE pathology. Knockout of IL-1R1 
or IL-1β was protective (305, 306) along with knockout of IL-23RA or IL-23p19 (29, 307). Studies 
have now shown that IL-23 is necessary for in vivo terminal differentiation and maintenance of 
Th17 cells (26, 29). Moreover, Codarri et al. and El-Behi et al. showed that IL-23 (27, 308), master 
Th17 transcription factor Rorγt (308), and IL-1β (27) was required for T cell GM-CSF production 
in EAE. In both reports, GM-CSF from Th17 cells contributed to EAE pathology (27, 308).   
Interestingly, recent work suggested a role for intestinal Th17 cell signaling in MS. The 
study evaluated intestinal biopsies from RRMS patients and healthy controls via flow cytometry 
and found that increased intestinal Th17 cells correlated with MS disease activity based on MRI 
and disability score (309). In addition to this, 16S sequencing of microbial DNA isolated from 
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tissue biopsies showed specific differences in RRMS patients as compared to controls (309), 
providing human data implicating not only intestinal Th17 signaling in MS but the intestinal 
microbiome as well.  
3.1.2.3 Intestinal Microbiome in Multiple Sclerosis 
A number of studies have examined the microbiome in the context of multiple sclerosis. 
Patients with MS exhibit an altered microbiome compared to healthy controls. A metanalysis of 
these works have described an increase in Methanobrevibacter and Enterobacteriaceae in MS 
patients with enrichment of Fecalibacterium prausnitzii and SCFA-producing bacteria such as 
Prevotella and Lachnospiraceae in controls (310). Additional studies have been done in EAE that 
further support the role of the microbiome in MS. Germ-free mice and mice treated with broad 
spectrum antibiotics were protected in EAE (311–313). This included combinations of 
metronidazole, ampicillin, neomycin, and vancomycin as well as kanamycin, colistin, and 
vancomycin. To show that the differences observed in patients may point to the microbiota as a 
cause rather than an association, a fecal microbiota transplant (FMT) was performed from MS 
patients into germ free mice prior to EAE induction. Results showed that mice receiving stool from 
MS patients as compared to healthy controls exhibited worsened EAE clinical scores (129). These 
data are highly suggestive of the microbiota as a contributing factor in MS, but also prompt the 
question of mechanism. 
The ways the microbiota is able to affect health and disease detailed in the initial 
introduction of this dissertation also apply here. There is evidence that the microbiome is 
influencing T cell immunology in EAE. The protection from EAE in germ-free mice and mice 
treated with broad spectrum antibiotics were all associated with a decrease in Th1 and Th17 cells 
partnered with an increase in Tregs (311–313). This suggests that the microbiota plays a role in 
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balancing the Treg population and the Th1/Th17 effector population. Though contradictory to the 
previous data showing increased Tregs in germ free mice, there is also evidence showing that 
SCFAs from the microbiota can promote Treg cell expansion and activation (62). SCFAs have 
been shown to signal through G protein-coupled receptors on Tregs, macrophages, dendritic, and 
intestinal epithelial cells (314, 315). For example, binding of butyrate on GPR109A on 
macrophages and dendritic cells promoted intestinal differentiation of Tregs (315). Moreover 
propionate binding to GPR43 on Tregs enhances intestinal Treg proliferation (314). In EAE, oral 
supplementation with the SCFA propionic acid increased T regulatory cells and ameliorated EAE 
(316). In contrast, long chain fatty acid (LCFA) lauric acid had the opposite effect (316). As a 
proof of concept study, propionic acid supplementation was implemented in a small cohort of MS 
patients. The treatment regimen called for 1g of oral propionic acid supplementation daily. Results 
showed that as compared to controls, supplementation with oral propionic acid increased Treg- 
and decreased Th17-cell frequencies (317). Aside from SCFAs, bacterial products that can activate 
toll like receptors (TLRs) also influence EAE. While there are conflicting reports regarding the 
relative contribution of specific TLRs in EAE, there is evidence showing that knockout of TLR4 
in CD4+ T cells was protective (318). In addition, global knockout of TLR2, TLR9, and MyD88 
also ameliorated disease (319). Taken together, these data and those previously discussed point to 
a role of the microbiome in EAE pathogenesis and supports the investigation of the microbiome 
as a potential therapeutic target in MS.  
3.1.3  Study Overview 
Given the relationship between the intestinal microbiome and Th17 cells and the role of 
each of these factors in MS/EAE, we investigated the significance of enteric IL-17R signaling in 
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EAE using intestinal specific IL-17 receptor knockouts (Il17rafl/fl x villin cre+ mice). We 
hypothesized that disruption of the reciprocal regulatory relationship between enteric IL-17 
signaling and the gut microbiota leads to dysbiosis, expansion of Th17 cells, and increased 
predisposition to autoimmune neuroinflammation. Our data suggested that Il17rafl/fl x villin cre+ 
mice, which have higher Sfb levels, exhibited earlier EAE onset and increased EAE incidence and 
severity as compared to littermate Il17rafl/fl controls. Treatment with vancomycin ameliorated 
disease, further supporting our hypothesis. Disease exacerbation was accompanied by systemic 
increases in IL-17 and GM-CSF responses. In addition, preliminary data indicated that Il17rafl/fl x 
villin cre+ mice have increased intestinal expression of Csf2, Ccr2, and Ccr6 and increased spinal 
cord expression of Nos2 immediately prior to disease onset. Together, this suggested that there 
could be increased migration into the CNS of Il17rafl/fl x villin cre+ mice, contributing to 
exacerbated disease. These studies elucidate how dysregulation of enteric IL-17R signaling and 
the commensal microbiota can contribute to the pathogenesis of MS and other autoimmune 
conditions. Moreover, it can provide insight into novel therapeutic strategies targeting the gut-
brain axis. 
3.2 Methods 
3.2.1  Experimental Model and Subject Details  
Mice 
All mouse work was performed in accordance with the Institutional Animal Care and Use 
Committees (IACUC) and relevant guidelines at the University of Pittsburgh, School of Medicine 
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(protocol #16109334). Il22ra2-/- mice were bred and housed at the UPMC Children’s Hospital of 
Pittsburgh. Il17rafl/fl and Il17rafl/fl x villin cre+ mice were generated at the UPMC Children’s 
Hospital of Pittsburgh by crossing Il17rafl/fl mice to Il17rafl/fl x villin cre+ mice. Both male and 
female age-matched mice from 6-10 weeks of age were used for all experiments. The 
aforementioned breeding strategy allowed for controls and knockout mice within each experiment 
to be littermates. Littermate age-matched males and females were randomly assigned to 
experimental groups. Both males and females were used within each group in order to account for 
sex-differences while maintaining littermate controls and sufficient n for statistical power. All 
mice were housed in pathogen-free conditions at the UPMC Children’s Hospital of Pittsburgh.  
 
Ex vivo cultures 
Ex vivo stimulation of splenocytes and lamina propria lymphocytes. Cells from 6-10-week-
old naïve Il17rafl/fl mice and Il17rafl/fl x villin cre+ mice were harvested and processed into single 
cell suspensions (protocol described below). In addition to detailed experiment-specific stimuli, 
cells were maintained at 37°C in Iscove’s Modified Dulbecco’s Medium (IMDM) with GlutaMAX 
Supplement (Gibco), 10% heat-inactivated fetal bovine serum, 100 units/mL of penicillin and 
streptomycin, and 0.3mg/mL of L-glutamine.  
 
Experimental Models 
Experimental autoimmune encephalomyelitis (EAE) was induced using myelin 
oligodendrocytes glycoprotein (MOG35-55) (Bio-Synthesis, Inc.) in complete Freund’s adjuvant 
(CFA) containing 100 µg M. tuberculosis strain H37Ra (Difco)  as well as pertussis toxin (Sigma-
Aldrich) (29). 
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3.2.2  Method Details 
Animal treatments 
ll17rafl/fl x villin cre+ and littermate control Il17rafl/fl mice were used for EAE experiments. 
Co-housed cre+ and cre- mice were separated and kept in separate cage 1 week before EAE 
induction. These mice were immunized at both sites on the hind flank with 100 µg peptide 
corresponding to the immunodominant epitope of myelin oligodendrocytes glycoprotein (MOG35-
55) (Bio-Synthesis, Inc.) in 200 µl CFA containing 100 µg M. tuberculosis strain H37Ra (Difco) as 
described previously (29). All immunized mice also received 200 ng of pertussis toxin (Sigma-
Aldrich) intraperitoneally on days 0 and 2. Mice severity scores for EAE were evaluated blindly 
according to the following scale: 1: flaccid tail; 2: impaired righting reflex and hind limb weakness; 
3: partial hind limb paralysis; 4: complete hind limb paralysis; 5: hind limb paralysis with partial 
fore limb paralysis; 6: moribund. 
 EAE was also induced after 2 weeks of vancomycin (0.5 g/L) in the drinking water ad 
libitum or control water treatment. Vancomycin or control water-treated ll17rafl/fl x villin cre+ mice 
were immunized as above. Mice were maintained on antibiotic water throughout EAE time course.  
Mice were also treated with 0.5mg/mouse Anakinra (Kineret) twice daily for 21 days 
beginning at day 0 of EAE and maintained throughout the disease course.  
 
qRT-PCR  
Spinal cords and intestines were harvested from 6-10-week-old littermate Il17rafl/fl and 
Il17rafl/fl x villin cre+ mice at the naïve state and day 9 post EAE induction. Tissues were 
homogenized in Trizol buffer (Life Technologies). Total RNA extraction was performed according 
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to Trizol manufacturer’s instructions. RNA was transcribed into cDNA using iScript reagent (Bio-
RAD) according to manufacturer’s instructions.  
For qRT-PCR, SYBR Green supermix (Bio-RAD) was used for analysis of small subunit 
ribosomal RNA gene (16S rRNA) expression. 16S primers included: forward: 
ACTCCTACGGGAGGCAGCAGT, reverse: ATTACCGCGGCTGCTGGC (47, 48, 192). 
SsoFast supermix (Bio-RAD) was used for qRT-PCR analysis with primers (Applied Biosystems) 
for mouse Hprt, Il17a, Csf2, Ccr2, Ccr6, Nox2, Il1b, and Il1rn. Expression of all genes was 
normalized relative to housekeeping gene mouse Hprt. Reaction: 95°C for 3 minutes, 49 cycles at 
95°C for 10 seconds (s) and 60°C for 30s. SYBR Green reactions also had an additional melt curve 
at the end of the reaction above: 60°C for 5s with +0.5°C increment every cycle up to 95°C.  
 
RNA sequencing 
Total RNA from terminal ileum (1-4 µg) of 6-week-old ll17rafl/fl x villin cre+ and littermate 
ll17rafl/fl control mice were used as starting material for deep sequencing using the in-house 
Illumina TrueSeq RNA Sample Preparation v2 Guide. Briefly, mRNA was purified with oligo-dT 
beads, fragmented with magnesium and heat-catalyzed hydrolysis, and used as a template for first- 
and second-strand cDNA synthesis with random primers. The cDNA 3’ ends were adenylated, 
followed by adaptor ligation and a 15-cycle PCR to enrich DNA fragments. Quantification of 
cDNA libraries were performed by using Kapa Biosystems primer premix kit with Illumina-
compatible DNA primers. The cDNA libraries were pooled at a final concentration 1.8 pM. Single-




Lamina propria lymphocyte isolation 
Briefly, 10 cm pieces of terminal small intestine were separated from mesentery and 
Peyer’s patches were carefully excised. Tissues were opened longitudinally and washed with 
HBSS. Epithelial cells were separated from lamina propria by incubating 1 cm pieces of small 
intestine in 5 mM EDTA on a shaker (100 rpm) for 10 minutes. Tissue were washed with HBSS 
without EDTA until supernatant was not cloudy. Tissues were cut into small pieces and incubated 
for 10 minutes at 370C in HBSS containing 0.3 mg/ml collagenase, 0.1 mg/ml DNase, 1 mM CaCl2 
and 1 mM MgCl2. 10% FBS was added and digested tissue suspension was filtered using 70-
micron cell strainer. After centrifugation, digested tissue pellet was re-suspended with 44% percoll 
and layered over 67% percoll. Mononuclear cells were isolated from an interphase of percoll 
gradients, washed, and resuspended for downstream applications. 
 
Splenocyte Isolation 
Spleens were harvested from mice into Iscove’s Modified Dulbecco’s Medium (IMDM) 
with GlutaMAX Supplement (Gibco), 10% heat-inactivated fetal bovine serum, 100 units/mL of 
penicillin and streptomycin, and 0.3mg/mL of L-glutamine (“Complete Media”). Spleens were 
then crushed and passed through a 70μm filter into a 50ml conical tube. Cells were washed with 
serum-free media. RBC lysis was performed. Cells were then washed 2x in complete media 
described above and resuspended for downstream applications. 
 
Flow cytometry 
 Small intestine lamina propria lymphocytes were isolated from littermate Il17rafl/fl and 
Il17rafl/fl x villin cre+ mice as described above. Single cell suspensions were stained with 
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eBiosciences antibodies against CD3 (17A2) and CD4 (RMA4-5) in a 96 well round bottom plate 
in the dark on ice for 20 minutes. Cells were washed 2.5x in cold FACS Buffer (0.5% FBS/0.01% 
NaN3/PBS), then fixed using BD Cyto-fix and incubated in the dark on ice for 20 minutes. Cells 
were washed and resuspended in PBS or FACS buffer and analyzed using the BD LSR II flow 
cytometer and FlowJo Software. 
 
ELISPOT 
MOG-specific IL-17A-producing T cells from the spleen of day 9 EAE induced mice were 
enumerated using peptide-driven ELIS POT. Briefly, 96-wells ELISPOT plates were coated with 
monoclonal anti-mouse IL-17, blocked with media containing 10% FBS. Cells from spleen were 
seeded at an initial concentration of 5×105 cells/well and subsequently diluted two-fold. Irradiated 
B6 splenocytes were used as APCs at a concentration of 1×106 cells/well in the presence of MOG 
(10 μg/ml) peptide. After 24 hours, plates were washed and probed with biotinylated anti-mouse 
IL-17. Spots were visualized and enumerated using a CTL-Immunospot S5 MicroAnalyzer and 
corrected with CD4 T cells number. Absolute CD4+ T cells percentage and number were 
determined by using flow cytometry and cells count. No spots were detected in cultures lacking 
antigen or when using cells from uninfected mice.  
 
Ex vivo cell stimulations 
Splenic and small intestine lamina propria lymphocytes were isolated as described above. 
Cells were plated at a concentration of 5 x 105 or 1 x 106 cells per well in a 96-well round bottom 
plate. Cells were then stimulated with various conditions at 37°C for the detailed incubation times.  
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Lamina propria lymphocytes were isolated from day 9 MOG immunized ll17rafl/fl x villin 
cre+ and littermate control ll17rafl/fl control mice, and re-stimulated with MOG peptide (200 µg/ml) 
for 24 hours. Cell culture supernatants were analyzed for GM-CSF using BioLegend mouse GM-
CSF ELISA kit as per manufacturer’s instruction (BioLegend).  
Splenocytes were isolated at the naïve state and day 9 post immunization of MOG-CFA or 
OVA-CFA. Cells were stimulated with MOG peptide (200ug/mL), OVA protein (200ug/mL), or 
anti-CD3/CD28 for three days. Supernatants were harvested and cytokine levels were measured 
via ELISA or Luminex. 
 
ELISA and Luminex Assays 
Cytokines from serum and cell culture supernatants were measured using the following 
ELISA or Luminex kits according to the manufacturer’s instructions: Mouse-IL-17 ELISA MAX 
Kit (BioLegend), Mouse GM-CSF ELISA MAX Kit (BioLegend), MILLIPLEX Mouse Th17 
Magnetic Bead Panel (Millipore Sigma), and Cytokine & Chemokine 36-Plex Mouse Procarta 
Plex Panel 1A (Thermo Fisher Scientific-Affymetrix), Human IL-1RA ELISA (Ebioscience).  
3.2.3  Quantification and Statistical Analysis 
Intestinal RNA sequencing 
Raw reads from Illumina NextSeq500’s in fastq format were trimmed to remove 
adaptor/primer sequences. Trimmed reads were then aligned using BWA (version 0.5.9, settings 
aln -o 1 -e 10 -i 5 - k 2 -t 8) against the mouse genome build 37.2 in geneSifter Analysis Edition 
for Next Generation Sequencing (Geospiza, Seattle, WA). Additional alignment and post-
processing were done with Picard tools (version 1.58) including local realignment and score 
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recalibration to generate a finale genomic aligned set of reads. Reads mapping to the genome were 
characterized as exon, intron, or intergenic using the matched annotation for the genomic reference 
sequence. The remaining unmapped reads from the genomic alignment were then aligned to a 
splice reference created using all possible combinations of known exons and then categorizing 
these as known or novel splice events. This aligned data was then used to calculate gene expression 
by taking the total of exon and known splice reads for each annotated gene to generate a count 
value per gene. For each gene there was also a normalized expression value generated in two ways: 
1) Reads per Mapped Million (RPM), which was calculated by taking the count value and dividing 
it by the number of million mapped reads, 2) Reads per Mapped Million per Kilobase (RPKM), 
which was calculated by taking the RPM vale and dividing it by the kilobase length of the longest 
transcript for each gene. The RPM values were subsequently used for comparing gene expression 
across samples to remove the bias of different numbers of reads mapped per sample. RPKM values 
were subsequently used for comparing relative expression of genes to one another to remove the 
bias of different numbers of mapped reads and different transcript lengths.  
 
Statistical Tests 
Statistical tests used are indicated in the figure legends. Data are presented as mean with 
individual samples visualized or mean + SEM. To compare differences between two groups, 
student-T test or non-parametric Mann-Whitney test was used depending on the distribution of the 
data. When comparing one variable in three or more groups, one-way ANOVA with multiple 
comparisons was used. When comparing multiple variables among two groups, two-way ANOVA 
with multiple comparisons or multiple T-tests per row was used. GraphPad Prism software was 
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used to analyze experimental groups. For all data, statistically significant was defined as p<0.05. 
The degree of statistical significance was defined as: p<0.05*, <0.01**, <0.001***, <0.0001****. 
 
Analysis Software 
GraphPad Prism was used for statistical analysis described above. Image J was used for 
histology analysis. BWA (version 0.5.9) in geneSifter Analysis Edition for Next Generation 
Sequencing (Geospiza, Seattle, WA) and Picard tools (version 1.58) were used for RNA 
sequencing analysis. 
3.2.4  Data and Software Availability  
The raw RNA sequencing data have been deposited into the sequencing read archive under 
SRA accession number SRP069071.  
Figure cartoons within this chapter were images adapted from Servier Medical Art by 
Servier. Original images are licensed under a Creative Commons Attribution 3.0 Unported License 
(https://creativecommons.org/licenses/by/3.0/legalcode). 
3.3 Results 
3.3.1  Disruption of enteric IL-17RA signaling exacerbates neuroinflammation. 
To investigate how intestinal IL-17 signaling regulates neuroinflammation, we induced 
experimental autoimmune encephalomyelitis (EAE) in intestinal epithelium-specific Il17ra 
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knockout mice (Il17rafl/fl x villin cre+) (48).  Knockout  mice and littermate l17rafl/fl controls were 
treated with subcutaneous injections of myelin oligodendrocyte glycoprotein (MOG) in complete 
Freund’s adjuvant along with intraperitoneal injections of pertussis toxin (PTx) given at day 0 and 
2 post immunization as described in Figure 3-2A.  
It has been previously shown that globally deleting Il17ra is protective in this model of 
EAE (126). Interestingly, deleting Il17ra signaling specifically in the intestinal epithelium 
exacerbated disease (Figure 3-2B). As compared to littermate Il17rafl/fl controls, Il17rafl/fl x villin 
cre+ mice exhibited earlier onset and increased clinical severity (Figure 3-2B). This correlated 
with an increase in proinflammatory cytokine production in the terminal ileum and serum as 
measured at the transcript and protein level prior to disease onset (day 9 post immunization) 
(Figure 3-2C-F). More specifically, there were increases in terminal ileum (TI) Il17a and Csf2 
(encodes GM-CSF) transcript (Figure 3-2E-F), but only significant differences in serum GM-CSF 
(Figure3-2D). Together, these data showed that disruption of intestinal IL-17RA signaling 
exacerbated disease potentially due to aberrant systemic cytokine responses reflective of cytokine 
changes observed in the intestine.  
Multiple IL-17 family cytokines signal through IL-17RA. IL-17A and IL-17F bind to IL-
17RA only through a multimeric receptor with IL-17RC (15). In order to test whether exacerbated 
disease is specifically due to IL-17A and F signaling, we induced EAE in Il17rcfl/fl x villin cre+ 
mice. Compared to littermate floxed controls, gut specific IL-17RC knockout mice appeared to 
have worse, but not significantly exacerbated disease (Figure 3-3A). In addition, disease onset was 
identical for both knockouts and controls (Figure 3-3A). This suggested that IL-17A and IL-17F 
may affect disease severity but not onset. Because knockout of intestinal IL-17RC did not 
 105 
exacerbate disease to the same severity as IL-17RA, it also implicates other IL-17 family members 
such as IL-25 (320)in disease progression.  
 
 
Figure 3-2 Disruption of enteric IL-17RA signaling exacerbates neuroinflammation. 
(A) Schematic of experimental autoimmune encephalomyelitis (EAE) model. (B) Data shown are EAE severity score 
in  Il17rafl/fl x villin cre+ (n = 8) mice and littermate Il17rafl/fl controls (n = 6).  (C-D) Il17rafl/fl x villin cre+ and 
littermate Il17rafl/fl control mice serum were harvested on day 9 after MOG immunization. Serum IL-17A and GM-
CSF concentrations were determined in the serum by Luminex assay.  (E-F) Terminal ileum of  Il17rafl/fl x villin cre+ 
and littermate Il17rafl/fl mice were harvested on day 9 post EAE induction and analyzed for Il17a and Csf2 expression 





Figure 3-3. Moderately exacerbated EAE in Il17rcfl/fl x villin cre+ mice is microbiome-dependent. 
(A) EAE severity score in  Il17rcfl/fl x villin cre+ (n = 8) mice and littermate Il17rcfl/fl controls (n = 7).  (B) Il17rcfl/fl x 
villin cre+ mice were treated with and without vancomycin (0.5g/L) in the drinking water ad libitum for two weeks 
followed by EAE induction. EAE severity scores in water control (n = 2) or vancomycin-treated  (n = 3) Il17rcfl/fl x 










3.3.2  Disease in Il17rafl/fl x villin cre+ mice is microbiome-dependent. 
We next tested whether disease in Il17rafl/fl x villin cre+ mice was dependent on the 
microbiome. Literature showed that segmented filamentous bacteria (Sfb) induced intestinal Th17 
responses (60). In Il17rafl/fl x villin cre+ mice, we found an overgrowth of Sfb and discovered that 
IL-17 worked to constrain the Sfb population in  a reciprocal regulatory relationship (48). Because 
Sfb is a gram-positive bacteria, we focused our investigation of the microbiome on this group of 
bacteria. For two weeks prior to EAE induction, mice were given vancomycin (0.5g/L) in the 
drinking water ad libitum to target gram-positive bacteria. Antibiotic treatment abrogated disease 
(Figure 3-4A, Figure 3-3B) along with intestinal levels of Sfb, Il17a, and Csf2 (Figure 3-4B-D). 
This suggested that disease in Il17rafl/fl x villin cre+ mice was microbiome-dependent potentially 









Figure 3-4. Disease in Il17rafl/fl x villin cre+ mice is microbiome-dependent. 
 Il17rafl/fl x villin cre+ mice were treated with and without vancomycin (0.5g/L) in the drinking water ad libitum for 
two weeks followed by EAE induction. (A)  EAE severity scores in water control (n = 7) or vancomycin-treated  (n = 
7) Il17rafl/fl x villin cre+ mice. (B-D) Terminal ilea of water control or vancomycin treated Il17rafl/fl x villin cre+ mice 
were harvested on day 9 after MOG-CFA immunization. Terminal ileum Sfb (B), Il17a (C), and Csf2 (D) gene 
expression were analyzed by qRT-PCR. p<0.05*, <0.01**, <0.001***, <0.0001**** (Mann-Whitney Test, Unpaired 
T Test, Area Under the Curve) 
3.3.3  Il17rafl/fl x villin cre+ mice exhibit increased splenic IL-17 responses and increased 
antigen-specific GM-CSF responses. 
Because the differences in disease severity occurred very early in the disease course, we 
hypothesized that there may be an increase in circulating effectors by disease onset. To test if there 
were increased antigen-specific effector responses prior to disease onset, we sacrificed the mice at 
day 9 post immunization when clinical disease scores were still zero. ELISPOT analysis of splenic 
CD4+ T cells showed there was not a significant increase in the number of splenic MOG-specific 
IL-17A+ cells (Figure 3-5A). In addition, we assessed the amount of cytokine produced by ELISA. 
Ex vivo stimulation of bulk splenocytes with MOG and negative control ovalbumin (OVA) showed 
no difference in the amount of antigen-specific IL-17 in culture supernatants (Figure 3-5B). To 
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validate this with another antigen, mice were immunized with CFA-OVA instead of CFA-MOG 
as detailed Figure 3-2A. Ex vivo OVA restimulation of splenocytes taken at day 9 post 
immunization replicated these findings (Figure 3-5C), confirming that Il17rafl/fl x villin cre+ mice 
did not exhibit increased splenic IL-17 responses specific to the antigen used in immunization. 
However, when splenic T cells taken from naïve mice were non-specifically stimulated with anti-
CD3/CD28, there was a significant increase in the amount of IL-17 produced (Figure 3-5D). 
Together, this suggested that while there was not an increase in MOG-specific IL-17 responses, 
there was an increase in general splenic IL-17A production. Because there was also an increase in 
serum GM-CSF at day 9 post immunization (Figure 3-2D), similar assays were performed to assess 
antigen specific GM-CSF production. Interestingly, increased antigen-specific GM-CSF was 





Figure 3-5 Il17rafl/fl x villin cre+ mice exhibit increased splenic IL-17 responses and increased antigen-specific 
GM-CSF responses. 
(A-B) Splenocytes from Il17rafl/fl and Il17rafl/fl x villin cre+ mice were isolated 9 days post myelin oligodendrocyte 
glycoprotein (MOG)-CFA immunization. (A) MOG specific IL-17 producing CD4+ T cells were measured by 
ELISPOT. (B) Bulk splenocytes were stimulated for ex vivo with media (unstimulated control), MOG, or ovalbumin 
(OVA) as a negative control. IL-17A was measured in culture supernatants by ELISA. (C, F) Splenocytes from 
Il17rafl/fl and Il17rafl/fl x villin cre+ mice were isolated 9 days post-OVA-CFA immunization and stimulated ex vivo 
with media (unstimulated control), OVA, or MOG as a negative control. (C) IL-17A was measured in culture 
supernatants by ELISA. (D) Splenocytes from naïve Il17rafl/fl and Il17rafl/fl x villin cre+ mice were isolated and 
stimulated ex vivo with media (unstimulated control) or anti-CD3/CD28. IL-17A was measured in culture supernatants 
by ELISA. (E) Small intestine lamina propria lymphocytes from Il17rafl/fl and Il17rafl/fl x villin cre+ mice were isolated 
9 days post myelin MOG-CFA immunization and stimulated ex vivo with media (unstimulated) or MOG. GM-CSF 
was measured in culture supernatants by ELISA. (F) GM-CSF in culture supernatants following stimulation described 
in (C). p<0.05*, <0.01** (Unpaired T Test, Two-way ANOVA with multiple comparisons) 
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3.3.4  Il17rafl/fl x villin cre+ disease exacerbation is IL-1β-independent. 
Pathogenic Th17 cells implicated in EAE characteristically double produce IL-17 and GM-
CSF (28, 30). Specific inflammatory signals favor the differentiation of these pathogenic Th17 
cells (Table 1-2). One of those factors is IL-1β (28). Previous data suggested that IL-1β was 
detrimental in EAE (305, 306). In Il17rafl/fl x villin cre+ mice, Il1b expression was increased by 
RNA sequencing in the terminal ileum at the naïve state and by qRT-PCR at day 9 post 
immunization (Figure 3-6A-B). In addition, transcript of Il1rn, which encodes for IL-1R antagonist 
(IL-1RA), was decreased at day 9 post immunization (Figure 3-6C). IL-1RA competitively inhibits 
binding of IL-1β to the IL-1 receptor (321). Because Il1b was increased and regulation of IL-1 was 
decreased based on Il1rn expression, we hypothesized that disease exacerbation was dependent on 
IL-1 promotion of pathogenic Th17 differentiation. To test this hypothesis, anakinra, the 
pharmaceutical name for IL-1RA, was injected into Il17rafl/fl x villin cre+ mice twice daily for 21 
days starting at immunization (Figure 3-6D). Contrary to our hypothesis, disease severity with 
treatment was unaltered compared to control treatment (Figure 3-6E). Due to previously 
documented concerns about drug half-life, a serum IL-1RA ELISA was performed to assess levels 
of IL-1RA prior to each of the two doses given per day. This confirmed that anakinra was indeed 
present systemically prior to each dose in the treated mice as compared to PBS-injected controls 
(Figure 3-6F). As expected, there was a higher level of drug on board prior to the PM dose as 
compared to the AM dose due to the smaller break between doses (Figure 3-6F). These data 
confirm that disease exacerbation in Il17rafl/fl x villin cre+ mice was not dependent on IL-1β 
signaling.     
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Figure 3-6 Il17rafl/fl x villin cre+ disease exacerbation is IL-1β-independent. 
(A) RNA sequencing was performed on the terminal ileum of naïve Il17rafl/fl and Il17rafl/fl x villin cre+ mice. Data 
shows Il1b expression. (B-C) Terminal ileum Il1b and Il1rn expression was measured by qRT-PCR in Il17rafl/fl and 
Il17rafl/fl x villin cre+ mice at the naïve state and 9 days post EAE immunization. (D-F) Il17rafl/fl x villin cre+ mice were 
treated with intraperitoneal (IP) Anakinra (IL-1RA) or PBS control injection twice daily for 21 days beginning on day 
0 of EAE induction. (D) Experiment schematic. (E) EAE disease severity scores. (F) IL-1RA was measured by ELISA 
on serum harvested prior to the AM and PM dose of anakinra. p<0.05*, <0.01**, <0.001***, <0.0001**** (Unpaired 







3.3.5  Il17rafl/fl x villin cre+ mice have increased intestinal Ccr2 and Ccr6 and spinal cord 
Nos2 prior to EAE onset. 
In addition to its function as a granulocyte and macrophage growth factor, GM-CSF has 
been shown to promote activation and infiltration of immune cells into the CNS during EAE. 
Indeed, GM-CSF deficient mice exhibited less severe EAE with less CNS myeloid cell infiltration 
(304, 308). In addition, GM-CSF can promote IL-23 production by dendritic cells to perpetuate a 
cycle of Th17 effector generation and activation (27). In Il17rafl/fl x villin cre+ mice, there is 
evidence of increased intestinal GM-CSF (Figure 3-2, 3-5). To explore these potential effects of 
GM-CSF within the gut specific knockout mice during EAE, intestinal Ccr2 expression, an 
inflammatory macrophage marker, was measured via qPCR at day 9 post immunization. There 
were significantly increased expression levels in Il17rafl/fl x villin cre+ mice as compared to 
littermate floxed controls (Figure 3-7A). Knockout mice also exhibited increased intestinal Ccr6 
(Figure 3-7B), a marker highly expressed by Th17 cells, though this may simply be due to the Sfb 
overgrowth previously mentioned. Expression of these genes were also measured in the spinal cord 
9 days after immunization. Ccr6 expression was undetectable (Figure 3-7C), but there were trends 
toward increased Ccr2 (Figure 3-7D) and significantly increased Nos2 (Figure 3-7E). Nos2 is 
expressed on proinflammatory M1 macrophages, suggesting there may be increased 
proinflammatory macrophages in the spinal cord already at day 9 post immunization.  
To assess what may be occurring during vancomycin-mediated protection, Il17rafl/fl x villin 
cre+ terminal ileum and spinal cord gene expression were measured by qRT-PCR at day 9 post 
immunization under vancomycin treatment. Ccr2, Ccr6, and Cd4 were all decreased in the 
terminal ileum (Figure 3-7F-H). In the spinal cord, there were trends toward decreased Cd4 
expression (Figure 3-7I). At the cellular level, the increase in small intestine lamina propria CD4+ 
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T cells during EAE was reduced by vancomycin treatment to levels similar to naïve mice (Figure 
3-7J-K). While additional experiments are certainly necessary to validate these findings and 
demonstrate causation, these preliminary data suggest that there may be increased spinal cord 










Figure 3-7 Il17rafl/fl x villin cre+ mice have increased intestinal Ccr2 and Ccr6 and spinal cord Nos2 prior to 
EAE onset. 
(A-E) Terminal ilea and spinal cords were harvested from Il17rafl/fl and Il17rafl/fl x villin cre+ mice 9 days post-MOG-
CFA immunization. Terminal ileum (TI) Ccr2 (A) and Ccr6 (B) were measured by qRT-PCR. Spinal cord Ccr6 (C), 
Ccr2 (D), and Nos2 (E) were measured by qRT-PCR. (F-K) Il17rafl/fl x villin cre+ mice were treated 2 weeks with 
vancomycin in the drinking water ad libitum followed by MOG-CFA immunization. Mice were sacrificed at 9 days 
post immunization. (F-H) Terminal ileum Ccr2 (F), Ccr6 (G), and Cd4 (H) was measured by qRT-PCR. (I) Spinal 
cord (SC) Cd4 was measured by qRT-PCR. (J) Quantification of lamina propria (LP) CD4+ T cells as measured by 
flow cytometry. (K) Representative FACS plots. p<0.05*, <0.01**, <0.001***, <0.0001**** (Mann-Whitney Test, 





Our results provide evidence that perturbation of intestinal IL-17 signaling is sufficient to 
exacerbate neuroinflammation. Abrogation of intestinal IL-17RA disrupted the intestinal 
microbiota and increased intestinal Il17 and Csf2 and systemic responses in both cytokines. 
Preliminary data also suggested a potential increase of inflammatory monocyte infiltration into the 
CNS, together exacerbating disease.  
As previously mentioned, Th17 cells have been previously implicated in EAE and MS as 
a detrimental factor. In mice, global knockout of IL-17RA was protective (126). However, the role 
of Th17 cells in autoimmune neuroinflammation is complex. By using Il17rafl/fl x villin cre+ mice, 
we again uncoupled intestinal IL-17RA signaling from systemic signaling to reveal a novel 
protective role of IL-17RA in neuroinflammation. This protection was accompanied by an increase 
in terminal ileum Csf2. This aligned with other reports on the pathogenicity of GM-CSF within 
this model  (303, 304). It also raises the possibility of the intestine as a source of pathogenic GM-
CSF within EAE and MS. The intestine does play a large role in the regulation of Th17 cells (322). 
Moreover, a recent study showed an upregulation of Th17 cells with intestines of MS patients 
(309). As such, it is possible that pathogenic Th17 cells that are detrimental in EAE can also arise 
from the intestine. These data may also help explain why there is only partial protection conferred 
by IL-17A deficiency or anti-IL-17A neutralization (298, 299). This partial protection may suggest 
a role for other Th17 related cytokines, or that IL-17 expression is associated with a gene module 
that allows traffic into the brain but is not critical for direct CNS damage. Our data suggest that 
the protective effects of blockade may also be diminished as a result of intestinal IL-17 signaling 
disruption with downstream consequences detrimental to neuroinflammation. Alternatively, 
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differences in results could be due to institutional differences in the intestinal microbiome of the 
respective mice.  
Our data showed that vancomycin treatment conferred protection in Il17rafl/fl x villin cre+ 
mice, implying a role of gram-positive bacteria in EAE. A gram-positive targeted antibiotic 
approach was employed to eliminate the bacteria we believed the most likely contributor in our 
model—Sfb. We previously showed that Sfb was overgrown in Il17rafl/fl x villin cre+ mice (48) 
and as expected, vancomycin treatment decreased the intestinal Sfb burden. These data corroborate 
with another report that monocolonization with Sfb in germ-free mice is sufficient to exacerbate 
EAE compared to germ-free mice (313). However, monocolonization with Sfb did not restore full 
susceptibility to EAE as compared to conventional SPF mice (313), implying a role of other 
bacteria in disease pathogenesis or that Sfb requires cooperation with other bacteria to exert its 
effects. This may explain why a report by Stockinger and colleagues showed that mice 
reconstituted with feces with high Sfb levels had no effect on EAE as compared to disease in mice 
reconstituted with low-Sfb feces (323). It is possible the “Sfb+” feces lacked the bacterial strains 
with which Sfb coordinates. Alternatively, it may have additional strains protective in EAE. With 
that said, it cannot be ruled out that there are other microbiota differences in Il17rafl/fl x villin cre+ 
mice that may exacerbate disease. Indeed, intestinal Th17 signaling is especially important for 
controlling microbes close to the intestinal epithelium. Similarly, it also cannot be ruled out that 
there are other bacteria that can induce pathogenic Th17 responses. In humans, Honda and 
colleagues identified a consortium of 20 bacterial strains capable of adhering to the mouse 
intestinal epithelium to induce a robust Th17 response (36). Vancomycin-mediated protection 
from EAE was accompanied by a decrease in intestinal Il17a and Csf2, suggesting that the 
microbiome may worsen disease through the intestinal regulation of these two cytokines.  
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When investigating the systemic responses of these cytokines, Il17rafl/fl x villin cre+ mice 
exhibited increased non-specific IL-17 responses. These responses may contribute disease through 
the bystander effect. The bystander effect refers to the non-antigen-specific activation of cells 
through other stimuli in the environment, which can in turn affect health and disease (324). Indeed, 
it has been shown that non-myelin specific bystander T cells can exacerbate EAE pathology (324, 
325). Lee et al. showed that adoptive transfer of activated memory OTII CD4+ T cells with myelin-
specific 2d2 cells into RAG knockout mice induced more severe EAE as compared to transfer of 
2d2 cells alone (324). In Il17rafl/fl x villin cre+ mice, it is possible that the disruption of intestinal 
Th17 signaling and subsequent changes in the microbiome caused increased activation of Th17 
cells potentially from an altered intestinal cytokine milieu and microbiome-induced activation. 
Studies showed that non-specific activation with anti-CD3/CD28 induced a greater IL-17 response 
in memory cells as compared to naïve cells (324). This paralleled results in Il17rafl/fl x villin cre+ 
mice in which non-specific anti-CD3/CD28 stimulation of splenocytes from naïve Il17rafl/fl x villin 
cre+ mice produced more IL-17 compared to Il17rafl/fl controls. This may suggest that there are 
increased memory-like cells in Il17rafl/fl x villin cre+ mice.  
These activated Th17 cells can then act systemically to influence disease. Though 
discussed in more detail later, one possibility is that these cells may be migrating into the CNS to 
influence disease directly, especially since T cell activation is required to cross the BBB (291). A 
more likely possibility is that the inflammatory mediators produced/induced by the cells as 
opposed to the cells themselves can act on the blood brain barrier and promote immune cell 
infiltration. Indeed IL-17RA, IL-17RC, and IL-22R are expressed on the BBB cells. Both IL-17 
and IL-22, which is also increased in Il17rafl/fl x villin cre+ mice (48), promoted migration of CD4+ 
T cells across human BBB endothelial cells with specific enrichment of migrating CD45RO+ 
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memory cells and increases in CCL2 and CXCL8 (294). Furthermore, immunostaining of 
autopsied patient brain specimens revealed numerous CD45RO+ cells co-staining with IL-17 or 
IL-22 in infiltrated MS lesions (294). In EAE, preliminary experiments with IL-22 binding protein 
knockout mice (Il22ra2-/-), which have increased IL-22 signaling, are protected from disease 
(Figure 3-8), supporting a protective role of IL-22. Therefore, Th17-induced cytokines and 
chemokines may contribute to EAE exacerbation through these mechanisms.  
 
  
Figure 3-8. Il22ra2-/- mice are protected from EAE. 
EAE severity scores in wildtype (WT) B6 mice (n = 5) and Il22ra2-/- mice (n = 5). p<0.05*, <0.01**, <0.001***, 
<0.0001**** (Unpaired T Test for Area Under the Curve) 
 
While the presence of bystander cells can worsen EAE, they can only do so in the presence 
of MOG-specific cells (324). In our study, Il17rafl/fl x villin cre+ mice exhibited increased antigen-
specific GM-CSF responses. The increase in MOG-specific GM-CSF response was perhaps 
indicative of the increase in pathogenic Th17 cells detrimental in EAE. The increase of this 
response in the intestine suggests that the systemic elevations in GM-CSF may also originate from 
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the intestine. Elevation in MOG-specific splenic responses at day 9 post immunization aligns with 
other reports describing increased MOG-specific effector responses in the spleen during the 
priming phase of EAE (326). Interestingly, this antigen-specific response was not limited to MOG. 
Rather, OVA-CFA immunization prompted the same elevated splenic GM-CSF response. 
Therefore, while the specific antigen dictates the site of tissue damage (i.e. MOG and the CNS), 
in this case it appears to play less of a role in the type of cytokine response. This emphasizes that 
the type of response to a given antigen is largely dependent on the host environment, whether that 
be the state of the immune system, the microbiome, genetic susceptibility, or even the epigenetic 
landscape. Disruption of intestinal Th17 signaling appears to be fostering a host environment that 
promotes increased antigen-specific GM-CSF responses characteristic of pathogenic Th17 cells. 
Because IL-1β has been shown to promote pathogenic Th17 differentiation (30, 327) and 
was increased by gene expression in the intestine of Il17rafl/fl x villin cre+ mice, we hypothesized 
that it was a contributing factor to disease exacerbation. Contrary to some reports showing that IL-
1R1 and IL-1β were detrimental in EAE (305, 306), treatment with anakinra, IL-1R antagonist 
(IL-1RA) did not ameliorate disease in gut-specific knockouts. However, there are other cytokines 
that promote pathogenic Th17 differentiation—namely IL-23. Multiple reports have shown that 
IL-23 is critical for T cell-GM-CSF production in EAE  (27, 308). While IL-23 is not increased in 
Il17rafl/fl x villin cre+ mice at baseline, it is possible that IL-23 is increased during the disease 
course, which may be more important in the context of EAE. Indeed, IL-23 was found to be critical 
during the effector phase of EAE and not the initiation (27). This is consistent with previous reports 
showing high tissue expression of IL-23, which can enhance local CNS effector function to drive 
neuroinflammation (29). In addition, IL-23 can act on APCs to stimulate a positive feedback loop 
in which IL-23 promotes GM-CSF production in Th17 cells, and GM-CSF then promotes IL-23 
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production in APCs (27). As such, further characterization of IL-23 in Il17rafl/fl x villin cre+ mice 
during EAE and its relation to IL-17 and GM-CSF production is warranted.   
The increase in GM-CSF found in Il17rafl/fl x villin cre+ mice during EAE could contribute 
to immune activation and infiltration in to the CNS. More specifically, GM-CSF can activate 
microglia within the CNS and promote recruitment of circulating monocytes (303, 328, 329). In 
GM-CSF deficient mice, myeloid cells, which express the GM-CSF receptor, do not accumulate 
in the CNS (303, 304). Our preliminary data show that there is a vancomycin-sensitive increase in 
terminal ileum Ccr2 and Ccr6 with a corresponding increases in spinal cord Ccr2 and Nos2, a gene 
upregulated in proinflammatory M1 macrophages. While these changes may be association, the 
fact that gene expression in the spinal cord reflects the changes in intestine also poses the 
hypothesis that there could be immune cell trafficking from the intestine into the circulation and 
CNS.  
This preliminary data must be confirmed at the cellular level and additional studies must 
be done, but there is evidence in the literature that supports the possibility of intestinal migration 
to distant immunoprivileged sites. Though not in EAE, Caspi and colleagues showed that 
autoreactive T cells in experimental autoimmune uveitis were primed in the intestine, migrated to 
the eye, and were activated via molecular mimicry to contribute to ocular pathology (121). In 
addition, Benakis et al. showed that intestinal cells migrated to the meninges after a mouse model 
of ischemic stroke (247). Benakis et al. utilized KikGR33 mice that ubiquitously expressed a 
fluorescent protein whose emission changed from green to red after violet light exposure. These 
mice underwent a laparotomy and exposure to violet light only on the intestine, distinguishing 
cells of intestinal origin. Analysis following ischemic stroke showed intestinal red-emitting T cells 
in the meninges (247). However, a caveat to this study is exposing cells within the gastrointestinal 
 122 
vasculature already in circulation. In addition to these studies, there are data showing that during 
EAE, encephalitogenic Th17 cells that produce GM-CSF switch from CCR6+CCR2- to CCR6-
CCR2+ (330). These cells were found in the CNS of mice already at day 5 post EAE immunization 
with increasing percentages observed at days 10 and 15 post immunization (330). Therefore, while 
the increase in spinal cord Ccr2 and Nox2 at day 9 post immunization in Il17rafl/fl x villin cre+ mice 
could be indicative of increased inflammatory monocyte infiltration, it could also be a result of 
Th17 cells switching from CCR6+ to CCR2+ cell. This may explain why there is a dramatic 
increase in Ccr2 and Ccr6 expression in the intestine at day 9 with undetectable spinal cord Ccr6 
and increased Ccr2.  
As previously mentioned, it may likely be the case that Th17 cells and other intestinal cells 
are not physically migrating into the CNS at all, but rather contributing to disease more indirectly 
via the bystander effect as discussed above. Our data leave open the possibility that cytokines, 
bacterial products and metabolites (316, 331), and other inflammatory mediators can be going 
from the intestine to the circulation and CNS. More locally, these factors can also act on the enteric 
nerves and affect disease in that way (246).  
These studies offer many future directions exploring other possibilities by which intestinal 
IL-17RA signaling could be contributing to neuroinflammation. As previously mentioned, 
bacterial metabolites can play a large role in disease development and could be altered due to the 
commensal dysbiosis in the gut specific knockouts. Alterations in the intestinal microbiome and 
microbial-derived SCFAs have been known to influence the intestinal Treg population (332). As 
such, characterization of the Treg population in Il17rafl/fl x villin cre+ mice may be important as 
well, especially since shifts in the balance of Tregs/Th17 have been linked to microbiome-
mediated effects on EAE (311–313). In terms of microbial product release into circulation, there 
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is no baseline defect in intestinal barrier integrity in Il17rafl/fl x villin cre+ mice. However, the 
barrier may be compromised after disease induction based on preliminary assessment of intestinal 
tight junction related genes (Figure 3-9). Increased permeability would allow for enhanced release 
of bacterial products including TLR ligands and SCFAs.  
 
 
Figure 3-9. Terminal ileum tight junction protein gene expression at day 9 post EAE immunization. 
Terminal ileum expression of Claudin 1 (Cldn1) (A), Claudin 2 (Cldn2) (B), Claudin 7 (Cldn7) (C), Claudin 8 (Cldn8) 





In addition to the intestinal barrier integrity, assessment of the integrity of the BBB in 
Il17rafl/fl x villin cre+ mice is critical, as there may not only be increased release and migration of 
cells and immune mediators into the circulation due to intestinal barrier defects but increased 
accessibility to the CNS due to BBB compromise. Finally, a more thorough investigation of 
pathogenic Th17 cells in the context of EAE in Il17rafl/fl x villin cre+ mice would be informative. 
Identifying their tissue of origin, what factors induce them (i.e. IL-23), and which cells ultimately 
migrate into the CNS will provide additional mechanistic insight into how intestinal Th17 
signaling can contribute to MS immunopathology. 
In summary, these studies support a novel protective role of intestinal Th17 signaling in 
autoimmune neuroinflammation. We show that mice with disrupted intestinal IL-17RA exhibited 
earlier EAE onset and increased EAE severity. The data suggest that disease exacerbation may be 
due to microbiome-mediated increases in pathogenic Th17 responses that promote CNS infiltration 
and worsened neuroinflammation. While more studies are necessary to validate these findings, this 
work elucidates potential mechanisms by which intestinal Th17 signaling and its relationship with 
the microbiome contribute to MS and other autoimmune pathologies. Moreover, it exposes novel 
therapeutic avenues targeting the gut-brain axis to ultimately improve patient health.   
 
 125 
3.5 Working Model 
 
Figure 3-10. Working Model 
In Il17rafl/fl x villin cre+ mice, where IL-17RA signaling is knocked out specifically in the intestinal epithelium, there 
was intestinal overgrowth of Sfb due to the lack of Th17-mediated regulation. Because of the reciprocal regulatory 
relationship between Th17 cells and Sfb, Sfb overgrowth induced intestinal IL-17 and increased non-pathogenic Th17 
cells. We hypothesize that the cytokine response to immunization with myelin oligodendrocyte glycoprotein (MOG) 
in Complete Freund’s adjuvant (CFA) partnered with microbiome-mediated cytokine changes promoted a switch from 
non-pathogenic to pathogenic Th17 cells that double produce IL-17 and GM-CSF. These two cytokines can then act 
systemically in a non-specific fashion to promote blood brain barrier weakening, recruitment and activation of myeloid 
cells, and chemokine release in the CNS to enhance bystander lymphocyte infiltration to ultimately exacerbate 
neuroinflammation.  
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4.0 Overall Conclusions & Future Directions 
These dissertation studies investigated the role of intestinal Type 17 signaling and the 
microbiome in extra-intestinal pathologies, specifically focusing on the gut-liver and gut-brain 
axes. Both studies utilized in Il17rafl/fl x villin cre+ mice to knockout IL-17RA signaling in the 
intestinal epithelium, uncoupling intestinal IL-17RA signaling from systemic signaling to reveal 
novel protective roles. In mouse models of liver and neuroinflammation, these works demonstrated 
how disruption of intestinal Th17 signaling and subsequent alterations in the intestinal microbiome 
were capable of exacerbating disease at distal sites.  
In the gut-liver axis, abrogation of intestinal IL-17RA was sufficient to worsen disease in 
a Con A mouse model of T cell-mediated hepatitis. More specifically, naïve Il17rafl/fl x villin cre+ 
mice exhibited microbiome dysbiosis and increased translocation of bacterial products (CpG 
DNA) to the liver, driving hepatic IL-18 production. Upon disease induction, absence of enteric 
IL-17RA signaling exacerbated hepatitis and hepatocyte cell death. IL-18 was necessary for 
disease exacerbation and associated with increased activated hepatic lymphocytes based on Ifng 
and Fasl expression. From these studies, we concluded that intestinal IL-17R regulated the 
translocation of TLR9 ligands and constrained susceptibility to hepatitis. These data connect 
enteric Th17 signaling and the microbiome in hepatitis, with broader implications on the effects 
of impaired intestinal immunity and subsequent release of microbial products observed in other 
extra-intestinal pathologies. 
In the gut-brain axis, perturbation of intestinal IL-17RA was sufficient to worsen disease 
in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Our 
data suggested that Il17rafl/fl x villin cre+ mice, which have higher Sfb levels, exhibited earlier EAE 
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onset and increased EAE incidence and severity as compared to littermate Il17rafl/fl controls. 
Treatment with vancomycin ameliorated disease, suggesting that the phenotype was microbiome-
dependent. Disease exacerbation was accompanied by systemic increases in IL-17 and GM-CSF 
responses. In addition, preliminary data indicated that Il17rafl/fl x villin cre+ mice had increased 
intestinal expression of Csf2, Ccr2, and Ccr6 and increased spinal cord expression of Nos2 
immediately prior to disease onset. Together, this suggested that there could be increased migration 
into the CNS of Il17rafl/fl x villin cre+ mice, contributing to exacerbated disease. These studies 
elucidated how dysregulation of enteric IL-17R signaling and the commensal microbiota may 
contribute to the pathogenesis of MS and other autoimmune conditions. Moreover, it provides 
insight into novel therapeutic strategies targeting the gut-brain axis. 
Together, both studies emphasize the importance of examining intestinal Th17 immunity 
in extra-intestinal diseases and mucosal immunity in general. It reaffirms the concept that mucosal 
immunity is critical in disease protection, and that when it fails or is disrupted, systemic immunity 
is affected. Specific to liver and neuroinflammation, many patients with Th17-associated diseases 
including multiple sclerosis and autoimmune hepatitis present with intestinal symptoms even early 
in the disease course. While this may be only a consequence rather than a cause, our studies argue 
for a potential role of the intestine in perpetuating further disease development and exacerbation. 
Previous research has shown that the intestine is a major regulator of Th17 signaling (322). Our 
work has demonstrated that intestinal Th17 signaling can contribute to extra-intestinal disease via 
its regulation of the microbiome and downstream release of cytokines, chemokines, and other 
inflammatory mediators. This link between intestinal Th17 immunity and extra-intestinal disease 
is supported by other work detailing intestinal Th17 downstream effects in other organs. McAleer 
et al. showed that in pulmonary  Aspergillus fumigatus infection, gastrointestinal delivery of Reg3γ 
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conferred protection in an IL-22 dependent manner (333). Moreover, these Th17-induced 
antimicrobial peptides can also have effects on chemotactic activity and TLR responsiveness 
(334), adding to the potential systemic effects on health and disease.  Ultimately, our studies 
support the idea that intestinal Th17 signaling is capable of affecting extra-intestinal disease 
through various mechanisms. What is especially interesting about these dissertation studies is that 
while there are parallels between the two mechanisms exacerbating hepatitis and 
neuroinflammation in Il17rafl/fl x villin cre+ mice, each model actually implicates different aspects 
of Th17 cells and the microbiome.  
In each model, it appears that different Th17 cytokines are playing a role in disease 
exacerbation. One reason for this may be the differences in IL-17RA signaling in the small versus 
large intestine. As such, it would be helpful to isolate the various intestinal segments and evaluate 
immunologic changes as well as alterations in the microbiome within each segment. Based on the 
data, the EAE phenotype is likely connected at least in-part to small intestinal IL-17RA signaling 
given the effect of Sfb overgrowth (predominantly in the terminal ileum) in the EAE model. Our 
working model in EAE suggests an increase in pathogenic Th17 cells that are double producing 
GM-CSF and IL-17. This was seen in the intestine as well as in systemic responses during ex vivo 
stimulations. Both of these cytokines may then contribute to CNS immune infiltration and 
recruitment to exacerbate neuroinflammation via chemokine release, effects on myeloid cells, and 
disruption of the BBB. Conversely, IL-17RA signaling in the large intestine may have more of an 
effect in the hepatitis phenotype relative to the EAE phenotype due to the role of the colon in the 
enterohepatic circulation. During hepatitis, disease in Il17rafl/fl x villin cre+ mice was more so 
driven by general Th17 control of the microbiome and subsequent IL-18 release discussed in more 
detail below. Our data in Nlrc4mutIl18bp-/- mice, which have increased intestinal IL-18 production 
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and decreased systemic regulation of IL-18, also suggested a role of intestinal IL-18 in disease 
exacerbation. Il17rafl/fl x villin cre+ mice do have an increase in intestinal IL-18 as well as IL-22 
(48). These data align with evidence showing that IL-22 can drive IL-18 production by intestinal 
epithelial cells (161). The elevated IL-18 in Il17rafl/fl x villin cre+ mice then enhanced liver 
inflammation by promoting lymphocyte activation as measured by Ifng and cell death through Fas-
FasL. While it was not investigated, the elevated IL-18 in Il17rafl/fl x villin cre+ mice could be 
influencing EAE exacerbation as well. Indeed, there was increased IL-18 in the CSF and serum of 
MS patients with active MRI lesions. In mice, however, IL-18 deficiency had no effect while 
knockout of IL-18Rα was protective against EAE (335, 336). Taken together, our data highlight 
the different mechanisms by which intestinal Th17 cells and subsequent Th17 related cytokines 
can influence disease in different organs. Moreover, it prompts further investigation of intestinal 
Th17 signaling in extra-intestinal diseases.   
Based on antibiotic and cohousing studies, disrupted intestinal IL-17 signaling mediated 
its effects on hepatitis and neuroinflammation through the intestinal microbiota. The intestinal 
microbiota has been previously implicated in both the Con A and EAE. Indeed, in both models, 
germ-free mice exhibit ameliorated disease (178, 313). Il17rafl/fl x villin cre+ mice have an altered 
intestinal microbiome as previously described (48). Our data suggested that different bacteria 
within the Il17rafl/fl x villin cre+ microbiota are contributing to each disease model. In EAE, 
vancomycin, which targets gram-positive bacteria, ameliorated disease. Based on the literature, it 
is likely that the disease inciting bacteria in EAE was gram-positive bacteria, Sfb. There is a large 
Sfb overgrowth in Il17rafl/fl x villin cre+ mice due to the loss of Th17 control (48), and 
monocolonization with Sfb into germ-free mice was sufficient to exacerbate disease as compared 
to germ-free mice (313). Conversely, in Con A hepatitis, vancomycin had no effect on disease in 
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Il17rafl/fl x villin cre+ mice, while neomycin, which targets gram negative bacteria, ameliorated 
disease. This effectively shifted the focus away from Sfb within the Con A model and also 
suggested that intestinal IL-17RA signaling controlled more than Sfb. This is not surprising as the 
mechanisms by which Th17 cells control Sfb,  such as sIgA and AMPs, are also applicable to other 
bacteria residing close to the intestinal epithelium. Indeed, we have evidence showing general 
bacterial overgrowth in the fecal content of Il17rafl/fl x villin cre+ mice with enrichment for IgA- 
bacteria. The fact that different bacteria within the same organism are exacerbating different 
diseases provides further support that the effect of the microbiome is contextual. For example, the 
Sfb-mediated IL-17 responses in Il17rafl/fl x villin cre+ mice may be detrimental in EAE but 
protective in a setting of fungal infection (337). Still within Il17rafl/fl x villin cre+ mice, gram-
negative bacteria mediated IL-18 elevations, which exacerbated hepatitis but may prove beneficial 
in  colitis (160). This challenges the concept of a “healthy” microbiome, as the various bacteria 
within one host’s microbiome may be protective or detrimental depending on the disease process 
and co-existing microbial community.  
Beyond the specific bacteria, our data have demonstrated a role for bacterial product 
translocation in disease exacerbation. In Il17rafl/fl x villin cre+ mice, translocation of CpG DNA 
from the gut to the liver promoted local hepatic IL-18 production and exacerbated disease. While 
systemic increases in bacterial products were not seen at the naïve state, it is possible that disease 
progression both in Con A and EAE may have compromised the intestinal barrier to release 
bacterial products into the circulation. Though there are some conflicting reports, TLR2, TLR4 
and TLR9 have all been implicated in EAE (319, 338, 339) and could have an effect on disease in 
Il17rafl/fl x villin cre+ mice. Our data may also have implications on other illnesses with “leaky 
gut” and increased bacterial translocation. With regards to the translocation of TLR ligands, much 
 131 
of the focus has been on LPS. For example, in HIV/AIDS, emphasis has been placed on leakage 
of LPS across the gut barrier causing wasting and chronic inflammation (181). Our data suggests 
extra-intestinal TLR9 ligand dissemination is regulated by intestinal IL-17R signaling and may 
therefore be another underlying mechanism in HIV/AIDS liver dysfunction (244). Our data also 
raise the possibility that intestinal Th17 dysregulation and subsequent bacterial translocation may 
also contribute neurological manifestations in HIV/AIDS. More broadly, our work reveals 
potential immune consequences of the subclinical bacteremia observed in many patients. 
With regards to future directions, it would be important to look beyond TLR ligands and 
address the potential role of bacterial metabolites, such as SCFAs, in Il17rafl/fl x villin cre+ disease 
exacerbation. It is likely that alterations in the intestinal microbiota within Il17rafl/fl x villin cre+ 
mice may have resulted in changes in the intestinal metabolome. SCFAs have been shown to have 
a wide range of immunologic functions including Treg induction, myeloid cell regulation, and 
inhibition of histone deacetylases (78, 79, 340, 341). The enhanced immune responses to ex vivo 
stimulation in both the Con A and EAE projects suggested that there may be epigenetic 
modifications in gut-specific knockout mice such that the splenocytes and hepatic mononuclear 
cells are primed to secrete more inflammatory cytokines in response to even non-specific stimuli 
such as anti-CD3/CD28. Moreover, ex vivo treatment with bromodomain extra-terminal protein 
inhibitors abrogated the enhanced liver IFNγ response, further supporting an epigenetic 
contribution.  
It would also advance the work to identify specific bacterial genera or species exacerbating 
Con A and EAE in Il17rafl/fl x villin cre+ mice. In EAE, vancomycin treatment partnered with the 
existing literature on Sfb in EAE focused the attention on Sfb. However, as seen in within the Con 
A project, Il17rafl/fl x villin cre+ mice exhibit an overall bacterial overgrowth. As such, it is possible 
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that additional bacteria beyond Sfb may be contributing to disease. Indeed, in the work 
monocolonizing germ-free mice with Sfb, EAE severity in Sfb-monocolonized mice did not reach 
the same level as conventional SPF mice (313). This suggested that other bacteria and microbial 
metabolites beyond Sfb contributed to disease or that Sfb requires other bacteria to exert its effects. 
To that end, following up on the elevated IgA-unbound bacteria in Il17rafl/fl x villin cre+ mice 
(detailed within the Gut-Liver Axis Chapter) may assist in identifying contributing bacteria in both 
the EAE and Con A models. To tailor the assay to identify the bacterial culprits in the EAE work, 
quantification of IgA-bound and unbound bacteria can be done after vancomycin treatment to 
determine if there is selective depletion of either subset. In addition, for both projects, the IgA 
bound and unbound fractions can be sorted via magnetic separation (194), sequenced, and analyzed 
for potential differences between Il17rafl/fl x villin cre+ mice and littermate floxed controls. That 
being said, the possibility still remains that it is not a specific bacterium, but rather changes in 
bacterial behavior or bacterial overgrowth of many species that could be enhancing disease.  
Overall, these dissertation studies have numerous therapeutic implications. It emphasizes 
that diseases are very often multifactorial, involving not just the target organ but other aspects of 
the body and immune system. As such, treatment of disease should reflect this multisystem 
involvement. Specifically in MS and hepatitis, our work raises intestinal Th17 signaling and the 
intestinal microbiome as therapeutic considerations when designing therapies. While IL-17 has 
been shown to be detrimental in both disease types, it is possible that global IL-17A blockade may 
have adverse effects on intestinal Th17 signaling with subsequent microbiome alterations and 
proinflammatory effects. Indeed, “gastrointestinal disorders” was one of the organ system 
groupings with adverse side effects in response to Secukinumab, the humanized anti-IL-17A 
monoclonal antibody approved for psoriasis (342). To address these potentially adverse effects, 
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our data support the investigation of combination therapy in these diseases. Partnering IL-17 
neutralization with blockade of other potentially pathogenic cytokines including IL-18 in hepatitis 
or GM-CSF in neuroinflammation may prove more effective. 
Our work also suggests the microbiome as a therapeutic target in these diseases. While the 
targeting the microbiome is unlikely to be a cure-all for these diseases, these dissertation studies 
demonstrate that it may be a exacerbating factor in disease development. Our data suggest the role 
of specific subtypes of bacteria in disease exacerbation. Based on our data with IgA-unbound 
bacteria enrichment potentially exacerbating hepatitis, a possible future therapy may be 
administration of secretory IgA specific to inciting bacteria in that particular disease state. As such, 
identification of bacteria detrimental in specific diseases can undoubtedly advance the field, 
particularly if the work becomes translatable to patients and proves helpful in disease management. 
However, an important caveat is that many previous studies have also defined other differences in 
the intestinal microbiota in patients and mouse models of these diseases. For example, in hepatitis, 
our work implicates a gram-negative bacteria in disease exacerbation and showed that eliminating 
gram-positive bacteria had no effect in Il17rafl/fl x villin cre+ mice. Another hepatitis mouse model 
using a different genetic background implicated a gram-positive bacterium (179). In MS, a meta-
analysis of the literature detailing the intestinal microbiome of patients with relapsing-remitting 
MS described multiple different bacteria that were altered in patients with RRMS patients as 
compared to controls (310). This study noted that many of these described differences were not 
shared among all of the reports (310). The variation in the “relevant” bacterial strains in disease 
highlight the biological differences observed in the microbiome, demonstrate the importance of 
performing studies to show cause as opposed to association, and stress the significance of gene-
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environment interaction, as these microbiota changes may stem from the genetic predisposition of 
the host.  
This type of variation certainly impacts the approach to targeting the microbiome in 
patients. For interventions such as fecal microbiota transfer, it would be important to consider the 
genetic predisposition of the host as well as what may be detrimental or beneficial in that specific 
health/disease state. Moreover, transferring of bacterial communities without first creating a niche 
may impede the success of the beneficial bacterial strain. Even then, the genetic predisposition of 
the host may prevent the more permanent establishment of the microbial communities of interest. 
Because of these challenges, it would be helpful to also go beyond identifying specific target 
strains and elucidate the mechanism by which these different bacteria contribute to disease. Doing 
so would then open up more therapeutic targets. For example, it may be more efficacious, though 
not necessarily sustained, to focus microbiota-related treatments to immunogenic bacterial 
products such as SCFAs. Overall, our studies partnered with those previously performed underline 
the role of the microbiome in extra-intestinal disease and the promising therapeutic avenue of 
targeting the microbiota.  
In summary, these dissertation studies demonstrate how disruption of intestinal Th17 
signaling and subsequent effects on the microbiome can exacerbate liver- and neuro-inflammation. 
The mechanisms by which this occurs further elucidate potential therapeutic targets in hepatitis 
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